2anl:A   (ASN297) to   (VAL324)  X-RAY CRYSTAL STRUCTURE OF THE ASPARTIC PROTEASE PLASMEPSIN 4 FROM THE MALARIAL PARASITE PLASMODIUM MALARIAE BOUND TO AN ALLOPHENYLNORSTATINE BASED INHIBITOR  |   PLASMODIUM PARASITE, PLASMEPSIN 4, ASPARTIC PROTEASE, HYDROLASE, HYDROLASE-HYDROLASE INHIBITOR COMPLEX 
2anl:B   (ASN297) to   (VAL324)  X-RAY CRYSTAL STRUCTURE OF THE ASPARTIC PROTEASE PLASMEPSIN 4 FROM THE MALARIAL PARASITE PLASMODIUM MALARIAE BOUND TO AN ALLOPHENYLNORSTATINE BASED INHIBITOR  |   PLASMODIUM PARASITE, PLASMEPSIN 4, ASPARTIC PROTEASE, HYDROLASE, HYDROLASE-HYDROLASE INHIBITOR COMPLEX 
2ohl:A   (GLY330) to   (VAL356)  X-RAY CRYSTAL STRUCTURE OF BETA SECRETASE COMPLEXED WITH 2- AMINOQUINOLINE  |   ALTERNATIVE SPLICING, ALZHEIMER'S DISEASE, ASPARTIC PROTEASE, ASPARTYL PROTEASE, BASE, BETA-SECRETASE, GLYCOPROTEIN, HYDROLASE, MEMAPSIN 2, SIGNAL, TRANSMEMBRANE, ZYMOGEN 
2ohn:A   (GLY330) to   (VAL356)  X-RAY CRYSTAL STRUCTURE OF BETA SECRETASE COMPLEXED WITH 4- (4-FLUOROBENZYL)PIPERIDINE  |   ALTERNATIVE SPLICING, ALZHEIMER'S DISEASE, ASPARTIC PROTEASE, ASPARTYL PROTEASE, BASE, BETA-SECRETASE, GLYCOPROTEIN, HYDROLASE, MEMAPSIN 2, SIGNAL, TRANSMEMBRANE, ZYMOGEN 
2oht:A   (GLY330) to   (VAL356)  X-RAY CRYSTAL STRUCTURE OF BETA SECRETASE COMPLEXED WITH COMPOUND 7  |   ALTERNATIVE SPLICING, ALZHEIMER'S DISEASE, ASPARTIC PROTEASE, ASPARTYL PROTEASE, BASE, BETA-SECRETASE, GLYCOPROTEIN, HYDROLASE, MEMAPSIN 2, SIGNAL, TRANSMEMBRANE, ZYMOGEN 
2apr:A   (GLY295) to   (PRO322)  STRUCTURE AND REFINEMENT AT 1.8 ANGSTROMS RESOLUTION OF THE ASPARTIC PROTEINASE FROM RHIZOPUS CHINENSIS  |   HYDROLASE (ASPARTIC PROTEINASE) 
3rtm:A   (GLY330) to   (VAL356)  STRUCTURE OF BACE-1 (BETA-SECRETASE) IN COMPLEX WITH 3-(2- AMINOQUINOLIN-3-YL)-N-CYCLOHEXYL-N-METHYLPROPANAMIDE  |   ASPARTYL PROTEASE, HYDROLASE-HYDROLASE INHIBITOR COMPLEX 
3ru1:A   (GLY330) to   (VAL356)  STRUCTURE OF BACE-1 (BETA-SECRETASE) IN COMPLEX WITH 3-(2- AMINOQUINOLIN-3-YL)-N-(CYCLOHEXYLMETHYL)PROPANAMIDE  |   ASPARTYL PROTEASE, HYDROLASE-HYDROLASE INHIBITOR COMPLEX 
1am5:A   (LEU298) to   (PRO324)  THE CRYSTAL STRUCTURE AND PROPOSED AMINO ACID SEQUENCE OF A PEPSIN FROM ATLANTIC COD (GADUS MORHUA)  |   ASPARTYL PROTEASE, ACID PROTEINASE, HYDROLASE 
4h3j:B   (GLY391) to   (VAL417)  STRUCTURE OF BACE BOUND TO 2-FLUORO-5-(5-(2-IMINO-3-METHYL-4-OXO-6- PHENYLOCTAHYDRO-1H-PYRROLO[3,4-D]PYRIMIDIN-7A-YL)THIOPHEN-2-YL) BENZONITRILE  |   BACE1, ALZHEIMERS, HYDROLASE-HYDROLASE INHIBITOR COMPLEX 
1apw:E   (PHE295) to   (PRO321)  CRYSTALLOGRAPHIC ANALYSIS OF TRANSITION STATE MIMICS BOUND TO PENICILLOPEPSIN: DIFLUOROSTATINE-AND DIFLUOROSTATONE-CONTAINING PEPTIDES  |   ACID PROTEINASE, HYDROLASE-HYDROLASE INHIBITOR COMPLEX 
4ha5:B   (GLY391) to   (VAL417)  STRUCTURE OF BACE BOUND TO (S)-3-(5-(2-IMINO-1,4-DIMETHYL-6- OXOHEXAHYDROPYRIMIDIN-4-YL)THIOPHEN-3-YL)BENZONITRILE  |   BACE1, ALZHEIMERS, HYDROLASE-HYDROLASE INHIBITOR COMPLEX 
2b8l:A   (GLY330) to   (VAL356)  CRYSTAL STRUCTURE OF HUMAN BETA SECRETASE COMPLEXED WITH INHIBITOR  |   ASPARTYL PROTEASE, BACE, HYDROLASE 
2b8v:A   (GLY330) to   (VAL356)  CRYSTAL STRUCTURE OF HUMAN BETA-SECRETASE COMPLEXED WITH L- L000430,469  |   ASPARTYL PROTEASE, BACE, HYDROLASE 
2p4j:A   (GLY330) to   (VAL356)  CRYSTAL STRUCTURE OF BETA-SECRETASE BOND TO AN INHIBITOR WITH ISOPHTHALAMIDE DERIVATIVES AT P2-P3  |   BETA-SECRETASE, MEMAPSIN, BACE, ASP, ASPARTIC PROTEASE, ACID PROTEASE, ALZHEIMER'S DISEASE, DRUG DESIGN, STRUCTURE BASED DRUG DESIGN, HYDROLASE 
2p4j:B   (GLY330) to   (VAL356)  CRYSTAL STRUCTURE OF BETA-SECRETASE BOND TO AN INHIBITOR WITH ISOPHTHALAMIDE DERIVATIVES AT P2-P3  |   BETA-SECRETASE, MEMAPSIN, BACE, ASP, ASPARTIC PROTEASE, ACID PROTEASE, ALZHEIMER'S DISEASE, DRUG DESIGN, STRUCTURE BASED DRUG DESIGN, HYDROLASE 
2p4j:C   (GLY330) to   (VAL356)  CRYSTAL STRUCTURE OF BETA-SECRETASE BOND TO AN INHIBITOR WITH ISOPHTHALAMIDE DERIVATIVES AT P2-P3  |   BETA-SECRETASE, MEMAPSIN, BACE, ASP, ASPARTIC PROTEASE, ACID PROTEASE, ALZHEIMER'S DISEASE, DRUG DESIGN, STRUCTURE BASED DRUG DESIGN, HYDROLASE 
2p83:B   (GLY330) to   (VAL356)  POTENT AND SELECTIVE ISOPHTHALAMIDE S2 HYDROXYETHYLAMINE INHIBITOR OF BACE1  |   PROTEIN-INHIBITOR COMPLEX, HYDROLASE 
2p83:C   (GLY330) to   (VAL356)  POTENT AND SELECTIVE ISOPHTHALAMIDE S2 HYDROXYETHYLAMINE INHIBITOR OF BACE1  |   PROTEIN-INHIBITOR COMPLEX, HYDROLASE 
1bbs:A   (THR298) to   (LEU324)  X-RAY ANALYSES OF PEPTIDE INHIBITOR COMPLEXES DEFINE THE STRUCTURAL BASIS OF SPECIFICITY FOR HUMAN AND MOUSE RENINS  |   ASPARTIC PROTEINASE 
1bbs:B   (THR298) to   (LEU324)  X-RAY ANALYSES OF PEPTIDE INHIBITOR COMPLEXES DEFINE THE STRUCTURAL BASIS OF SPECIFICITY FOR HUMAN AND MOUSE RENINS  |   ASPARTIC PROTEINASE 
3s2o:A   (GLY117) to   (ILE176)  FRAGMENT BASED DISCOVERY AND OPTIMISATION OF BACE-1 INHIBITORS  |   PROTEASE, ALZHEIMER'S DISEASE, ASPARTIC PROTEASE, ASPARTYL PROTEASE, BASE, BETA-SECRETASE, GLYCOPROTEIN, MEMAPSIN 2, AMYLOID PRECURSOR PROTEIN SECRETASES, ASPARTIC ENDOPEPTIDASES, FRAGMENT-BASED DRUG DESIGN, FLUORESCENCE POLARISATION, TRANSMEMBRANE, HYDROLASE- HYDROLASE INHIBITOR COMPLEX 
3exo:A   (GLY330) to   (VAL356)  CRYSTAL STRUCTURE OF BACE1 BOUND TO INHIBITOR  |   BETA SECRETASE, BACE 1, ASPARTYL PROTEASE, GLYCOPROTEIN, HYDROLASE, MEMBRANE, PROTEASE, TRANSMEMBRANE, ZYMOGEN 
2bju:A   (PRO297) to   (LEU324)  PLASMEPSIN II COMPLEXED WITH A HIGHLY ACTIVE ACHIRAL INHIBITOR  |   PLASMEPSIN, ASPARTIC PROTEINASE, DRUG DESIGN, MALARIA, ASPARTYL PROTEASE, GLYCOPROTEIN, HYDROLASE, SIGNAL, ZYMOGEN 
1bil:A   (THR298) to   (LEU324)  CRYSTALLOGRAPHIC STUDIES ON THE BINDING MODES OF P2-P3 BUTANEDIAMIDE RENIN INHIBITORS  |   ASPARTIC PROTEINASE, ASPARTYL PROTEASE, CLEAVAGE ON PAIR OF BASIC RESIDUES, DISEASE MUTATION, DISULFIDE BOND, GLYCOPROTEIN, HYDROLASE, MEMBRANE, PROTEASE, SECRETED, ZYMOGEN, HYDROLASE-HYDROLASE INHIBITOR COMPLEX 
1bil:B   (THR298) to   (LEU324)  CRYSTALLOGRAPHIC STUDIES ON THE BINDING MODES OF P2-P3 BUTANEDIAMIDE RENIN INHIBITORS  |   ASPARTIC PROTEINASE, ASPARTYL PROTEASE, CLEAVAGE ON PAIR OF BASIC RESIDUES, DISEASE MUTATION, DISULFIDE BOND, GLYCOPROTEIN, HYDROLASE, MEMBRANE, PROTEASE, SECRETED, ZYMOGEN, HYDROLASE-HYDROLASE INHIBITOR COMPLEX 
1bim:A   (THR298) to   (LEU324)  CRYSTALLOGRAPHIC STUDIES ON THE BINDING MODES OF P2-P3 BUTANEDIAMIDE RENIN INHIBITORS  |   ASPARTIC PROTEINASE, ASPARTYL PROTEASE, CLEAVAGE ON PAIR OF BASIC RESIDUES, DISEASE MUTATION, DISULFIDE BOND, GLYCOPROTEIN, HYDROLASE, MEMBRANE, PROTEASE, SECRETED, ZYMOGEN, HYDROLASE-HYDROLASE INHIBITOR COMPLEX 
1bim:B   (THR298) to   (LEU324)  CRYSTALLOGRAPHIC STUDIES ON THE BINDING MODES OF P2-P3 BUTANEDIAMIDE RENIN INHIBITORS  |   ASPARTIC PROTEINASE, ASPARTYL PROTEASE, CLEAVAGE ON PAIR OF BASIC RESIDUES, DISEASE MUTATION, DISULFIDE BOND, GLYCOPROTEIN, HYDROLASE, MEMBRANE, PROTEASE, SECRETED, ZYMOGEN, HYDROLASE-HYDROLASE INHIBITOR COMPLEX 
2bks:A   (THR305) to   (LEU331)  CRYSTAL STRUCTURE OF RENIN-PF00074777 COMPLEX  |   HYDROLASE, ASPARTIC PROTEINASE, ASPARTYL PROTEASE, GLYCOPROTEIN, PLASMA, SIGNAL, ZYMOGEN, POLYMORPHISM 
2bks:B   (THR305) to   (LEU331)  CRYSTAL STRUCTURE OF RENIN-PF00074777 COMPLEX  |   HYDROLASE, ASPARTIC PROTEINASE, ASPARTYL PROTEASE, GLYCOPROTEIN, PLASMA, SIGNAL, ZYMOGEN, POLYMORPHISM 
3s8i:A   (ASP327) to   (ILE351)  THE RETROVIRAL-LIKE PROTEASE (RVP) DOMAIN OF HUMAN DDI1  |   PROTEASE, STRUCTURAL GENOMICS, STRUCTURAL GENOMICS CONSORTIUM, SGC, RETROPEPSIN-LIKE DOMAIN, PROTEIN TURNOVER, HYDROLASE 
3s8i:B   (ASP327) to   (ILE351)  THE RETROVIRAL-LIKE PROTEASE (RVP) DOMAIN OF HUMAN DDI1  |   PROTEASE, STRUCTURAL GENOMICS, STRUCTURAL GENOMICS CONSORTIUM, SGC, RETROPEPSIN-LIKE DOMAIN, PROTEIN TURNOVER, HYDROLASE 
3f9q:A   (PRO297) to   (LEU324)  RE-REFINEMENT OF UNCOMPLEXED PLASMEPSIN II FROM PLASMODIUM FALCIPARUM.  |   HYDROLASE, ASPARTYL PROTEASE, GLYCOPROTEIN, PROTEASE, VACUOLE, ZYMOGEN 
1bxo:A   (PHE295) to   (PRO321)  ACID PROTEINASE (PENICILLOPEPSIN) (E.C.3.4.23.20) COMPLEX WITH PHOSPHONATE INHIBITOR: METHYL CYCLO[(2S)-2-[[(1R)-1-(N-(L-N-(3- METHYLBUTANOYL)VALYL-L-ASPARTYL)AMINO)-3-METHYLBUT YL] HYDROXYPHOSPHINYLOXY]-3-(3-AMINOMETHYL) PHENYLPROPANOATE  |   HYDROLASE, PHOSPHONATE INHIBITORS, MACROCYCLE 
1bxq:A   (PHE295) to   (PRO321)  ACID PROTEINASE (PENICILLOPEPSIN) COMPLEX WITH PHOSPHONATE INHIBITOR.  |   HYDROLASE, PHOSPHONATE INHIBITORS 
1od1:A   (ILE302) to   (SER329)  ENDOTHIAPEPSIN PD135,040 COMPLEX  |   ACID PROTEINASE, INHIBITOR, ASPARTYL PROTEASE, HYDROLASE-HYDROLASE INHIBITOR COMPLEX 
2ph6:A   (GLY330) to   (VAL356)  CRYSTAL STRUCTURE OF HUMAN BETA SECRETASE COMPLEXED WITH INHIBITOR  |   ASPARTYL PROTEASE, BACE, HYDROLASE 
4i0e:A   (GLY391) to   (VAL417)  DESIGN AND SYNTHESIS OF THIOPHENE DIHYDROISOQUINOLINS AS NOVEL BACE-1 INHIBITORS  |   BACE, ASPARTIC PROTEASE, HYDROLYSIS, HYDROLASE-HYDROLASE INHIBITOR COMPLEX 
4i0f:A   (GLY391) to   (VAL417)  DESIGN AND SYNTHESIS OF THIOPHENE DIHYDROISOQUINOLINS AS NOVEL BACE-1 INHIBITORS  |   BACE, ASPARTIC PROTEASE, HYDROLYSIS, HYDROLASE-HYDROLASE INHIBITOR COMPLEX 
4i0g:A   (GLY391) to   (VAL417)  DESIGN AND SYNTHESIS OF THIOPHENE DIHYDROISOQUINOLINS AS NOVEL BACE-1 INHIBITORS  |   BACE, ASPARTIC PROTEASE, HYDROLYSIS, HYDROLASE-HYDROLASE INHIBITOR COMPLEX 
3sfc:A   (THR298) to   (LEU324)  STRUCTURE-BASED OPTIMIZATION OF POTENT 4- AND 6-AZAINDOLE-3- CARBOXAMIDES AS RENIN INHIBITORS  |   RENIN HUMAN, ASPARTYL PROTEASE, RENIN INHIBITION, HYPERTENSION, BETA BARREL, PEPSIN-LIKE PROTEASE, GLYCOSYLATION, EXTRACELLULAR SPACE, HYDROLASE-HYDROLASE INHIBITOR COMPLEX 
3sfc:B   (THR298) to   (LEU324)  STRUCTURE-BASED OPTIMIZATION OF POTENT 4- AND 6-AZAINDOLE-3- CARBOXAMIDES AS RENIN INHIBITORS  |   RENIN HUMAN, ASPARTYL PROTEASE, RENIN INHIBITION, HYPERTENSION, BETA BARREL, PEPSIN-LIKE PROTEASE, GLYCOSYLATION, EXTRACELLULAR SPACE, HYDROLASE-HYDROLASE INHIBITOR COMPLEX 
3fkt:A   (GLY350) to   (VAL376)  CRYSTAL STRUCTURE OF HUMAN BETA SECRETASE COMPLEXED WITH SPIROPIPERDINE IMINOHYDANTOIN INHIBITOR  |   ASPARTYL PROTEASE, BACE, ALTERNATIVE SPLICING, GLYCOPROTEIN, HYDROLASE, MEMBRANE, POLYMORPHISM, PROTEASE, TRANSMEMBRANE, ZYMOGEN 
3skf:A   (GLY330) to   (VAL356)  CRYSTAL STRUCTURE OF BETA-SITE APP-CLEAVING ENZYME 1 (BACE-WT) COMPLEX WITH (2S)-2-((3S)-3-(ACETYLAMINO)-3-(BUTAN-2-YL)-2-OXOPYRROLIDIN-1- YL)-N-((2S,3R)-3-HYDROXY-4-((3-METHOXYBENZYL)AMINO)-1-PHENYLBUTAN-2- YL)-4-PHENYLBUTANAMIDE  |   ALZHEIMER'S DISEASE, BACE, HYDROLASE-HYDROLASE INHIBITOR COMPLEX 
3skf:B   (GLY330) to   (VAL356)  CRYSTAL STRUCTURE OF BETA-SITE APP-CLEAVING ENZYME 1 (BACE-WT) COMPLEX WITH (2S)-2-((3S)-3-(ACETYLAMINO)-3-(BUTAN-2-YL)-2-OXOPYRROLIDIN-1- YL)-N-((2S,3R)-3-HYDROXY-4-((3-METHOXYBENZYL)AMINO)-1-PHENYLBUTAN-2- YL)-4-PHENYLBUTANAMIDE  |   ALZHEIMER'S DISEASE, BACE, HYDROLASE-HYDROLASE INHIBITOR COMPLEX 
3skg:D   (GLY330) to   (VAL356)  CRYSTAL STRUCTURE OF BETA-SITE APP-CLEAVING ENZYME 1 (BACE-WT) COMPLEX WITH (2S)-2-((3R)-3-ACETAMIDO-3-ISOBUTYL-2-OXO-1-PYRROLIDINYL)-N- ((1S,2R)-1-(3,5-DIFLUOROBENZYL)-2-HYDROXY-2-(1,2,3,4-TETRAHYDRO-3- ISOQUINOLINYL)ETHYL)-4-PHENYLBUTANAMIDE  |   ALZHEIMER'S DISEASE, BACE, HYDROLASE-HYDROLASE INHIBITOR COMPLEX 
3fns:A   (ASN297) to   (LEU324)  CRYSTAL STRUCTURE OF HISTO-ASPARTIC PROTEASE (HAP) FROM PLASMODIUM FALCIPARUM  |   HISTO-ASPARTIC PROTEASE, HAP, PLASMEPSIN, ASPARTIC PROTEASE, HORMONE, HYDROLASE 
3fns:B   (ASN297) to   (LEU324)  CRYSTAL STRUCTURE OF HISTO-ASPARTIC PROTEASE (HAP) FROM PLASMODIUM FALCIPARUM  |   HISTO-ASPARTIC PROTEASE, HAP, PLASMEPSIN, ASPARTIC PROTEASE, HORMONE, HYDROLASE 
3fnt:A   (ASN297) to   (LEU324)  CRYSTAL STRUCTURE OF PEPSTATIN A BOUND HISTO-ASPARTIC PROTEASE (HAP) FROM PLASMODIUM FALCIPARUM  |   HISTO-ASPARTIC PROTEASE, HAP, PLASMEPSIN, PEPSTATIN A, ASPARTIC PROTEASE, HYDROLASE-HYDROLASE INHIBITOR COMPLEX 
3fnu:A   (ASN297) to   (LEU324)  CRYSTAL STRUCTURE OF KNI-10006 BOUND HISTO-ASPARTIC PROTEASE (HAP) FROM PLASMODIUM FALCIPARUM  |   HISTO-ASPARTIC PROTEASE,HYDROLASE, PLASMEPSIN, ASPARTIC PROTEASE, KNI, KNI-10006, HYDROLASE-HYDROLASE INHIBITOR COMPLEX 
3fnu:B   (ASN297) to   (LEU324)  CRYSTAL STRUCTURE OF KNI-10006 BOUND HISTO-ASPARTIC PROTEASE (HAP) FROM PLASMODIUM FALCIPARUM  |   HISTO-ASPARTIC PROTEASE,HYDROLASE, PLASMEPSIN, ASPARTIC PROTEASE, KNI, KNI-10006, HYDROLASE-HYDROLASE INHIBITOR COMPLEX 
3fnu:C   (ASN297) to   (LEU324)  CRYSTAL STRUCTURE OF KNI-10006 BOUND HISTO-ASPARTIC PROTEASE (HAP) FROM PLASMODIUM FALCIPARUM  |   HISTO-ASPARTIC PROTEASE,HYDROLASE, PLASMEPSIN, ASPARTIC PROTEASE, KNI, KNI-10006, HYDROLASE-HYDROLASE INHIBITOR COMPLEX 
3fnu:D   (ASN297) to   (LEU324)  CRYSTAL STRUCTURE OF KNI-10006 BOUND HISTO-ASPARTIC PROTEASE (HAP) FROM PLASMODIUM FALCIPARUM  |   HISTO-ASPARTIC PROTEASE,HYDROLASE, PLASMEPSIN, ASPARTIC PROTEASE, KNI, KNI-10006, HYDROLASE-HYDROLASE INHIBITOR COMPLEX 
3slz:A    (TYR90) to   (GLY116)  THE CRYSTAL STRUCTURE OF XMRV PROTEASE COMPLEXED WITH TL-3  |   BETA SHEET AND DIMER, PROTEASE, PEPTIDE INHIBITOR, TL-3 PEPSTATINA, VIRUS, HYDROLASE-HYDROLASE INHIBITOR COMPLEX 
3slz:B    (TYR90) to   (GLY116)  THE CRYSTAL STRUCTURE OF XMRV PROTEASE COMPLEXED WITH TL-3  |   BETA SHEET AND DIMER, PROTEASE, PEPTIDE INHIBITOR, TL-3 PEPSTATINA, VIRUS, HYDROLASE-HYDROLASE INHIBITOR COMPLEX 
3sm2:B    (TYR90) to   (GLY116)  THE CRYSTAL STRUCTURE OF XMRV PROTEASE COMPLEXED WITH AMPRENAVIR  |   BETA-SHEET, PROTEASE, AMPRENAVIR, VIRUS, HYDROLASE-HYDROLASE INHIBITOR COMPLEX 
1cms:A   (LYS295) to   (LYS321)  THE THREE-DIMENSIONAL STRUCTURE OF RECOMBINANT BOVINE CHYMOSIN AT 2.3 ANGSTROMS RESOLUTION  |   HYDROLASE(ACID PROTEINASE) 
2q11:A   (GLY330) to   (VAL356)  STRUCTURE OF BACE COMPLEXED TO COMPOUND 1  |   BACE INHIBITOR COMPLEX, HYDROLASE 
2q11:B   (GLY330) to   (VAL356)  STRUCTURE OF BACE COMPLEXED TO COMPOUND 1  |   BACE INHIBITOR COMPLEX, HYDROLASE 
2q11:C   (GLY330) to   (VAL356)  STRUCTURE OF BACE COMPLEXED TO COMPOUND 1  |   BACE INHIBITOR COMPLEX, HYDROLASE 
1czi:E   (LYS298) to   (LYS324)  CHYMOSIN COMPLEX WITH THE INHIBITOR CP-113972  |   ACID PROTEINASE, ASPARTYL PROTEASE, HYDROLASE-HYDROLASE INHIBITOR COMPLEX 
3g6z:A   (THR312) to   (LEU338)  DESIGN AND PREPARATION OF POTENT, NON-PEPTIDIC, BIOAVAILABLE RENIN INHIBITORS  |   RENIN HUMAN, ASPARTYL PROTEASE, CLEAVAGE ON PAIR OF BASIC RESIDUES, DISEASE MUTATION, GLYCOPROTEIN, HYDROLASE, MEMBRANE, PROTEASE, SECRETED, ZYMOGEN 
3g6z:B   (THR312) to   (LEU338)  DESIGN AND PREPARATION OF POTENT, NON-PEPTIDIC, BIOAVAILABLE RENIN INHIBITORS  |   RENIN HUMAN, ASPARTYL PROTEASE, CLEAVAGE ON PAIR OF BASIC RESIDUES, DISEASE MUTATION, GLYCOPROTEIN, HYDROLASE, MEMBRANE, PROTEASE, SECRETED, ZYMOGEN 
3g72:A   (THR312) to   (LEU338)  DESIGN AND PREPARATION OF POTENT, NON-PEPTIDIC, BIOAVAILABLE RENIN INHIBITORS  |   RENIN HUMAN, ASPARTYL PROTEASE, CLEAVAGE ON PAIR OF BASIC RESIDUES, DISEASE MUTATION, GLYCOPROTEIN, HYDROLASE, MEMBRANE, PROTEASE, SECRETED, ZYMOGEN 
3g72:B   (THR312) to   (LEU338)  DESIGN AND PREPARATION OF POTENT, NON-PEPTIDIC, BIOAVAILABLE RENIN INHIBITORS  |   RENIN HUMAN, ASPARTYL PROTEASE, CLEAVAGE ON PAIR OF BASIC RESIDUES, DISEASE MUTATION, GLYCOPROTEIN, HYDROLASE, MEMBRANE, PROTEASE, SECRETED, ZYMOGEN 
2qk5:B   (GLY391) to   (VAL417)  STRUCTURE OF BACE1 BOUND TO SCH626485  |   BACE1, PROTEASE, ALTERNATIVE SPLICING, ASPARTYL PROTEASE, GLYCOPROTEIN, HYDROLASE, MEMBRANE, TRANSMEMBRANE, ZYMOGEN 
1pfz:A   (PRO297) to   (LEU324)  PROPLASMEPSIN II FROM PLASMODIUM FALCIPARUM  |   ASPARTIC PROTEINASE ZYMOGEN, HEMOGLOBINASE, MALARIA, HYDROLASE, ASPARTYL PROTEASE, GLYCOPROTEIN, ASPARTIC PROTEASE ZYMOGEN 
1pfz:B   (PRO297) to   (LEU324)  PROPLASMEPSIN II FROM PLASMODIUM FALCIPARUM  |   ASPARTIC PROTEINASE ZYMOGEN, HEMOGLOBINASE, MALARIA, HYDROLASE, ASPARTYL PROTEASE, GLYCOPROTEIN, ASPARTIC PROTEASE ZYMOGEN 
1pfz:C   (PRO297) to   (LEU324)  PROPLASMEPSIN II FROM PLASMODIUM FALCIPARUM  |   ASPARTIC PROTEINASE ZYMOGEN, HEMOGLOBINASE, MALARIA, HYDROLASE, ASPARTYL PROTEASE, GLYCOPROTEIN, ASPARTIC PROTEASE ZYMOGEN 
1pfz:D   (PRO297) to   (LEU324)  PROPLASMEPSIN II FROM PLASMODIUM FALCIPARUM  |   ASPARTIC PROTEINASE ZYMOGEN, HEMOGLOBINASE, MALARIA, HYDROLASE, ASPARTYL PROTEASE, GLYCOPROTEIN, ASPARTIC PROTEASE ZYMOGEN 
2qmg:A   (GLY391) to   (VAL417)  STRUCTURE OF BACE BOUND TO SCH745966  |   BACE1, PROTEASE, ALTERNATIVE SPLICING, ASPARTYL PROTEASE, GLYCOPROTEIN, HYDROLASE, MEMBRANE, TRANSMEMBRANE, ZYMOGEN 
1dp5:A   (PRO297) to   (LYS324)  THE STRUCTURE OF PROTEINASE A COMPLEXED WITH A IA3 MUTANT INHIBITOR  |   PROTEINASE A, MMM, IA3 MUTANT, HYDROLASE-HYDROLASE INHIBITOR COMPLEX 
1dpj:A   (PRO297) to   (LYS324)  THE STRUCTURE OF PROTEINASE A COMPLEXED WITH IA3 PEPTIDE INHIBITOR  |   PROTEINASE A, IA3 PEPTIDE, HYDROLASE-HYDROLASE INHIBITOR COMPLEX 
4xx3:A   (THR378) to   (LEU404)  RENIN IN COMPLEX WITH (S)-1-(3-(BENZYLCARBAMOYL)BENZYL)-4-ISOPROPYL-4- METHYL-6-OXOTETRAHYDROPYRIMIDIN-2(1H)-IMINIUM  |   ANIMALS, ANTIHYPERTENSIVE AGENTS, BLOOD PRESSURE, DRUG DESIGN, ENZYME INHIBITORS, MODELS, MOLECULAR, PROTEIN CONFORMATION, RATS, RENIN, STRUCTURE-ACTIVITY RELATIONSHIP, HYDROLASE-HYDROLASE INHIBITOR COMPLEX 
4xx3:B   (THR378) to   (LEU404)  RENIN IN COMPLEX WITH (S)-1-(3-(BENZYLCARBAMOYL)BENZYL)-4-ISOPROPYL-4- METHYL-6-OXOTETRAHYDROPYRIMIDIN-2(1H)-IMINIUM  |   ANIMALS, ANTIHYPERTENSIVE AGENTS, BLOOD PRESSURE, DRUG DESIGN, ENZYME INHIBITORS, MODELS, MOLECULAR, PROTEIN CONFORMATION, RATS, RENIN, STRUCTURE-ACTIVITY RELATIONSHIP, HYDROLASE-HYDROLASE INHIBITOR COMPLEX 
4xx4:A   (THR378) to   (LEU404)  RENIN IN COMPLEX WITH (4S)-4-ISOPROPYL-4-METHYL-6-OXO-1-(3-(2-OXO-4- PHENYLPYRROLIDIN-1-YL)BENZYL)TETRAHYDROPYRIMIDIN-2(1H)-IMINIUM  |   ANIMALS, ANTIHYPERTENSIVE AGENTS, BLOOD PRESSURE, DRUG DESIGN, ENZYME INHIBITORS, MODELS, MOLECULAR, PROTEIN CONFORMATION, RENIN, STRUCTURE-ACTIVITY RELATIONSHIP, HYDROLASE-HYDROLASE INHIBITOR COMPLEX 
4xx4:B   (THR378) to   (LEU404)  RENIN IN COMPLEX WITH (4S)-4-ISOPROPYL-4-METHYL-6-OXO-1-(3-(2-OXO-4- PHENYLPYRROLIDIN-1-YL)BENZYL)TETRAHYDROPYRIMIDIN-2(1H)-IMINIUM  |   ANIMALS, ANTIHYPERTENSIVE AGENTS, BLOOD PRESSURE, DRUG DESIGN, ENZYME INHIBITORS, MODELS, MOLECULAR, PROTEIN CONFORMATION, RENIN, STRUCTURE-ACTIVITY RELATIONSHIP, HYDROLASE-HYDROLASE INHIBITOR COMPLEX 
1ppk:E   (PHE295) to   (PRO321)  CRYSTALLOGRAPHIC ANALYSIS OF TRANSITION STATE MIMICS BOUND TO PENICILLOPEPSIN: PHOSPHOROUS-CONTAINING PEPTIDE ANALOGUES  |   ACID PROTEINASE, HYDROLASE-HYDROLASE INHIBITOR COMPLEX 
1ppl:E   (PHE295) to   (PRO321)  CRYSTALLOGRAPHIC ANALYSIS OF TRANSITION-STATE MIMICS BOUND TO PENICILLOPEPSIN: PHOSPHORUS-CONTAINING PEPTIDE ANALOGUES  |   ACID PROTEINASE, HYDROLASE-HYDROLASE INHIBITOR COMPLEX 
1ppm:E   (PHE295) to   (PRO321)  CRYSTALLOGRAPHIC ANALYSIS OF TRANSITION-STATE MIMICS BOUND TO PENICILLOPEPSIN: PHOSPHORUS-CONTAINING PEPTIDE ANALOGUES  |   ACID PROTEINASE, HYDROLASE-HYDROLASE INHIBITOR COMPLEX 
3t7p:A   (ILE302) to   (SER329)  ENDOTHIAPEPSIN IN COMPLEX WITH A HYDRAZIDE DERIVATIVE  |   HYDROLASE-HYDROLASE INHIBITOR COMPLEX 
3t7q:A   (ILE302) to   (SER329)  ENDOTHIAPEPSIN IN COMPLEX WITH AN INHIBITOR BASED ON THE GEWALD REACTION  |   HYDROLASE-HYDROLASE INHIBITOR COMPLEX 
3t7x:A   (ILE302) to   (SER329)  ENDOTHIAPEPSIN IN COMPLEX WITH AN INHIBITOR BASED ON THE GEWALD REACTION  |   HYDROLASE-HYDROLASE INHIBITOR COMPLEX 
1psa:A   (GLU297) to   (PRO324)  STRUCTURE OF A PEPSIN(SLASH)RENIN INHIBITOR COMPLEX REVEALS A NOVEL CRYSTAL PACKING INDUCED BY MINOR CHEMICAL ALTERATIONS IN THE INHIBITOR  |   ACID PROTEINASE, HYDROLASE-HYDROLASE INHIBITOR COMPLEX 
1psa:B   (GLU297) to   (PRO324)  STRUCTURE OF A PEPSIN(SLASH)RENIN INHIBITOR COMPLEX REVEALS A NOVEL CRYSTAL PACKING INDUCED BY MINOR CHEMICAL ALTERATIONS IN THE INHIBITOR  |   ACID PROTEINASE, HYDROLASE-HYDROLASE INHIBITOR COMPLEX 
1psn:A   (GLU297) to   (PRO324)  THE CRYSTAL STRUCTURE OF HUMAN PEPSIN AND ITS COMPLEX WITH PEPSTATIN  |   HYDROLASE (ACID PROTEINASE) 
1pso:E   (GLU297) to   (PRO324)  THE CRYSTAL STRUCTURE OF HUMAN PEPSIN AND ITS COMPLEX WITH PEPSTATIN  |   ACID PROTEINASE, HYDROLASE-HYDROLASE INHIBITOR COMPLEX 
4y36:A   (ILE302) to   (SER329)  ENDOTHIAPEPSIN IN COMPLEX WITH FRAGMENT 4  |   FRAGMENT SCREENING, ASPARTIC PROTEASE, INHIBITION, HYDROLASE 
4j0p:A   (GLY391) to   (VAL417)  CRYSTAL STRUCTURE OF BACE-1 IN COMPLEX WITH 5-CYANO-PYRIDINE-2- CARBOXYLIC ACID [3-((S)-2-AMINO-4-METHYL-5,6-DIHYDRO-4H-[1,3]OXAZIN- 4-YL)-4-FLUORO-PHENYL]-AMIDE  |   PROTEASE INHIBITOR, HYDROLASE-HYDROLASE INHIBITOR COMPLEX 
4j0t:A   (GLY391) to   (VAL417)  CRYSTAL STRUCTURE OF BACE-1 IN COMPLEX WITH 5-ETHOXY-PYRIDINE-2- CARBOXYLIC ACID [3-((R)-2-AMINO-5,5-DIFLUORO-4-METHYL-5,6-DIHYDRO-4H- [1,3]OXAZIN-4-YL)-4-FLUORO-PHENYL]-AMIDE  |   POTEASE INHIBITOR, HYDROLASE-HYDROLASE INHIBITOR COMPLEX 
4y35:A   (ILE302) to   (SER329)  ENDOTHIAPEPSIN IN COMPLEX WITH FRAGMENT 290  |   FAGMENT SCREENING, HYDROLASE, INHIBITION 
4y38:A   (ILE302) to   (SER329)  ENDOTHIAPEPSIN IN COMPLEX WITH FRAGMENT B29  |   FRAGMENT SCREENING, ASPARTIC PROTEASE INHIBITION, HYDROLASE 
4y3a:A   (ILE302) to   (SER329)  ENDOTHIAPEPSIN IN COMPLEX WITH FRAGMENT 181  |   FRAGMENT SCREENING, ASPARTIC PROTEASE, INHIBITION, HYDROLASE 
4y3e:A   (ILE302) to   (SER329)  ENDOTHIAPEPSIN IN COMPLEX WITH FRAGMENT 5  |   FRAGMENT SCREENING, HYDROLASE, INHIBITION 
4j1c:A   (GLY391) to   (VAL417)  CRYSTAL STRUCTURE OF BACE-1 IN COMPLEX WITH 5-CYANO-PYRIDINE-2- CARBOXYLIC ACID [3-((S)-2-AMINO-5,5-DIFLUORO-4-FLUOROMETHYL-5,6- DIHYDRO-4H-[1,3]OXAZIN-4-YL)-4-FLUORO-PHENYL]-AMIDE  |   PROTEASE INHIBITOR, HYDROLASE-HYDROLASE INHIBITOR COMPLEX 
4j1e:A   (GLY391) to   (VAL417)  CRYSTAL STRUCTURE OF BACE-1 IN COMPLEX WITH 5-CYANO-PYRIDINE-2- CARBOXYLIC ACID [3-((4S,6S)-2-AMINO-4-FLUOROMETHYL-6-TRIFLUOROMETHYL- 5,6-DIHYDRO-4H-[1,3]OXAZIN-4-YL)-4-FLUORO-PHENYL]-AMIDE  |   PROTEASE INHIBITOR, HYDROLASE-HYDROLASE INHIBITOR COMPLEX 
4y3h:A   (ILE302) to   (SER329)  ENDOTHIAPEPSIN IN COMPLEX WITH FRAGMENT 189  |   FRAGMENT SCREENING, HYDROLASE, INHIBITION 
4y3j:A   (ILE302) to   (SER329)  ENDOTHIAPEPSIN IN COMPLEX WITH FRAGMENT B30  |   FRAGMENT SCREENING, ASPARTIC PROTEASE INHIBITION, HYDROLASE 
4j1h:A   (GLY391) to   (VAL417)  CRYSTAL STRUCTURE OF BACE-1 IN COMPLEX WITH 5-CYANO-PYRIDINE-2- CARBOXYLIC ACID [3-((4S,6R)-2-AMINO-4-METHYL-6-TRIFLUOROMETHYL-5,6- DIHYDRO-4H-[1,3]OXAZIN-4-YL)-4-FLUORO-PHENYL]-AMIDE  |   PROTEASE INHIBITOR, HYDROLASE-HYDROLASE INHIBITOR COMPLEX 
4j1i:A   (GLY391) to   (VAL417)  CRYSTAL STRUCTURE OF BACE-1 IN COMPLEX WITH 5-CYANO-PYRIDINE-2- CARBOXYLIC ACID [3-((4R,5R,6R)-2-AMINO-5-FLUORO-4-METHYL-6- TRIFLUOROMETHYL-5,6-DIHYDRO-4H-[1,3]OXAZIN-4-YL)-4-FLUORO-PHENYL]- AMIDE  |   PROTEASE INHIBITOR, HYDROLASE-HYDROLASE INHIBITOR COMPLEX 
4y3l:A   (ILE302) to   (SER329)  ENDOTHIAPEPSIN IN COMPLEX WITH FRAGMENT 205  |   FRAGMENT SCREENING, HYDROLASE, INHIBITION 
4y3m:A   (ILE302) to   (SER329)  ENDOTHIAPEPSIN IN COMPLEX WITH FRAGMENT 103  |   FRAGMENT SCREENING, HYDROLASE, INHIBITION 
4j1k:A   (GLY391) to   (VAL417)  CRYSTAL STRUCTURE OF BACE-1 IN COMPLEX WITH 5-CYANO-PYRIDINE-2- CARBOXYLIC ACID [3-((4R,5R,6S)-2-AMINO-5-FLUORO-4-METHYL-6- TRIFLUOROMETHYL-5,6-DIHYDRO-4H-[1,3]OXAZIN-4-YL)-4-FLUORO-PHENYL]- AMIDE  |   PROTEASE INHIBITOR, HYDROLASE-HYDROLASE INHIBITOR COMPLEX 
4y3t:A   (ILE302) to   (SER329)  ENDOTHIAPEPSIN IN COMPLEX WITH FRAGMENT 207  |   FRAGMENT SCREENING, ASPARTIC PROTEASE, INHIBITION, HYDROLASE 
4y3p:A   (ILE302) to   (SER329)  ENDOTHIAPEPSIN IN COMPLEX WITH FRAGMENT 17  |   FRAGMENT SCREENING, ASPARTIC PROTEASE, INHIBITION, HYDROLASE 
4y3q:A   (ILE302) to   (SER329)  ENDOTHIAPEPSIN IN COMPLEX WITH FRAGMENT 109  |   FRAGMENT SCREENING, ASPARTIC PROTEASE, INHIBITION, HYDROLASE 
4y3r:A   (ILE302) to   (SER329)  ENDOTHIAPEPSIN IN COMPLEX WITH FRAGMENT 306  |   FRAGMENT SCREENING, ASPARTIC PROTEASE, INHIBITION, HYDROLASE 
4y3s:A   (ILE302) to   (SER329)  ENDOTHIAPEPSIN IN COMPLEX WITH FRAGMENT 266  |   FRAGMENT SCREENING, HYDROLASE, INHIBITION 
4y3w:A   (ILE302) to   (SER329)  ENDOTHIAPEPSIN IN COMPLEX WITH FRAGMENT 35  |   FRAGMENT SCREENING, ASPARTIC PROTEASE, INHIBITION, HYDROLASE 
4y3x:A   (ILE302) to   (SER329)  ENDOTHIAPEPSIN IN COMPLEX WITH FRAGMENT 171  |   FRAGMENT SCREENING, HYDROLASE, INHIBITION 
4y3y:A   (ILE302) to   (SER329)  ENDOTHIAPEPSIN IN COMPLEX WITH FRAGMENT B42  |   FRAGMENT SCREENING, ASPARTIC PROTEASE INHIBITION, HYDROLASE 
4y43:A   (ILE302) to   (SER329)  ENDOTHIAPEPSIN IN COMPLEX WITH FRAGMENT 42  |   FRAGMENT SCREENING, HYDROLASE, INHIBITION 
4y44:A   (ILE302) to   (SER329)  ENDOTHIAPEPSIN IN COMPLEX WITH FRAGMENT 164  |   FRAGMENT SCREENING, HYDROLASE, INHIBITION 
4y48:A   (ILE302) to   (SER329)  ENDOTHIAPEPSIN IN COMPLEX WITH FRAGMENT B50  |   FRAGMENT SCREENING, HYDROLASE, INHIBITION 
2qzx:A   (ASP303) to   (PRO329)  SECRETED ASPARTIC PROTEINASE (SAP) 5 FROM CANDIDA ALBICANS  |   ASPARTIC PROTEINASE, CANDIDA ALBICANS, ASPARTYL PROTEASE, CLEAVAGE ON PAIR OF BASIC RESIDUES, GLYCOPROTEIN, PROTEASE, SECRETED, ZYMOGEN, HYDROLASE-HYDROLASE INHIBITOR COMPLEX 
4y4a:A   (ILE302) to   (SER329)  ENDOTHIAPEPSIN IN COMPLEX WITH FRAGMENT 286  |   FRAGMENT SCREENING, HYDROLASE, INHIBITION 
4y4c:A   (ILE302) to   (SER329)  ENDOTHIAPEPSIN IN COMPLEX WITH FRAGMENT 158  |   FRAGMENT SCREENING, HYDROLASE, INHIBITION 
4y4d:A   (ILE302) to   (SER329)  ENDOTHIAPEPSIN IN COMPLEX WITH FRAGMENT B51  |   FRAGMENT SCREENING, ASPARTIC PROTEASE INHIBITION, HYDROLASE 
4y4j:A   (ILE302) to   (SER329)  ENDOTHIAPEPSIN IN COMPLEX WITH FRAGMENT B97  |   FRAGMENT SCREENING, ASPARTIC PROTEASE INHIBITION, HYDROLASE 
4y4t:A   (ILE302) to   (SER329)  ENDOTHIAPEPSIN IN COMPLEX WITH FRAGMENT 114  |   FRAGMENT SCREENING, HYDROLASE, INHIBITION 
4y4w:A   (ILE302) to   (SER329)  ENDOTHIAPEPSIN IN COMPLEX WITH FRAGMENT 125  |   FRAGMENT SCREENING, HYDROLASE, INHIBITION 
4y4z:A   (ILE302) to   (SER329)  ENDOTHIAPEPSIN IN COMPLEX WITH FRAGMENT 73  |   FRAGMENT SCREENING, HYDROLASE, INHIBITION 
4y51:A   (ILE302) to   (SER329)  ENDOTHIAPEPSIN IN COMPLEX WITH FRAGMENT 52  |   FRAGMENT SCREENING, HYDROLASE, INHIBITION 
4y53:A   (ILE302) to   (SER329)  ENDOTHIAPEPSIN IN COMPLEX WITH FRAGMENT 54  |   FRAGMENT SCREENING, HYDROLASE, INHIBITION 
4y56:A   (ILE302) to   (SER329)  ENDOTHIAPEPSIN IN COMPLEX WITH FRAGMENT 58  |   FRAGMENT SCREENING, HYDROLASE, INHIBITION 
4y57:A   (ILE302) to   (SER329)  ENDOTHIAPEPSIN IN COMPLEX WITH FRAGMENT 63  |   FRAGMENT SCREENING, HYDROLASE, INHIBITION 
4y5a:A   (ILE302) to   (SER329)  ENDOTHIAPEPSIN IN COMPLEX WITH FRAGMENT 206  |   FRAGMENT SCREENING, ASPARTIC PROTEASE, INHIBITION, HYDROLASE 
4y5b:A   (ILE302) to   (SER329)  ENDOTHIAPEPSIN IN COMPLEX WITH FRAGMENT 261  |   FRAGMENT SCREENING, ASPARTIC PROTEASE, INHIBITION, HYDROLASE 
4y5c:A   (ILE302) to   (SER329)  ENDOTHIAPEPSIN IN COMPLEX WITH FRAGMENT 267  |   FRAGMENT SCREENING, HYDROLASE, INHIBITION 
4y5e:A   (ILE302) to   (SER329)  ENDOTHIAPEPSIN IN COMPLEX WITH FRAGMENT 268  |   FRAGMENT SCREENING, ASPARTIC PROTEASE, INHIBITION, HYDROLASE 
4y5l:A   (ILE302) to   (SER329)  ENDOTHIAPEPSIN IN ITS APO FORM  |   FRAGMENT SCREENING, HYDROLASE, INHIBITION 
4y5k:A   (ILE302) to   (SER329)  ENDOTHIAPEPSIN IN COMPLEX WITH FRAGMENT 274  |   FRAGMENT SCREENING, ASPARTIC PROTEASE, INHIBITION, HYDROLASE 
4y5m:A   (ILE302) to   (SER329)  ENDOTHIAPEPSIN IN COMPLEX WITH FRAGMENT 328  |   FRAGMENT SCREENING, HYDROLASE, INHIBITION 
4y5n:A   (ILE302) to   (SER329)  ENDOTHIAPEPSIN IN COMPLEX WITH FRAGMENT 337  |   FRAGMENT SCREENING, HYDROLASE, INHIBITION 
4y5p:A   (ILE302) to   (SER329)  ENDOTHIAPEPSIN IN COMPLEX WITH FRAGMENT 338  |   FRAGMENT SCREENING, HYDROLASE, INHIBITION 
1e5o:E   (ILE299) to   (SER325)  ENDOTHIAPEPSIN COMPLEX WITH INHIBITOR DB2  |   HYDROLASE, ACID PROTEINASE, HYDROLASE-HYDROLASE INHIBITOR COMPLEX 
4y6m:A   (PRO297) to   (LEU324)  STRUCTURE OF PLASMEPSIN II FROM PLASMODIUM FALCIPARUM COMPLEXED WITH INHIBITOR PG418  |   PLASMEPSIN II HYDROXYETHYLAMINE-BASD INHIBITOR, HYDROLASE 
4y6m:B   (THR298) to   (LEU324)  STRUCTURE OF PLASMEPSIN II FROM PLASMODIUM FALCIPARUM COMPLEXED WITH INHIBITOR PG418  |   PLASMEPSIN II HYDROXYETHYLAMINE-BASD INHIBITOR, HYDROLASE 
4y6m:C   (PRO297) to   (LEU324)  STRUCTURE OF PLASMEPSIN II FROM PLASMODIUM FALCIPARUM COMPLEXED WITH INHIBITOR PG418  |   PLASMEPSIN II HYDROXYETHYLAMINE-BASD INHIBITOR, HYDROLASE 
1e80:E   (ILE299) to   (SER325)  ENDOTHIAPEPSIN COMPLEX WITH RENIN INHIBITOR MERCK-KGAA-EMD56133  |   HYDROLASE-HYDROLASE INHIBITOR COMPLEX, ACID PROTEINASE 
1e82:E   (ILE299) to   (SER325)  ENDOTHIAPEPSIN COMPLEX WITH RENIN INHIBITOR MERCK-KGAA-EMD59601  |   ACID PROTEINASE, HYDROLASE-HYDROLASE INHIBITOR COMPLEX 
3gw5:A   (THR312) to   (LEU338)  CRYSTAL STRUCTURE OF HUMAN RENIN COMPLEXED WITH A NOVEL INHIBITOR  |   RENIN, ASPARTATE PROTEASE, HYPERTENSION, RENIN EXPRESSION, RENIN INHIBITOR, ASPARTYL PROTEASE, CLEAVAGE ON PAIR OF BASIC RESIDUES, DISEASE MUTATION, DISULFIDE BOND, GLYCOPROTEIN, HYDROLASE, MEMBRANE, PROTEASE, SECRETED, ZYMOGEN, HYDROLASE-HYDROLASE INHIBITOR COMPLEX 
3gw5:B   (THR312) to   (LEU338)  CRYSTAL STRUCTURE OF HUMAN RENIN COMPLEXED WITH A NOVEL INHIBITOR  |   RENIN, ASPARTATE PROTEASE, HYPERTENSION, RENIN EXPRESSION, RENIN INHIBITOR, ASPARTYL PROTEASE, CLEAVAGE ON PAIR OF BASIC RESIDUES, DISEASE MUTATION, DISULFIDE BOND, GLYCOPROTEIN, HYDROLASE, MEMBRANE, PROTEASE, SECRETED, ZYMOGEN, HYDROLASE-HYDROLASE INHIBITOR COMPLEX 
2r9b:A   (PRO297) to   (LEU324)  STRUCTURAL ANALYSIS OF PLASMEPSIN 2 FROM PLASMODIUM FALCIPARUM COMPLEXED WITH A PEPTIDE-BASED INHIBITOR  |   BETA FOLD ASPARTYL PROTEASE, GLYCOPROTEIN, VACUOLE, ZYMOGEN, HYDROLASE-HYDROLASE INHIBITOR COMPLEX 
2r9b:B   (PRO297) to   (LEU324)  STRUCTURAL ANALYSIS OF PLASMEPSIN 2 FROM PLASMODIUM FALCIPARUM COMPLEXED WITH A PEPTIDE-BASED INHIBITOR  |   BETA FOLD ASPARTYL PROTEASE, GLYCOPROTEIN, VACUOLE, ZYMOGEN, HYDROLASE-HYDROLASE INHIBITOR COMPLEX 
3tne:A   (ASP301) to   (GLN327)  THE CRYSTAL STRUCTURE OF PROTEASE SAPP1P FROM CANDIDA PARAPSILOSIS IN COMPLEX WITH THE HIV PROTEASE INHIBITOR RITONAVIR  |   ASPARTIC ACID ENDOPEPTIDASES, CATALYTIC DOMAIN, RITONAVIR, HYDROLASE- HYDROLASE INHIBITOR COMPLEX 
3tne:B   (ASP301) to   (GLN327)  THE CRYSTAL STRUCTURE OF PROTEASE SAPP1P FROM CANDIDA PARAPSILOSIS IN COMPLEX WITH THE HIV PROTEASE INHIBITOR RITONAVIR  |   ASPARTIC ACID ENDOPEPTIDASES, CATALYTIC DOMAIN, RITONAVIR, HYDROLASE- HYDROLASE INHIBITOR COMPLEX 
4ya8:A   (PRO297) to   (LEU324)  STRUCTURE OF PLASMEPSIN II FROM PLASMODIUM FALCIPARUM COMPLEXED WITH INHIBITOR PG394  |   PLASMEPSIN II, MALARIA, INHIBITOR, HYDROLASE 
4ya8:B   (PRO297) to   (LEU324)  STRUCTURE OF PLASMEPSIN II FROM PLASMODIUM FALCIPARUM COMPLEXED WITH INHIBITOR PG394  |   PLASMEPSIN II, MALARIA, INHIBITOR, HYDROLASE 
4ya8:C   (THR298) to   (LEU324)  STRUCTURE OF PLASMEPSIN II FROM PLASMODIUM FALCIPARUM COMPLEXED WITH INHIBITOR PG394  |   PLASMEPSIN II, MALARIA, INHIBITOR, HYDROLASE 
4ya8:D   (PRO297) to   (LEU324)  STRUCTURE OF PLASMEPSIN II FROM PLASMODIUM FALCIPARUM COMPLEXED WITH INHIBITOR PG394  |   PLASMEPSIN II, MALARIA, INHIBITOR, HYDROLASE 
3tpj:A   (GLY330) to   (VAL356)  APO STRUCTURE OF BACE1  |   HYDROLASE, PROTEASE, MEMAPSIN 2, BACE1 
3tpl:B   (GLY330) to   (VAL356)  APO STRUCTURE OF BACE1  |   HYDROLASE, MEMAPSIN 2, PROTEASE, BETA-SECRETASE 1 
3tpp:A   (GLY330) to   (VAL356)  CRYSTAL STRUCTURE OF BACE1 COMPLEXED WITH AN INHIBITOR  |   MEMAPSIN 2, PROTEASE, BACE1, HYDROLASE-HYDROLASE INHIBITOR COMPLEX 
4yck:A   (ILE302) to   (SER329)  ENDOTHIAPEPSIN IN COMPLEX WITH FRAGMENT 211  |   FRAGMENT SCREENING, HYDROLASE, INHIBITION 
3tpr:A   (GLY330) to   (VAL356)  CRYSTAL STRUCTURE OF BACE1 COMPLEXED WITH AN INHIBITOR  |   MEMAPSIN 2, PROTEASE, BETA-SECRETASE 1, HYDROLASE-HYDROLASE INHIBITOR COMPLEX 
1qdm:A   (PRO309) to   (LYS336)  CRYSTAL STRUCTURE OF PROPHYTEPSIN, A ZYMOGEN OF A BARLEY VACUOLAR ASPARTIC PROTEINASE.  |   ASPARTIC PROTEINASES, PHYTEPSIN, SAPOSIN-LIKE DOMAIN, ZYMOGEN STRUCTURE, HYDROLASE 
1qdm:B   (PRO309) to   (LYS336)  CRYSTAL STRUCTURE OF PROPHYTEPSIN, A ZYMOGEN OF A BARLEY VACUOLAR ASPARTIC PROTEINASE.  |   ASPARTIC PROTEINASES, PHYTEPSIN, SAPOSIN-LIKE DOMAIN, ZYMOGEN STRUCTURE, HYDROLASE 
1qdm:C   (PRO309) to   (LYS336)  CRYSTAL STRUCTURE OF PROPHYTEPSIN, A ZYMOGEN OF A BARLEY VACUOLAR ASPARTIC PROTEINASE.  |   ASPARTIC PROTEINASES, PHYTEPSIN, SAPOSIN-LIKE DOMAIN, ZYMOGEN STRUCTURE, HYDROLASE 
4yct:A   (ILE302) to   (SER329)  ENDOTHIAPEPSIN IN COMPLEX WITH FRAGMENT 216  |   FRAGMENT SCREENING, HYDROLASE, INHIBITION 
4yd3:A   (ILE302) to   (SER329)  ENDOTHIAPEPSIN IN COMPLEX WITH FRAGMENT 224  |   FRAGMENT SCREENING, HYDROLASE, INHIBITION 
4yd5:A   (ILE302) to   (SER329)  ENDOTHIAPEPSIN IN COMPLEX WITH FRAGMENT 236  |   FRAGMENT SCREENING, HYDROLASE, INHIBITION 
4yd6:A   (ILE302) to   (SER329)  ENDOTHIAPEPSIN IN COMPLEX WITH FRAGMENT 240  |   FRAGMENT SCREENING, HYDROLASE, INHIBITION 
2ren:A   (THR312) to   (LEU338)  STRUCTURE OF RECOMBINANT HUMAN RENIN, A TARGET FOR CARDIOVASCULAR- ACTIVE DRUGS, AT 2.5 ANGSTROMS RESOLUTION  |   HYDROLASE(ACID PROTEINASE) 
1ent:E   (ILE299) to   (SER325)  X-RAY ANALYSES OF ASPARTIC PROTEINASES. THE THREE-DIMENSIONAL STRUCTURE AT 2.1 ANGSTROMS RESOLUTION OF ENDOTHIAPEPSIN  |   ACID PROTEINASE, HYDROLASE-HYDROLASE INHIBITOR COMPLEX 
1epo:E   (ILE299) to   (SER325)  ENDOTHIA ASPARTIC PROTEINASE (ENDOTHIAPEPSIN) COMPLEXED WITH CP-81,282 (MOR PHE NLE CHF NME)  |   ACID PROTEINASE, HYDROLASE-HYDROLASE INHIBITOR COMPLEX 
1epp:E   (ILE299) to   (SER325)  ENDOTHIA ASPARTIC PROTEINASE (ENDOTHIAPEPSIN) COMPLEXED WITH PD-130, 693 (MAS PHE LYS+MTF STA MBA)  |   HYDROLASE-HYDROLASE INHIBITOR COMPLEX, ACID PROTEINASE 
1qrp:E   (GLU297) to   (PRO324)  HUMAN PEPSIN 3A IN COMPLEX WITH A PHOSPHONATE INHIBITOR IVA-VAL-VAL- LEU(P)-(O)PHE-ALA-ALA-OME  |   ASPARTIC PROTEINASE, PHOSPHONATE INHIBITOR, TRANSITION STATE ANALOGUE, HYDROLASE-HYDROLASE INHIBITOR COMPLEX 
1qs8:A   (ASN297) to   (ILE324)  CRYSTAL STRUCTURE OF THE P. VIVAX ASPARTIC PROTEINASE PLASMEPSIN COMPLEXED WITH THE INHIBITOR PEPSTATIN A  |   PLASMEPSIN, ASPARTIC PROTEINASE, HAEMOGLOBINASE, MALARIA, PEPSTATIN A, HYDROLASE-HYDROLASE INHIBITOR COMPLEX 
1qs8:B   (ASN297) to   (ILE324)  CRYSTAL STRUCTURE OF THE P. VIVAX ASPARTIC PROTEINASE PLASMEPSIN COMPLEXED WITH THE INHIBITOR PEPSTATIN A  |   PLASMEPSIN, ASPARTIC PROTEINASE, HAEMOGLOBINASE, MALARIA, PEPSTATIN A, HYDROLASE-HYDROLASE INHIBITOR COMPLEX 
1f34:A   (GLU297) to   (PRO324)  CRYSTAL STRUCTURE OF ASCARIS PEPSIN INHIBITOR-3 BOUND TO PORCINE PEPSIN  |   PROTEINASE-INHIBITOR COMPLEX, HYDROLASE/HYDROLASE INHIBITOR COMPLEX 
3u6a:A   (GLY330) to   (VAL356)  RATIONAL DESIGN AND SYNTHESIS OF AMINOPIPERAZINONES AS BETA SECRETASE (BACE) INHIBITORS  |   BETA-SITE APP CLEAVING ENZYME 1, HYDROLASE-HYDROLASE INHIBITOR COMPLEX 
3u6a:B   (GLY330) to   (VAL356)  RATIONAL DESIGN AND SYNTHESIS OF AMINOPIPERAZINONES AS BETA SECRETASE (BACE) INHIBITORS  |   BETA-SITE APP CLEAVING ENZYME 1, HYDROLASE-HYDROLASE INHIBITOR COMPLEX 
3u6a:C   (GLY330) to   (VAL356)  RATIONAL DESIGN AND SYNTHESIS OF AMINOPIPERAZINONES AS BETA SECRETASE (BACE) INHIBITORS  |   BETA-SITE APP CLEAVING ENZYME 1, HYDROLASE-HYDROLASE INHIBITOR COMPLEX 
2v00:A   (ILE302) to   (SER329)  X-RAY CRYSTAL STRUCTURE OF ENDOTHIAPEPSIN COMPLEXED WITH COMPOUND 1  |   FRAGMENT HIT, B- SECRETASE, ENDOTHIAPEPSIN, BACE, ZYMOGEN, PROTEASE, HYDROLASE, ISOCYTOSINE, ALZHEIMER'S DISEASE, FRAGMENT-BASED LEAD GENERATION, ASPARTYL PROTEASE, SURROGATE PROTEIN 
2v10:C   (THR312) to   (LEU338)  CRYSTAL STRUCTURE OF RENIN WITH INHIBITOR 9  |   GLYCOPROTEIN, INHIBITOR-COMPLEX, ASPARTYL PROTEASE, ZYMOGEN, PROTEASE, HYDROLASE, POLYMORPHISM, ALTERNATIVE SPLICING, HYDROLASE(ACID PROTEINASE), CLEAVAGE ON PAIR OF BASIC RESIDUES 
2v10:O   (THR312) to   (LEU338)  CRYSTAL STRUCTURE OF RENIN WITH INHIBITOR 9  |   GLYCOPROTEIN, INHIBITOR-COMPLEX, ASPARTYL PROTEASE, ZYMOGEN, PROTEASE, HYDROLASE, POLYMORPHISM, ALTERNATIVE SPLICING, HYDROLASE(ACID PROTEINASE), CLEAVAGE ON PAIR OF BASIC RESIDUES 
2v11:C   (THR312) to   (LEU338)  CRYSTAL STRUCTURE OF RENIN WITH INHIBITOR 6  |   GLYCOPROTEIN, INHIBITOR-COMPLEX, ASPARTYL PROTEASE, ZYMOGEN, PROTEASE, HYDROLASE, POLYMORPHISM, ALTERNATIVE SPLICING, HYDROLASE(ACID PROTEINASE), CLEAVAGE ON PAIR OF BASIC RESIDUES 
2v11:O   (THR312) to   (LEU338)  CRYSTAL STRUCTURE OF RENIN WITH INHIBITOR 6  |   GLYCOPROTEIN, INHIBITOR-COMPLEX, ASPARTYL PROTEASE, ZYMOGEN, PROTEASE, HYDROLASE, POLYMORPHISM, ALTERNATIVE SPLICING, HYDROLASE(ACID PROTEINASE), CLEAVAGE ON PAIR OF BASIC RESIDUES 
2v12:C   (THR312) to   (LEU338)  CRYSTAL STRUCTURE OF RENIN WITH INHIBITOR 8  |   GLYCOPROTEIN, INHIBITOR-COMPLEX, ASPARTYL PROTEASE, ZYMOGEN, PROTEASE, HYDROLASE, POLYMORPHISM, ALTERNATIVE SPLICING, HYDROLASE(ACID PROTEINASE), CLEAVAGE ON PAIR OF BASIC RESIDUES 
2v12:O   (THR312) to   (LEU338)  CRYSTAL STRUCTURE OF RENIN WITH INHIBITOR 8  |   GLYCOPROTEIN, INHIBITOR-COMPLEX, ASPARTYL PROTEASE, ZYMOGEN, PROTEASE, HYDROLASE, POLYMORPHISM, ALTERNATIVE SPLICING, HYDROLASE(ACID PROTEINASE), CLEAVAGE ON PAIR OF BASIC RESIDUES 
2v13:A   (THR312) to   (LEU338)  CRYSTAL STRUCTURE OF RENIN WITH INHIBITOR 7  |   GLYCOPROTEIN, INHIBITOR-COMPLEX, ASPARTYL PROTEASE, ZYMOGEN, PROTEASE, HYDROLASE, POLYMORPHISM, ALTERNATIVE SPLICING, HYDROLASE(ACID PROTEINASE), CLEAVAGE ON PAIR OF BASIC RESIDUES 
2v16:C   (THR298) to   (LEU324)  CRYSTAL STRUCTURE OF RENIN WITH INHIBITOR 3  |   GLYCOPROTEIN, INHIBITOR-COMPLEX, ASPARTYL PROTEASE, ZYMOGEN, PROTEASE, HYDROLASE, POLYMORPHISM, ALTERNATIVE SPLICING, HYDROLASE(ACID PROTEINASE), CLEAVAGE ON PAIR OF BASIC RESIDUES 
2v16:O   (THR298) to   (LEU324)  CRYSTAL STRUCTURE OF RENIN WITH INHIBITOR 3  |   GLYCOPROTEIN, INHIBITOR-COMPLEX, ASPARTYL PROTEASE, ZYMOGEN, PROTEASE, HYDROLASE, POLYMORPHISM, ALTERNATIVE SPLICING, HYDROLASE(ACID PROTEINASE), CLEAVAGE ON PAIR OF BASIC RESIDUES 
1fmu:A   (PRO299) to   (LYS326)  STRUCTURE OF NATIVE PROTEINASE A IN P3221 SPACE GROUP.  |   PROTEINASE A, HYDROLASE 
1fmx:A   (PRO300) to   (LYS327)  STRUCTURE OF NATIVE PROTEINASE A IN THE SPACE GROUP P21  |   PROTEINASE A, HYDROLASE 
1fmx:B   (PRO300) to   (LYS327)  STRUCTURE OF NATIVE PROTEINASE A IN THE SPACE GROUP P21  |   PROTEINASE A, HYDROLASE 
2ewy:A   (ALA342) to   (ALA368)  CRYSTAL STRUCTURE OF HUMAN BACE2 IN COMPLEX WITH A HYDROXYETHYLENAMINE TRANSITION-STATE INHIBITOR  |   BACE2, ASPARTIC PROTEASE, HYDROLASE 
2ewy:B   (ALA342) to   (ALA368)  CRYSTAL STRUCTURE OF HUMAN BACE2 IN COMPLEX WITH A HYDROXYETHYLENAMINE TRANSITION-STATE INHIBITOR  |   BACE2, ASPARTIC PROTEASE, HYDROLASE 
2ewy:C   (ALA342) to   (ALA368)  CRYSTAL STRUCTURE OF HUMAN BACE2 IN COMPLEX WITH A HYDROXYETHYLENAMINE TRANSITION-STATE INHIBITOR  |   BACE2, ASPARTIC PROTEASE, HYDROLASE 
2ewy:D   (ALA342) to   (ALA368)  CRYSTAL STRUCTURE OF HUMAN BACE2 IN COMPLEX WITH A HYDROXYETHYLENAMINE TRANSITION-STATE INHIBITOR  |   BACE2, ASPARTIC PROTEASE, HYDROLASE 
1fq4:A   (PRO297) to   (LYS324)  CRYSTAL STRUCTURE OF A COMPLEX BETWEEN HYDROXYETHYLENE INHIBITOR CP- 108,420 AND YEAST ASPARTIC PROTEINASE A  |   ASPARTIC PROTEINASE-INHIBITOR COMPLEX, EXTENDED BETA-STRAND (INHIBITOR), HYDROLASE-HYDROLASE INHIBITOR COMPLEX 
1fq5:A   (PRO297) to   (LYS324)  X-RAY STRUTURE OF A CYCLIC STATINE INHIBITOR PD-129,541 BOUND TO YEAST PROTEINASE A  |   HYDROLASE-HYDROLASE INHIBITOR COMPLEX 
1fq6:A   (PRO297) to   (LYS324)  X-RAY STRUCTURE OF GLYCOL INHIBITOR PD-133,450 BOUND TO SACCHAROPEPSIN  |   HYDROLASE, HYDROLASE-HYDROLASE INHIBITOR COMPLEX 
1fq7:A   (PRO297) to   (LYS324)  X-RAY STRUCTURE OF INHIBITOR CP-72,647 BOUND TO SACCHAROPEPSIN  |   HYDROPHOBIC INHIBITOR, HYDROLASE-HYDROLASE INHIBITOR COMPLEX 
1fq8:A   (PRO297) to   (LYS324)  X-RAY STRUCTURE OF DIFLUOROSTATINE INHIBITOR CP81,198 BOUND TO SACCHAROPEPSIN  |   HYDROLASE-HYDROLASE INHIBITOR COMPLEX 
4k8s:C   (GLY330) to   (VAL356)  HYDROXYETHYLAMINE-BASED INHIBITORS OF BACE1: P1-P3 MACROCYCLIZATION CAN IMPROVE POTENCY, SELECTIVITY, AND CELL ACTIVITY  |   PROTEASE, HYDROLASE-HYDROLASE INHIBITOR COMPLEX 
2va5:A   (GLY330) to   (VAL356)  X-RAY CRYSTAL STRUCTURE OF BETA SECRETASE COMPLEXED WITH COMPOUND 8C  |   BASE, ZYMOGEN, PROTEASE, MEMBRANE, HYDROLASE, ALZHEIMER'S DISEASE, ALTERNATIVE SPLICING, MEMAPSIN 2, GLYCOPROTEIN, TRANSMEMBRANE, BETA-SECRETASE, ASPARTYL PROTEASE, ASPARTIC PROTEASE 
4k9h:A   (GLY330) to   (VAL356)  BACE-1 INHIBITOR COMPLEX  |   ASPARTIC PROTEASE, PROTEASE, HYDROLASE-HYDROLASE INHIBITOR COMPLEX 
4k9h:C   (GLY330) to   (VAL356)  BACE-1 INHIBITOR COMPLEX  |   ASPARTIC PROTEASE, PROTEASE, HYDROLASE-HYDROLASE INHIBITOR COMPLEX 
1rne:A   (THR298) to   (LEU324)  THE CRYSTAL STRUCTURE OF RECOMBINANT GLYCOSYLATED HUMAN RENIN ALONE AND IN COMPLEX WITH A TRANSITION STATE ANALOG INHIBITOR  |   HYDROLASE(ACID PROTEINASE) 
1g0v:A   (PRO297) to   (LYS324)  THE STRUCTURE OF PROTEINASE A COMPLEXED WITH A IA3 MUTANT, MVV  |   PROTEINASE A, MVV, HYDROLASE-HYDROLASE INHIBITOR COMPLEX 
4z2z:A   (ASP286) to   (ALA311)  NEW CRYSTAL STRUCTURE OF YEAST DDI1 ASPARTYL PROTEASE REVEALS SUBSTRATE ENGAGEMENT MODE  |   PROTEASE, DDI1, HYDROLASE 
3uqp:A   (GLY330) to   (VAL356)  CRYSTAL STRUCTURE OF BACE1 WITH ITS INHIBITOR  |   HYDROLASE, HYDROLASE-HYDROLASE INHIBITOR COMPLEX 
3uqr:A   (GLY330) to   (VAL356)  CRYSTAL STRUCTURE OF BACE1 WITH ITS INHIBITOR  |   HYDROLASE, HYDROLASE-HYDROLASE INHIBITOR COMPLEX 
3uqu:A   (GLY330) to   (VAL356)  CRYSTAL STRUCTURE OF BACE1 WITH ITS INHIBITOR  |   HYDROLASE, BETA-SECRETASE, BACE1, MEMAPSIN 2, HYDROLASE-HYDROLASE INHIBITOR COMPLEX 
3uqx:A   (GLY330) to   (VAL356)  CRYSTAL STRUCTURE OF BACE1 WITH ITS INHIBITOR  |   HYDROLASE, BETA-SECRETASE, BACE1, MEMAPSIN 2, HYDROLASE-HYDROLASE INHIBITOR COMPLEX 
3utl:A   (GLU297) to   (PRO324)  HUMAN PEPSIN 3B  |   ASPARTIC PROTEINASE, STOMACH LUMEN, HYDROLASE 
2fs4:A   (THR305) to   (LEU331)  KETOPIPERAZINE-BASED RENIN INHIBITORS: OPTIMIZATION OF THE C RING  |   PROTEIN-LIGAND COMPLEXES, HYDROLASE 
2fs4:B   (THR305) to   (LEU331)  KETOPIPERAZINE-BASED RENIN INHIBITORS: OPTIMIZATION OF THE C RING  |   PROTEIN-LIGAND COMPLEXES, HYDROLASE 
3hvg:A   (GLY330) to   (VAL356)  STRUCTURE OF BACE (BETA SECRETASE) IN COMPLEX WITH EV0  |   PROTEASE, ALZHEIMER'S DISEASE, ASPARTIC PROTEASE, ASPARTYL PROTEASE, BASE, BETA-SECRETASE, GLYCOPROTEIN, HYDROLASE, MEMAPSIN 2, AMYLOID PRECURSOR PROTEIN SECRETASES, ASPARTIC ENDOPEPTIDASES, FRAGMENT- BASED DRUG DESIGN, FLUORESCENCE POLARISATION, DISULFIDE BOND, TRANSMEMBRANE, ZYMOGEN 
3hvg:C   (GLY330) to   (VAL356)  STRUCTURE OF BACE (BETA SECRETASE) IN COMPLEX WITH EV0  |   PROTEASE, ALZHEIMER'S DISEASE, ASPARTIC PROTEASE, ASPARTYL PROTEASE, BASE, BETA-SECRETASE, GLYCOPROTEIN, HYDROLASE, MEMAPSIN 2, AMYLOID PRECURSOR PROTEIN SECRETASES, ASPARTIC ENDOPEPTIDASES, FRAGMENT- BASED DRUG DESIGN, FLUORESCENCE POLARISATION, DISULFIDE BOND, TRANSMEMBRANE, ZYMOGEN 
4zea:A   (ILE302) to   (SER329)  ENDOTHIAPEPSIN IN COMPLEX WITH FRAGMENT B91  |   FRAGMENT SCREENING, HYDROLASE, INHIBITION 
2g1n:A   (THR307) to   (LEU333)  KETOPIPERAZINE-BASED RENIN INHIBITORS: OPTIMIZATION OF THE "C" RING  |   PROTEIN-LIGAND COMPLEXES, HYDROLASE 
2g1n:B   (THR307) to   (LEU333)  KETOPIPERAZINE-BASED RENIN INHIBITORS: OPTIMIZATION OF THE "C" RING  |   PROTEIN-LIGAND COMPLEXES, HYDROLASE 
2g1o:A   (THR307) to   (LEU333)  KETOPIPERAZINE-BASED RENIN INHIBITORS: OPTIMIZATION OF THE "C" RING  |   PROTEIN-LIGAND COMPLEXES, HYDROLASE 
2g1o:B   (THR307) to   (LEU333)  KETOPIPERAZINE-BASED RENIN INHIBITORS: OPTIMIZATION OF THE "C" RING  |   PROTEIN-LIGAND COMPLEXES, HYDROLASE 
2g1s:A   (THR307) to   (LEU333)  KETOPIPERAZINE-BASED RENIN INHIBITORS: OPTIMIZATION OF THE C RING  |   PROTEIN-LIGAND COMPLEXES, HYDROLASE 
2g1s:B   (THR307) to   (LEU333)  KETOPIPERAZINE-BASED RENIN INHIBITORS: OPTIMIZATION OF THE C RING  |   PROTEIN-LIGAND COMPLEXES, HYDROLASE 
2g1y:A   (THR307) to   (LEU333)  KETOPIPERAZINE-BASED RENIN INHIBITORS: OPTIMIZATION OF THE "C" RING  |   PROTEIN-LIGAND COMPLEXES, HYDROLASE 
2g1y:B   (THR307) to   (LEU333)  KETOPIPERAZINE-BASED RENIN INHIBITORS: OPTIMIZATION OF THE "C" RING  |   PROTEIN-LIGAND COMPLEXES, HYDROLASE 
2g20:A   (THR307) to   (LEU333)  KETOPIPERAZINE-BASED RENIN INHIBITORS: OPTIMIZATION OF THE C RING  |   PROTEIN-LIGAND COMPLEXES, HYDROLASE 
2g20:B   (THR307) to   (LEU333)  KETOPIPERAZINE-BASED RENIN INHIBITORS: OPTIMIZATION OF THE C RING  |   PROTEIN-LIGAND COMPLEXES, HYDROLASE 
2g21:A   (THR305) to   (LEU331)  KETOPIPERAZINE-BASED RENIN INHIBITORS: OPTIMIZATION OF THE "C" RING  |   PROTEIN-LIGAND COMPLEXES, HYDROLASE 
2g21:B   (THR305) to   (LEU331)  KETOPIPERAZINE-BASED RENIN INHIBITORS: OPTIMIZATION OF THE "C" RING  |   PROTEIN-LIGAND COMPLEXES, HYDROLASE 
2g22:A   (THR307) to   (LEU333)  KETOPIPERAZINE-BASED RENIN INHIBITORS: OPTIMIZATION OF THE "C" RING  |   PROTEIN-LIGAND COMPLEXES, HYDROLASE 
2g22:B   (THR307) to   (LEU333)  KETOPIPERAZINE-BASED RENIN INHIBITORS: OPTIMIZATION OF THE "C" RING  |   PROTEIN-LIGAND COMPLEXES, HYDROLASE 
2g24:A   (THR305) to   (LEU331)  KETOPIPERAZINE-BASED RENIN INHIBITORS: OPTIMIZATION OF THE "C" RING  |   PROTEIN-LIGAND COMPLEXES, HYDROLASE 
2g24:B   (THR305) to   (LEU331)  KETOPIPERAZINE-BASED RENIN INHIBITORS: OPTIMIZATION OF THE "C" RING  |   PROTEIN-LIGAND COMPLEXES, HYDROLASE 
2g26:A   (THR305) to   (LEU331)  KETOPIPERAZINE-BASED RENIN INHIBITORS: OPTIMIZATION OF THE "C" RING  |   PROTEIN-LIGAND COMPLEXES, HYDROLASE 
2g26:B   (THR305) to   (LEU331)  KETOPIPERAZINE-BASED RENIN INHIBITORS: OPTIMIZATION OF THE "C" RING  |   PROTEIN-LIGAND COMPLEXES, HYDROLASE 
2g27:A   (THR305) to   (LEU331)  KETOPIPERAZINE-BASED RENIN INHIBITORS: OPTIMIZATION OF THE "C" RING  |   PROTEIN-LIGAND COMPLEXES, HYDROLASE 
1sme:A   (PRO297) to   (LEU324)  PLASMEPSIN II, A HEMOGLOBIN-DEGRADING ENZYME FROM PLASMODIUM FALCIPARUM, IN COMPLEX WITH PEPSTATIN A  |   ASPARTYL PROTEINASE, ASPARTIC PROTEINASE, ASPARTYL PROTEASE, HYDROLASE-HYDROLASE INHIBITOR COMPLEX 
1sme:B   (PRO297) to   (LEU324)  PLASMEPSIN II, A HEMOGLOBIN-DEGRADING ENZYME FROM PLASMODIUM FALCIPARUM, IN COMPLEX WITH PEPSTATIN A  |   ASPARTYL PROTEINASE, ASPARTIC PROTEINASE, ASPARTYL PROTEASE, HYDROLASE-HYDROLASE INHIBITOR COMPLEX 
1smr:A   (VAL298) to   (LEU324)  THE 3-D STRUCTURE OF MOUSE SUBMAXILLARY RENIN COMPLEXED WITH A DECAPEPTIDE INHIBITOR CH-66 BASED ON THE 4-16 FRAGMENT OF RAT ANGIOTENSINOGEN  |   ASPARTIC PROTEINASE, HYDROLASE-HYDROLASE INHIBITOR COMPLEX 
1smr:C   (VAL298) to   (LEU324)  THE 3-D STRUCTURE OF MOUSE SUBMAXILLARY RENIN COMPLEXED WITH A DECAPEPTIDE INHIBITOR CH-66 BASED ON THE 4-16 FRAGMENT OF RAT ANGIOTENSINOGEN  |   ASPARTIC PROTEINASE, HYDROLASE-HYDROLASE INHIBITOR COMPLEX 
1smr:E   (VAL298) to   (LEU324)  THE 3-D STRUCTURE OF MOUSE SUBMAXILLARY RENIN COMPLEXED WITH A DECAPEPTIDE INHIBITOR CH-66 BASED ON THE 4-16 FRAGMENT OF RAT ANGIOTENSINOGEN  |   ASPARTIC PROTEINASE, HYDROLASE-HYDROLASE INHIBITOR COMPLEX 
1smr:G   (VAL298) to   (LEU324)  THE 3-D STRUCTURE OF MOUSE SUBMAXILLARY RENIN COMPLEXED WITH A DECAPEPTIDE INHIBITOR CH-66 BASED ON THE 4-16 FRAGMENT OF RAT ANGIOTENSINOGEN  |   ASPARTIC PROTEINASE, HYDROLASE-HYDROLASE INHIBITOR COMPLEX 
4kup:A   (ILE302) to   (SER329)  ENDOTHIAPEPSIN IN COMPLEX WITH 20MM ACYLHYDRAZONE INHIBITOR  |   HYDROLASE, ASPARTIC PROTEASE, HYDROLASE-HYDROLASE INHIBITOR COMPLEX 
1gvx:A   (ILE302) to   (SER329)  ENDOTHIAPEPSIN COMPLEXED WITH H256  |   HYDROLASE, ASPARTIC PROTEINASE MECHANISM, TETRAHEDRAL INTERMEDIATE, HYDROLASE-HYDROLASE INHIBITOR COMPLEX 
4l6b:A   (ILE302) to   (SER329)  ENDOTHIAPEPSIN IN COMPLEX WITH THIOPHEN-BASED INHIBITOR SAP128  |   ASPARTATE PROTEASE, INHIBITOR COMPLEX, HYDROLASE-HYDROLASE INHIBITOR COMPLEX 
4zpe:A   (GLY330) to   (VAL356)  BACE1 IN COMPLEX WITH 4-(CYCLOHEXYLAMINO)-1-(3-FLUOROPHENYL)-8-(3- ISOPROPOXYBENZYL)-1,3,8-TRIAZASPIRO[4.5]DEC-3-EN-2-ONE  |   ALZHEIMER DISEASE, AMYLOID PRECURSOR PROTEIN SECRETASES, AMYLOID BETA-PEPTIDES, ASPARTIC ACID ENDOPEPTIDASES, BINDING SITES, DRUG DESIGN, TRANSGENIC, MODELS, MOLECULAR, PROTEASE INHIBITORS, STRUCTURE-ACTIVITY RELATIONSHIP, HYDROLASE-HYDROLASE INHIBITOR COMPLEX 
4zpf:A   (GLY330) to   (VAL356)  BACE1 IN COMPLEX WITH 8-(3-((1-AMINOPROPAN-2-YL)OXY)BENZYL)-4- (CYCLOHEXYLAMINO)-1-(3-FLUOROPHENYL)-1,3,8-TRIAZASPIRO[4.5]DEC-3-EN- 2-ONE  |   ALZHEIMER DISEASE, AMYLOID PRECURSOR PROTEIN SECRETASES, AMYLOID BETA-PEPTIDES, ASPARTIC ACID ENDOPEPTIDASES, BINDING SITES, DRUG DESIGN, TRANSGENIC, MODELS, MOLECULAR, PROTEASE INHIBITORS, STRUCTURE-ACTIVITY RELATIONSHIP, HYDROLASE-HYDROLASE INHIBITOR COMPLEX 
4zpg:A   (GLY330) to   (VAL356)  BACE1 IN COMPLEX WITH 8-BENZYL-4-(CYCLOHEXYLAMINO)-1-(3-FLUOROPHENYL)- 7-METHYL-1,3,8-TRIAZASPIRO[4.5]DEC-3-EN-2-ONE  |   ALZHEIMER DISEASE, AMYLOID PRECURSOR PROTEIN SECRETASES, AMYLOID BETA-PEPTIDES, ASPARTIC ACID ENDOPEPTIDASES, BINDING SITES, DRUG DESIGN, MOLECULAR, PROTEASE INHIBITORS, STRUCTURE-ACTIVITY RELATIONSHIP, HYDROLASE-HYDROLASE INHIBITOR COMPLEX 
4lbt:A   (ILE302) to   (SER329)  ENDOTHIAPEPSIN IN COMPLEX WITH 100MM ACYLHYDRAZONE INHIBITOR  |   HYDROLASE, ASPARTIC PROTEASE, HYDROLASE-HYDROLASE INHIBITOR COMPLEX 
4zsm:A   (GLY330) to   (VAL356)  BACE CRYSTAL STRUCTURE WITH BICYCLIC AMINOTHIAZINE FRAGMENT  |   ASPARTYL, PROTEASE, BETA-SECRETASE, HYDROLASE-HYDROLASE INHIBITOR COMPLEX 
4lhh:A   (ILE302) to   (SER329)  ENDOTHIAPEPSIN IN COMPLEX WITH 2MM ACYLHYDRAZONE INHIBITOR  |   HYDROLASE, ASPARTIC PROTEASE, HYDROLASE-HYDROLASE INHIBITOR COMPLEX 
1tqf:A   (GLY330) to   (VAL356)  CRYSTAL STRUCTURE OF HUMAN BETA SECRETASE COMPLEXED WITH INHIBITOR  |   ASPARTYL PROTEASE, BACE, HYDROLASE 
2wea:A   (PHE295) to   (PRO321)  ACID PROTEINASE (PENICILLOPEPSIN) (E.C.3.4.23.20) COMPLEX WITH PHOSPHONATE INHIBITOR: METHYL[CYCLO-7[(2R)-((N-VALYL) AMINO)-2-(HYDROXYL-(1S)-1-METHYOXYCARBONYL-2-PHENYLETHOXY) PHOSPHINYLOXY-ETHYL]-1-NAPHTHALENEACETAMIDE], SODIUM SALT  |   PENICILLOPEPSIN, PHOSPHONATE INHIBITOR, HYDROLASE 
2web:A   (PHE295) to   (PRO321)  ACID PROTEINASE (PENICILLOPEPSIN) (E.C.3.4.23.20) COMPLEX WITH PHOSPHONATE INHIBITOR: METHYL(2S)-[1-(((N-FORMYL)-L- VALYL)AMINO-2-(2-NAPHTHYL)ETHYL)HYDROXYPHOSPHINYLOXY]-3- PHENYLPROPANOATE, SODIUM SALT  |   PENICILLOPEPSIN, PHOSPHONATE INHIBITOR, HYDROLASE 
1hrn:A   (THR298) to   (LEU324)  HIGH RESOLUTION CRYSTAL STRUCTURES OF RECOMBINANT HUMAN RENIN IN COMPLEX WITH POLYHYDROXYMONOAMIDE INHIBITORS  |   ASPARTIC PROTEINASE, HYDROLASE-HYDROLASE INHIBITOR COMPLEX 
1hrn:B   (THR298) to   (LEU324)  HIGH RESOLUTION CRYSTAL STRUCTURES OF RECOMBINANT HUMAN RENIN IN COMPLEX WITH POLYHYDROXYMONOAMIDE INHIBITORS  |   ASPARTIC PROTEINASE, HYDROLASE-HYDROLASE INHIBITOR COMPLEX 
1htr:B   (PRO300) to   (THR327)  CRYSTAL AND MOLECULAR STRUCTURES OF HUMAN PROGASTRICSIN AT 1.62 ANGSTROMS RESOLUTION  |   ASPARTYL PROTEASE 
3vsw:A   (THR312) to   (LEU338)  HUMAN RENIN IN COMPLEX WITH COMPOUND 8  |   RAS, HYPERTENSION, INHIBITOR, ASPARTYL PROTEASE, HYDROLASE-HYDROLASE INHIBITOR COMPLEX 
3vsw:B   (THR312) to   (LEU338)  HUMAN RENIN IN COMPLEX WITH COMPOUND 8  |   RAS, HYPERTENSION, INHIBITOR, ASPARTYL PROTEASE, HYDROLASE-HYDROLASE INHIBITOR COMPLEX 
3vsx:A   (THR312) to   (LEU338)  HUMAN RENIN IN COMPLEX WITH COMPOUND 18  |   RAS, HYPERTENSION, INHIBITOR, ASPARTYL PROTEASE, HYDROLASE-HYDROLASE INHIBITOR COMPLEX 
3vsx:B   (THR312) to   (LEU338)  HUMAN RENIN IN COMPLEX WITH COMPOUND 18  |   RAS, HYPERTENSION, INHIBITOR, ASPARTYL PROTEASE, HYDROLASE-HYDROLASE INHIBITOR COMPLEX 
2wjo:A   (GLY330) to   (VAL356)  HUMAN BACE (BETA SECRETASE) IN COMPLEX WITH CYCLOHEXANECARBOXYLIC ACID (2-(2-AM INO-6-PHENOXY-4H- QUINAZOLIN-3-YL)-2-CYCLOHEXYL-ETHYL)-AMIDE  |   ZYMOGEN, MEMBRANE, HYDROLASE, GLYCOPROTEIN, TRANSMEMBRANE 
3vuc:A   (THR312) to   (LEU338)  HUMAN RENIN IN COMPLEX WITH COMPOUND 5  |   ASPARTYL PROTEASE, RAS, HYPERTENSION, INHIBITOR, HYDROLASE-HYDROLASE INHIBITOR COMPLEX 
3vuc:B   (THR312) to   (LEU338)  HUMAN RENIN IN COMPLEX WITH COMPOUND 5  |   ASPARTYL PROTEASE, RAS, HYPERTENSION, INHIBITOR, HYDROLASE-HYDROLASE INHIBITOR COMPLEX 
4lp9:A   (ILE299) to   (SER325)  ENDOTHIAPEPSIN COMPLEXED WITH PHE-REDUCED-TYR PEPTIDE.  |   ASPARTIC PROTEINASE FOLD, PROTEOLYSIS, HYDROLASE (ACID PROTEINASE), HYDROLASE-HYDROLASE INHIBITOR COMPLEX 
1tzs:A   (LEU314) to   (PRO340)  CRYSTAL STRUCTURE OF AN ACTIVATION INTERMEDIATE OF CATHEPSIN E  |   HYDROLASE, ASPARTIC PROTEASE, ACTIVATION INTERMEDIATE 
3vyf:A   (THR312) to   (LEU338)  HUMAN RENIN IN COMPLEX WITH INHIBITOR 9  |   ASPARTYL PROTEASE, RAS, HYPERTENSION, INHIBITOR, HYDROLASE-HYDROLASE INHIBITOR COMPLEX 
3vyf:B   (THR312) to   (LEU338)  HUMAN RENIN IN COMPLEX WITH INHIBITOR 9  |   ASPARTYL PROTEASE, RAS, HYPERTENSION, INHIBITOR, HYDROLASE-HYDROLASE INHIBITOR COMPLEX 
3vyd:A   (THR312) to   (LEU338)  HUMAN RENIN IN COMPLEX WITH INHIBITOR 6  |   ASPARTYL PROTEASE, RAS, HYPERTENSION, INHIBITOR, HYDROLASE-HYDROLASE INHIBITOR COMPLEX 
3vyd:B   (THR312) to   (LEU338)  HUMAN RENIN IN COMPLEX WITH INHIBITOR 6  |   ASPARTYL PROTEASE, RAS, HYPERTENSION, INHIBITOR, HYDROLASE-HYDROLASE INHIBITOR COMPLEX 
1ibq:A   (LEU297) to   (ALA323)  ASPERGILLOPEPSIN FROM ASPERGILLUS PHOENICIS  |   ASPERGILLOPEPSIN, ASPARTIC PROTEINASE, HYDROLASE 
1ibq:B   (SER298) to   (ALA323)  ASPERGILLOPEPSIN FROM ASPERGILLUS PHOENICIS  |   ASPERGILLOPEPSIN, ASPARTIC PROTEINASE, HYDROLASE 
1uh7:A   (PHE296) to   (PRO322)  CRYSTAL STRUCTURE OF RHIZOPUSPEPSIN AT PH 4.6  |   PEPSIN, ASPARTIC PROTEINASE, HYDROLASE 
1uh8:A   (PHE296) to   (PRO322)  CRYSTAL STRUCTURE OF RHIZOPUSPEPSIN AT PH 8.0  |   PEPSIN, ASPARTIC PROTEINASE, HYDROLASE 
2i4q:A   (THR307) to   (LEU333)  HUMAN RENIN/PF02342674 COMPLEX  |   RENIN INHIBITOR, PROTEIN-LIGAND COMPLEX, HYDROLASE 
2igx:A   (PRO297) to   (LEU324)  ACHIRAL, CHEAP AND POTENT INHIBITORS OF PLASMEPSINS II  |   ACHIRAL INHIBITOR, HYDROLASE 
2igy:A   (PRO297) to   (LEU324)  ACHIRAL, CHEAP AND POTENT INHIBITORS OF PLASMEPSINS II  |   ACHIRAL INHIBITOR, HYDROLASE 
2igy:B   (PRO297) to   (LEU324)  ACHIRAL, CHEAP AND POTENT INHIBITORS OF PLASMEPSINS II  |   ACHIRAL INHIBITOR, HYDROLASE 
2x0b:A   (THR305) to   (LEU331)  CRYSTAL STRUCTURE OF HUMAN ANGIOTENSINOGEN COMPLEXED WITH RENIN  |   HYDROLASE-HORMONE COMPLEX, HYDROLASE HORMONE COMPLEX, VASOCONSTRICTOR, GLYCOPROTEIN, HYPERTENSION, SERPINS, ZYMOGEN, HYDROLASE, VASOACTIVE 
2x0b:C   (THR305) to   (LEU331)  CRYSTAL STRUCTURE OF HUMAN ANGIOTENSINOGEN COMPLEXED WITH RENIN  |   HYDROLASE-HORMONE COMPLEX, HYDROLASE HORMONE COMPLEX, VASOCONSTRICTOR, GLYCOPROTEIN, HYPERTENSION, SERPINS, ZYMOGEN, HYDROLASE, VASOACTIVE 
2x0b:E   (THR305) to   (LEU331)  CRYSTAL STRUCTURE OF HUMAN ANGIOTENSINOGEN COMPLEXED WITH RENIN  |   HYDROLASE-HORMONE COMPLEX, HYDROLASE HORMONE COMPLEX, VASOCONSTRICTOR, GLYCOPROTEIN, HYPERTENSION, SERPINS, ZYMOGEN, HYDROLASE, VASOACTIVE 
2x0b:G   (THR305) to   (LEU331)  CRYSTAL STRUCTURE OF HUMAN ANGIOTENSINOGEN COMPLEXED WITH RENIN  |   HYDROLASE-HORMONE COMPLEX, HYDROLASE HORMONE COMPLEX, VASOCONSTRICTOR, GLYCOPROTEIN, HYPERTENSION, SERPINS, ZYMOGEN, HYDROLASE, VASOACTIVE 
1iyk:A   (ARG116) to   (PRO157)  CRYSTAL STRUCTURE OF CANDIDA ALBICANS N-MYRISTOYLTRANSFERASE WITH MYRISTOYL-COA AND PEPTIDIC INHIBITOR  |   TRANSFERASE 
2iko:A   (THR307) to   (LEU333)  CRYSTAL STRUCTURE OF HUMAN RENIN COMPLEXED WITH INHIBITOR  |   RENIN, INHIBITORS, DRUG DESIGN, HYDROLASE 
2iko:B   (THR307) to   (LEU333)  CRYSTAL STRUCTURE OF HUMAN RENIN COMPLEXED WITH INHIBITOR  |   RENIN, INHIBITORS, DRUG DESIGN, HYDROLASE 
2iku:A   (THR307) to   (LEU333)  CRYSTAL STRUCTURE OF HUMAN RENIN COMPLEXED WITH INHIBITORS  |   RENIN, INHIBITORS, DRUG DESIGN, HYDROLASE 
2iku:B   (THR307) to   (LEU333)  CRYSTAL STRUCTURE OF HUMAN RENIN COMPLEXED WITH INHIBITORS  |   RENIN, INHIBITORS, DRUG DESIGN, HYDROLASE 
2il2:A   (THR307) to   (LEU333)  CRYSTAL STRUCTURE OF HUMAN RENIN COMPLEXED WITH INHIBITOR  |   RENIN, INHIBITORS, DRUG DESIGN, HYDROLASE 
2il2:B   (THR307) to   (LEU333)  CRYSTAL STRUCTURE OF HUMAN RENIN COMPLEXED WITH INHIBITOR  |   RENIN, INHIBITORS, DRUG DESIGN, HYDROLASE 
1ize:A   (PHE295) to   (ALA321)  CRYSTAL STRUCTURE OF ASPERGILLUS ORYZAE ASPARTIC PROTEINASE COMPLEXED WITH PEPSTATIN  |   ACID PROTEASE, SUGAR BINDING, HYDROLASE-HYDROLASE INHIBITOR COMPLEX 
2irz:A   (GLY330) to   (VAL356)  CRYSTAL STRUCTURE OF HUMAN BETA-SECRETASE COMPLEXED WITH INHIBITOR  |   ASPARTYL PROTEASE, HYDROLASE 
2is0:A   (GLY330) to   (VAL356)  CRYSTAL STRUCTURE OF HUMAN BETA-SECRETASE COMPLEXED WITH INHIBITOR  |   ASPARTYL PROTEASE, HYDROLASE 
5apr:E   (GLY295) to   (ALA321)  STRUCTURES OF COMPLEXES OF RHIZOPUSPEPSIN WITH PEPSTATIN AND OTHER STATINE-CONTAINING INHIBITORS  |   ACID PROTEINASE, HYDROLASE-HYDROLASE INHIBITOR COMPLEX 
3j6f:A     (ARG2) to    (PRO63)  MINIMIZED AVERAGE STRUCTURE OF GDP-BOUND DYNAMIC MICROTUBULES  |   MICROTUBULE, GDP, DYNAMIC, STRUCTURAL PROTEIN 
3j6f:C     (ARG2) to    (PRO63)  MINIMIZED AVERAGE STRUCTURE OF GDP-BOUND DYNAMIC MICROTUBULES  |   MICROTUBULE, GDP, DYNAMIC, STRUCTURAL PROTEIN 
3j6f:E     (ARG2) to    (PRO63)  MINIMIZED AVERAGE STRUCTURE OF GDP-BOUND DYNAMIC MICROTUBULES  |   MICROTUBULE, GDP, DYNAMIC, STRUCTURAL PROTEIN 
3j6f:G     (ARG2) to    (PRO63)  MINIMIZED AVERAGE STRUCTURE OF GDP-BOUND DYNAMIC MICROTUBULES  |   MICROTUBULE, GDP, DYNAMIC, STRUCTURAL PROTEIN 
3j6f:I     (ARG2) to    (PRO63)  MINIMIZED AVERAGE STRUCTURE OF GDP-BOUND DYNAMIC MICROTUBULES  |   MICROTUBULE, GDP, DYNAMIC, STRUCTURAL PROTEIN 
3j6f:K     (ARG2) to    (PRO63)  MINIMIZED AVERAGE STRUCTURE OF GDP-BOUND DYNAMIC MICROTUBULES  |   MICROTUBULE, GDP, DYNAMIC, STRUCTURAL PROTEIN 
3j6f:M     (ARG2) to    (PRO63)  MINIMIZED AVERAGE STRUCTURE OF GDP-BOUND DYNAMIC MICROTUBULES  |   MICROTUBULE, GDP, DYNAMIC, STRUCTURAL PROTEIN 
3j6f:O     (ARG2) to    (PRO63)  MINIMIZED AVERAGE STRUCTURE OF GDP-BOUND DYNAMIC MICROTUBULES  |   MICROTUBULE, GDP, DYNAMIC, STRUCTURAL PROTEIN 
3j6f:Q     (ARG2) to    (PRO63)  MINIMIZED AVERAGE STRUCTURE OF GDP-BOUND DYNAMIC MICROTUBULES  |   MICROTUBULE, GDP, DYNAMIC, STRUCTURAL PROTEIN 
3wz6:A   (ILE302) to   (SER329)  ENDOTHIAPEPSIN IN COMPLEX WITH GEWALD REACTION-DERIVED INHIBITOR (5)  |   ASPARTIC PROTEASE, HYDROLASE-HYDROLASE INHIBITOR COMPLEX 
3wz7:A   (ILE302) to   (SER329)  ENDOTHIAPEPSIN IN COMPLEX WITH GEWALD REACTION-DERIVED INHIBITOR (6)  |   ASPARTIC PROTEASE, HYDROLASE-HYDROLASE INHIBITOR COMPLEX 
1w50:A   (GLY330) to   (VAL356)  APO STRUCTURE OF BACE (BETA SECRETASE)  |   ALTERNATIVE SPLICING, ALZHEIMER'S DISEASE, ASPARTIC PROTEASE, ASPARTYL PROTEASE, BASE, BETA-SECRETASE, GLYCOPROTEIN, HYDROLASE, MEMAPSIN 2, SIGNAL, TRANSMEMBRANE, ZYMOGEN 
1w6h:A   (PRO297) to   (LEU324)  NOVEL PLASMEPSIN II-INHIBITOR COMPLEX  |   MALARIA, DRUG, ASPARTIC PROTEASE, PLASMEPSIN, HYDROLASE, GLYCOPROTEIN 
1w6h:B   (PRO297) to   (LEU324)  NOVEL PLASMEPSIN II-INHIBITOR COMPLEX  |   MALARIA, DRUG, ASPARTIC PROTEASE, PLASMEPSIN, HYDROLASE, GLYCOPROTEIN 
1w6i:A   (PRO297) to   (LEU324)  PLASMEPSIN II-PEPSTATIN A COMPLEX  |   MALARIA, DRUG, ASPARTIC PROTEASE, PLASMEPSIN, GLYCOPROTEIN, HYDROLASE-HYDROLASE INHIBITOR COMPLEX 
1w6i:C   (PRO297) to   (LEU324)  PLASMEPSIN II-PEPSTATIN A COMPLEX  |   MALARIA, DRUG, ASPARTIC PROTEASE, PLASMEPSIN, GLYCOPROTEIN, HYDROLASE-HYDROLASE INHIBITOR COMPLEX 
2jxr:A   (PRO297) to   (LYS324)  STRUCTURE OF YEAST PROTEINASE A  |   HYDROLASE-HYDROLASE INHIBITOR COMPLEX, ASPARTYL PROTEASE, GLYCOPROTEIN, ZYMOGEN 
5bwy:A   (PRO297) to   (LEU324)  STRUCTURE OF PROPLASMEPSIN II FROM PLASMODIUM FALCIPARUM, SPACE GROUP P43212  |   MALARIA, HYDROLASE 
3zl7:A   (ALA342) to   (ALA368)  BACE2 FYNOMER COMPLEX  |   HYDROLASE, ASPARTYL PROTEASE 
1xdh:A   (PRO297) to   (LEU324)  STRUCTURE OF PLASMEPSIN II IN COMPLEX WITH PEPSTATIN A  |   HYDROLASE-HYDROLASE INHIBITOR COMPLEX 
1xdh:B   (PRO297) to   (LEU324)  STRUCTURE OF PLASMEPSIN II IN COMPLEX WITH PEPSTATIN A  |   HYDROLASE-HYDROLASE INHIBITOR COMPLEX 
5c9d:A   (ILE206) to   (ASN230)  CRYSTAL STRUCTURE OF A RETROPEPSIN-LIKE ASPARTIC PROTEASE FROM RICKETTSIA CONORII  |   PEPSIN, APRICK, HYDROLASE 
1xe5:A   (PRO297) to   (LEU324)  STRUCTURE OF PLASMEPSIN II IN COMPLEX OF AN PEPSTATIN ANALOGUE  |   HYDROLASE-HYDROLASE INHIBITOR COMPLEX 
1xe5:B   (PRO297) to   (LEU324)  STRUCTURE OF PLASMEPSIN II IN COMPLEX OF AN PEPSTATIN ANALOGUE  |   HYDROLASE-HYDROLASE INHIBITOR COMPLEX 
1xe6:A   (PRO297) to   (LEU324)  STRUCTURE OF PLASMEPSIN II IN COMPLEX OF AN PEPSTATIN ANALOGUE  |   HYDROLASE-HYDROLASE INHIBITOR COMPLEX 
1xe6:B   (PRO297) to   (LEU324)  STRUCTURE OF PLASMEPSIN II IN COMPLEX OF AN PEPSTATIN ANALOGUE  |   HYDROLASE-HYDROLASE INHIBITOR COMPLEX 
3jw7:E   (GLU295) to   (LEU344)  CRYSTAL STRUCTURE OF DIPEPTIDE EPIMERASE FROM ENTEROCOCCUS FAECALIS V583 COMPLEXED WITH MG AND DIPEPTIDE L-ILE-L-TYR  |   DIPEPTIDE EPIMERASE, ENOLASE SUPERFAMILY, DIPEPTIDE L-ILE-L-TYR, ISOMERASE 
3jw7:H   (GLU295) to   (LEU344)  CRYSTAL STRUCTURE OF DIPEPTIDE EPIMERASE FROM ENTEROCOCCUS FAECALIS V583 COMPLEXED WITH MG AND DIPEPTIDE L-ILE-L-TYR  |   DIPEPTIDE EPIMERASE, ENOLASE SUPERFAMILY, DIPEPTIDE L-ILE-L-TYR, ISOMERASE 
3k11:A   (ARG410) to   (GLN450)  CRYSTAL STRUCTURE OF PUTATIVE GLYCOSYL HYDROLASE (NP_813087.1) FROM BACTEROIDES THETAIOTAOMICRON VPI-5482 AT 1.80 A RESOLUTION  |   PUTATIVE GLYCOSYL HYDROLASE, STRUCTURAL GENOMICS, JOINT CENTER FOR STRUCTURAL GENOMICS, JCSG, PROTEIN STRUCTURE INITIATIVE, PSI-2, UNKNOWN FUNCTION, HYDROLASE 
1lf3:A   (PRO297) to   (LEU324)  CRYSTAL STRUCTURE OF PLASMEPSIN II FROM P FALCIPARUM IN COMPLEX WITH INHIBITOR EH58  |   PLASMEPSIN, PLASMODIUM FALCIPARUM, ASPARTIC PROTEASE, HYDROLASE 
1lf2:A   (PRO297) to   (LEU324)  CRYSTAL STRUCTURE OF PLASMEPSIN II FROM P FALCIPARUM IN COMPLEX WITH INHIBITOR RS370  |   PLASMEPSIN, PLASMODIUM FALCIPARUM, ASPARTIC PROTEASE, HYDROLASE 
1lf4:A   (PRO297) to   (LEU324)  STRUCTURE OF PLASMEPSIN II  |   HYDROLASE 
4od9:B   (PRO317) to   (GLU344)  STRUCTURE OF CATHEPSIN D WITH INHIBITOR N-(3,4-DIMETHOXYBENZYL)- NALPHA-{N-[(3,4-DIMETHOXYPHENYL)ACETYL]CARBAMIMIDOYL}-D- PHENYLALANINAMIDE  |   LYSOSOMAL ASPARTIC PROTEASE, HYDROLASE-HYDROLASE INHIBITOR COMPLEX 
4od9:D   (PRO317) to   (GLU344)  STRUCTURE OF CATHEPSIN D WITH INHIBITOR N-(3,4-DIMETHOXYBENZYL)- NALPHA-{N-[(3,4-DIMETHOXYPHENYL)ACETYL]CARBAMIMIDOYL}-D- PHENYLALANINAMIDE  |   LYSOSOMAL ASPARTIC PROTEASE, HYDROLASE-HYDROLASE INHIBITOR COMPLEX 
3k5d:A   (GLY330) to   (VAL356)  CRYSTAL STRUCTURE OF BACE-1 IN COMPLEX WITH AHM178  |   ASPARTYL PROTEASE, ALZHEIMER'S DISEASE, ENDOPLASMIC RETICULUM, ENDOSOME, GLYCOPROTEIN, GOLGI APPARATUS, MEMBRANE, PROTEASE, TRANSMEMBRANE, HYDROLASE-HYDROLASE INHIBITOR COMPLEX 
3k5d:B   (GLY330) to   (VAL356)  CRYSTAL STRUCTURE OF BACE-1 IN COMPLEX WITH AHM178  |   ASPARTYL PROTEASE, ALZHEIMER'S DISEASE, ENDOPLASMIC RETICULUM, ENDOSOME, GLYCOPROTEIN, GOLGI APPARATUS, MEMBRANE, PROTEASE, TRANSMEMBRANE, HYDROLASE-HYDROLASE INHIBITOR COMPLEX 
3k5d:C   (GLY330) to   (VAL356)  CRYSTAL STRUCTURE OF BACE-1 IN COMPLEX WITH AHM178  |   ASPARTYL PROTEASE, ALZHEIMER'S DISEASE, ENDOPLASMIC RETICULUM, ENDOSOME, GLYCOPROTEIN, GOLGI APPARATUS, MEMBRANE, PROTEASE, TRANSMEMBRANE, HYDROLASE-HYDROLASE INHIBITOR COMPLEX 
1ls5:A   (ASN297) to   (VAL324)  CRYSTAL STRUCTURE OF PLASMEPSIN IV FROM P. FALCIPARUM IN COMPLEX WITH PEPSTATIN A  |   EUKARYOTIC ASPARTIC PROTEINASE, HYDROLASE-HYDROLASE INHIBITOR COMPLEX 
1ls5:B   (ASN297) to   (VAL324)  CRYSTAL STRUCTURE OF PLASMEPSIN IV FROM P. FALCIPARUM IN COMPLEX WITH PEPSTATIN A  |   EUKARYOTIC ASPARTIC PROTEINASE, HYDROLASE-HYDROLASE INHIBITOR COMPLEX 
1lya:B   (LEU318) to   (GLU344)  CRYSTAL STRUCTURES OF NATIVE AND INHIBITED FORMS OF HUMAN CATHEPSIN D: IMPLICATIONS FOR LYSOSOMAL TARGETING AND DRUG DESIGN  |   LYSOSOMAL ASPARTIC PROTEASE 
1lya:D   (LEU318) to   (GLU344)  CRYSTAL STRUCTURES OF NATIVE AND INHIBITED FORMS OF HUMAN CATHEPSIN D: IMPLICATIONS FOR LYSOSOMAL TARGETING AND DRUG DESIGN  |   LYSOSOMAL ASPARTIC PROTEASE 
1lyw:B   (PRO317) to   (GLU344)  CATHEPSIN D AT PH 7.5  |   ASPARTIC PROTEASE, HYDROLASE, GLYCOPROTEIN 
1lyw:D   (PRO317) to   (GLU344)  CATHEPSIN D AT PH 7.5  |   ASPARTIC PROTEASE, HYDROLASE, GLYCOPROTEIN 
1lyw:F   (PRO317) to   (GLU344)  CATHEPSIN D AT PH 7.5  |   ASPARTIC PROTEASE, HYDROLASE, GLYCOPROTEIN 
2zhr:B   (GLY330) to   (VAL356)  CRYSTAL STRUCTURE OF BACE1 IN COMPLEX WITH OM99-2 AT PH 5.0  |   OM99-2 COMPLEX, PH 5.0, ASPARTYL PROTEASE, GLYCOPROTEIN, MEMBRANE, PROTEASE, TRANSMEMBRANE, ZYMOGEN, HYDROLASE-HYDROLASE INHIBITOR COMPLEX 
2zhv:A   (GLY330) to   (VAL356)  CRYSTAL STRUCTURE OF BACE1 AT PH 7.0  |   PH 7.0, ALTERNATIVE SPLICING, ASPARTYL PROTEASE, GLYCOPROTEIN, HYDROLASE, MEMBRANE, PROTEASE, TRANSMEMBRANE, ZYMOGEN 
1m43:A   (PRO297) to   (LEU324)  CRYSTAL STRUCTURE OF PMII IN COMPLEX WITH PEPSTATIN A TO 2.4 A  |   PLASMEPSIN II, HYDROLASE-HYDROLASE INHIBITOR COMPLEX 
1m43:B   (PRO297) to   (LEU324)  CRYSTAL STRUCTURE OF PMII IN COMPLEX WITH PEPSTATIN A TO 2.4 A  |   PLASMEPSIN II, HYDROLASE-HYDROLASE INHIBITOR COMPLEX 
1xs7:D   (GLY330) to   (VAL356)  CRYSTAL STRUCTURE OF A CYCLOAMIDE-URETHANE-DERIVED NOVEL INHIBITOR BOUND TO HUMAN BRAIN MEMAPSIN 2 (BETA-SECRETASE).  |   BETA SECRETASE, MEMAPSIN2, BACE, ASP2, ASPARTIC PROTEASE, ACID PROTEASE, ALZHEIMER'S DISEASE, DRUG DESIGN, CRYSTALLOGRAPHY, HYDROLASE 
2zjm:A   (GLY330) to   (VAL356)  CRYSTAL STRUCTURE OF THE HUMAN BACE1 CATALYTIC DOMAIN IN COMPLEX WITH N-[1-(5-CHLORO-2-ISOPROPOXY-3-METHOXY-BENZYL)- PIPERIDIN-4-YL]-2-(4-SULFAMOYL-PHENOXY)-ACETAMIDE  |   BACE, SMALL-MOLECULE INHIBITOR, FRAGMENT-BASED DISCOVERY, ALTERNATIVE SPLICING, ASPARTYL PROTEASE, GLYCOPROTEIN, HYDROLASE, MEMBRANE, PROTEASE, TRANSMEMBRANE, ZYMOGEN 
4aa9:A   (LEU295) to   (LYS321)  CAMEL CHYMOSIN AT 1.6A RESOLUTION  |   HYDROLASE, ASPARTIC PEPTIDASE, RENNET 
1me6:A   (PRO297) to   (LEU324)  CRYSTAL STRUCTURE OF PLASMEPSIN II, AN ASPARTYL PROTEASE FROM PLASMODIUM FALCIPARUM, IN COMPLEX WITH A STATINE-BASED INHIBITOR  |   PROTEIN-LIGAND COMPLEX, HYDROLASE 
1me6:B   (PRO297) to   (LEU324)  CRYSTAL STRUCTURE OF PLASMEPSIN II, AN ASPARTYL PROTEASE FROM PLASMODIUM FALCIPARUM, IN COMPLEX WITH A STATINE-BASED INHIBITOR  |   PROTEIN-LIGAND COMPLEX, HYDROLASE 
1miq:A   (ASN297) to   (ILE324)  CRYSTAL STRUCTURE OF PROPLASMEPSIN FROM THE HUMAN MALARIAL PATHOGEN PLASMODIUM VIVAX  |   ASPARTIC PROTEINASE ZYMOGEN, DOMAIN OPENING, HYDROLASE 
1miq:B   (ASN297) to   (ILE324)  CRYSTAL STRUCTURE OF PROPLASMEPSIN FROM THE HUMAN MALARIAL PATHOGEN PLASMODIUM VIVAX  |   ASPARTIC PROTEINASE ZYMOGEN, DOMAIN OPENING, HYDROLASE 
3km4:A   (THR312) to   (LEU338)  OPTIMIZATION OF ORALLY BIOAVAILABLE ALKYL AMINE RENIN INHIBITORS  |   RENIN, ASPARTATE PROTEASE, HYPERTENSION, RENIN EXPRESSION, RENIN INHIBITOR, ASPARTYL PROTEASE, CLEAVAGE ON PAIR OF BASIC RESIDUES, DISULFIDE BOND, GLYCOPROTEIN, HYDROLASE, PROTEASE, SECRETED, ZYMOGEN, HYDROLASE-HYDROLASE INHIBITOR COMPLEX 
3km4:B   (THR312) to   (LEU338)  OPTIMIZATION OF ORALLY BIOAVAILABLE ALKYL AMINE RENIN INHIBITORS  |   RENIN, ASPARTATE PROTEASE, HYPERTENSION, RENIN EXPRESSION, RENIN INHIBITOR, ASPARTYL PROTEASE, CLEAVAGE ON PAIR OF BASIC RESIDUES, DISULFIDE BOND, GLYCOPROTEIN, HYDROLASE, PROTEASE, SECRETED, ZYMOGEN, HYDROLASE-HYDROLASE INHIBITOR COMPLEX 
1yg9:A   (HIS298) to   (ARG324)  THE STRUCTURE OF MUTANT (N93Q) OF BLA G 2  |   BLA G 2, ALLEGREN, HYDROLASE, ALLERGEN 
4pep:A   (GLU297) to   (PRO324)  THE MOLECULAR AND CRYSTAL STRUCTURES OF MONOCLINIC PORCINE PEPSIN REFINED AT 1.8 ANGSTROMS RESOLUTION  |   HYDROLASE (ACID PROTEINASE) 
1ym4:A   (GLY330) to   (VAL356)  CRYSTAL STRUCTURE OF HUMAN BETA SECRETASE COMPLEXED WITH NVP-AMK640  |   BETA-SECRETASE, MEMAPSIN2, ALZHEIMER'S DISEASE, ASPARTIC PROTEASE, HYDROLASE, HYDROLASE-HYDROLASE INHIBITOR COMPLEX 
1ym4:C   (GLY330) to   (VAL356)  CRYSTAL STRUCTURE OF HUMAN BETA SECRETASE COMPLEXED WITH NVP-AMK640  |   BETA-SECRETASE, MEMAPSIN2, ALZHEIMER'S DISEASE, ASPARTIC PROTEASE, HYDROLASE, HYDROLASE-HYDROLASE INHIBITOR COMPLEX 
3l58:B   (GLY391) to   (VAL417)  STRUCTURE OF BACE BOUND TO SCH589432  |   BACE1, ALZHEIMERS, ALTERNATIVE SPLICING, ASPARTYL PROTEASE, DISULFIDE BOND, ENDOPLASMIC RETICULUM, ENDOSOME, GLYCOPROTEIN, GOLGI APPARATUS, HYDROLASE, MEMBRANE, POLYMORPHISM, PROTEASE, TRANSMEMBRANE, ZYMOGEN 
1yx9:A   (GLU298) to   (PRO325)  EFFECT OF DIMETHYL SULPHOXIDE ON THE CRYSTAL STRUCTURE OF PORCINE PEPSIN  |   PEPSIN, DIMETHYL SULPHOXIDE, PROTEIN DENATURATION, HYDROLASE 
5dpz:A   (ILE302) to   (SER329)  ENDOTHIAPEPSIN IN COMPLEX WITH FRAGMENT 31  |   FRAGMENT SCREENING, HYDROLASE, INHIBITION 
5dq1:A   (ILE302) to   (SER329)  ENDOTHIAPEPSIN IN COMPLEX WITH FRAGMENT 34  |   FRAGMENT SCREENING, HYDROLASE, INHIBITION 
5dq5:A   (ILE302) to   (SER329)  ENDOTHIAPEPSIN IN COMPLEX WITH FRAGMENT 209  |   FRAGMENT SCREENING, HYDROLASE, INHIBITION 
5dqc:B   (GLY330) to   (VAL356)  CO-CRYSTAL OF BACE1 WITH COMPOUND 0211  |   B-SECRETASE, INHIBITOR, ALZHEIMER'S DISEASE, HYDROLASE-HYDROLASE INHIBITOR COMPLEX 
5dqc:C   (GLY330) to   (VAL356)  CO-CRYSTAL OF BACE1 WITH COMPOUND 0211  |   B-SECRETASE, INHIBITOR, ALZHEIMER'S DISEASE, HYDROLASE-HYDROLASE INHIBITOR COMPLEX 
5dr0:A   (ILE302) to   (SER329)  ENDOTHIAPEPSIN IN COMPLEX WITH FRAGMENT 203  |   FRAGMENT SCREENING, HYDROLASE, INHIBITION 
5dr1:A   (ILE302) to   (SER329)  ENDOTHIAPEPSIN IN COMPLEX WITH FRAGMENT 278  |   FRAGMENT SCREENING, HYDROLASE, INHIBITION 
5dr8:A   (ILE302) to   (SER329)  ENDOTHIAPEPSIN IN COMPLEX WITH FRAGMENT 330  |   FRAGMENT SCREENING, HYDROLASE, INHIBITION 
4pyv:A   (THR298) to   (LEU324)  CRYSTAL STRUCTURE OF RENIN IN COMPLEX WITH COMPOUND4  |   RENIN INHIBITOR, 3,5-SUBSTITUTED PIPERIDINES, HYDROLASE INHIBITOR COMPLEX, HYDROLASE, HYDROLASE-HYDROLASE INHIBITOR COMPLEX 
4pyv:B   (THR298) to   (LEU324)  CRYSTAL STRUCTURE OF RENIN IN COMPLEX WITH COMPOUND4  |   RENIN INHIBITOR, 3,5-SUBSTITUTED PIPERIDINES, HYDROLASE INHIBITOR COMPLEX, HYDROLASE, HYDROLASE-HYDROLASE INHIBITOR COMPLEX 
3app:A   (PHE295) to   (PRO321)  STRUCTURE AND REFINEMENT OF PENICILLOPEPSIN AT 1.8 ANGSTROMS RESOLUTION  |   HYDROLASE (ACID PROTEINASE) 
3apr:E   (GLY295) to   (ALA321)  BINDING OF A REDUCED PEPTIDE INHIBITOR TO THE ASPARTIC PROTEINASE FROM RHIZOPUS CHINENSIS. IMPLICATIONS FOR A MECHANISM OF ACTION  |   HYDROLASE, ASPARTIC PROTEINASE, HYDROLASE-HYDROLASE INHIBITOR COMPLEX 
3lzy:A   (ILE302) to   (SER329)  CRYSTAL STRUCTURE OF ENDOTHIAPESIN IN COMPLEX WITH XENON  |   PROTEIN-XE COMPLEX, HYDROLASE, B-SECRETASE, ENDOTHIAPEPSIN, ASPARTYL PROTEASE, PROTEASE, ZYMOGEN 
4bek:A   (GLY391) to   (VAL417)  CRYSTAL STRUCTURE OF BACE-1 IN COMPLEX WITH CHEMICAL LIGAND  |   HYDROLASE 
4bfd:A   (GLY391) to   (VAL417)  CRYSTAL STRUCTURE OF BACE-1 IN COMPLEX WITH CHEMICAL LIGAND  |   HYDROLASE 
5ezx:A   (GLY391) to   (VAL417)  CRYSTAL STRUCTURE OF BACE-1 IN COMPLEX WITH {(1R,2R)-2-[(R)-2-AMINO-4- (4-DIFLUOROMETHOXY-PHENYL)-4,5-DIHYDRO-OXAZOL-4-YL]-CYCLOPROPYL}-(5- CHLORO-PYRIDIN-3-YL)-METHANONE  |   PROTEASE INHIBITOR, HYDROLASE, HYDROLASE INHIBITOR COMPLEX, HYDROLASE-INHIBITOR COMPLEX 
5ezz:A   (GLY391) to   (VAL417)  CRYSTAL STRUCTURE OF BACE-1 IN COMPLEX WITH (4S)-4-[3-(5-CHLORO-3- PYRIDYL)PHENYL]-4-[4-(DIFLUOROMETHOXY)-3-METHYL-PHENYL]-5H-OXAZOL-2- AMINE  |   PROTEASE INHIBITOR, HYDROLASE-HYDROLASE INHIBITOR COMPLEX, HYDROLASE- INHIBITOR COMPLEX 
5f00:A   (GLY391) to   (VAL417)  CRYSTAL STRUCTURE OF BACE-1 IN COMPLEX WITH 5-[3-[(3-CHLORO-8- QUINOLYL)AMINO]PHENYL]-5-METHYL-2,6-DIHYDRO-1,4-OXAZIN-3-AMINE  |   PROTEASE INHIBITOR, HYDROLASE-HYDROLASE INHIBITOR COMPLEX, HYDROLASE 
3bra:A   (GLY330) to   (VAL356)  BACE-1 COMPLEXED WITH COMPOUND 1  |   ALZHEIMER'S DISEASE, ASPARTIC PROTEASE, BETA-SECRETASE, MEMAPSIN 2, FRAGMENT SCREEN, ALTERNATIVE SPLICING, ASPARTYL PROTEASE, GLYCOPROTEIN, HYDROLASE, MEMBRANE, TRANSMEMBRANE, ZYMOGEN 
3buh:A   (GLY330) to   (VAL356)  BACE-1 COMPLEXED WITH COMPOUND 4  |   ALZHEIMER'S DISEASE, ASPARTIC PROTEASE, BETA-SECRETASE, MEMAPSIN 2, FRAGMENT SCREEN, ALTERNATIVE SPLICING, ASPARTYL PROTEASE, GLYCOPROTEIN, HYDROLASE, MEMBRANE, TRANSMEMBRANE, ZYMOGEN 
4rgh:A   (ASP287) to   (ILE311)  HUMAN DNA DAMAGE-INDUCIBLE PROTEIN: FROM PROTEIN CHEMISTRY AND 3D STRUCTURE TO DECIPHERING ITS CELLULAR ROLE  |   RETROVIRAL PROTEASE-LIKE DOMAIN, PUTATIVE PROTEOLYTICAL ACTIVITY, HYDROLASE 
4rgh:B   (ASP287) to   (ILE311)  HUMAN DNA DAMAGE-INDUCIBLE PROTEIN: FROM PROTEIN CHEMISTRY AND 3D STRUCTURE TO DECIPHERING ITS CELLULAR ROLE  |   RETROVIRAL PROTEASE-LIKE DOMAIN, PUTATIVE PROTEOLYTICAL ACTIVITY, HYDROLASE 
3ckr:A   (GLY330) to   (VAL356)  CRYSTAL STRUCTURE OF BACE-1 IN COMPLEX WITH INHIBITOR  |   BETA-SECRETASE, ASPARTYL PROTEASE, ALTERNATIVE SPLICING, GLYCOPROTEIN, HYDROLASE, MEMBRANE, TRANSMEMBRANE, ZYMOGEN 
3ckr:B   (GLU116) to   (GLY177)  CRYSTAL STRUCTURE OF BACE-1 IN COMPLEX WITH INHIBITOR  |   BETA-SECRETASE, ASPARTYL PROTEASE, ALTERNATIVE SPLICING, GLYCOPROTEIN, HYDROLASE, MEMBRANE, TRANSMEMBRANE, ZYMOGEN 
3ckr:C   (GLY330) to   (VAL356)  CRYSTAL STRUCTURE OF BACE-1 IN COMPLEX WITH INHIBITOR  |   BETA-SECRETASE, ASPARTYL PROTEASE, ALTERNATIVE SPLICING, GLYCOPROTEIN, HYDROLASE, MEMBRANE, TRANSMEMBRANE, ZYMOGEN 
3cms:A   (LYS298) to   (LYS324)  ENGINEERING ENZYME SUB-SITE SPECIFICITY: PREPARATION, KINETIC CHARACTERIZATION AND X-RAY ANALYSIS AT 2.0-ANGSTROMS RESOLUTION OF VAL111PHE SITE-MUTATED CALF CHYMOSIN  |   HYDROLASE, ACID PROTEINASE 
4rld:A   (HIS298) to   (ARG324)  CRYSTAL STRUCTURE OF KKF MUTANT OF BLA G 2 PROTEIN  |   BLA G 2, ALLEGEN, HYDROLASE 
4rld:B   (HIS298) to   (ARG324)  CRYSTAL STRUCTURE OF KKF MUTANT OF BLA G 2 PROTEIN  |   BLA G 2, ALLEGEN, HYDROLASE 
4rld:C   (HIS298) to   (ARG324)  CRYSTAL STRUCTURE OF KKF MUTANT OF BLA G 2 PROTEIN  |   BLA G 2, ALLEGEN, HYDROLASE 
4rld:D   (HIS298) to   (ARG324)  CRYSTAL STRUCTURE OF KKF MUTANT OF BLA G 2 PROTEIN  |   BLA G 2, ALLEGEN, HYDROLASE 
3nr6:B    (TYR90) to   (GLY116)  CRYSTAL STRUCTURE OF XENOTROPIC MURINE LEUKEMIA VIRUS-RELATED VIRUS (XMRV) PROTEASE  |   DIMER, PROTEASE, HYDROLASE-INHIBITOR COMPLEX 
4cku:A   (PRO297) to   (LEU324)  THREE DIMENSIONAL STRUCTURE OF PLASMEPSIN II IN COMPLEX WITH HYDROXYETHYLAMINE-BASED INHIBITOR  |   HYDROLASE, MALARIA, DRUG DESIGN 
4cku:B   (THR298) to   (LEU324)  THREE DIMENSIONAL STRUCTURE OF PLASMEPSIN II IN COMPLEX WITH HYDROXYETHYLAMINE-BASED INHIBITOR  |   HYDROLASE, MALARIA, DRUG DESIGN 
4cku:C   (PRO297) to   (LEU324)  THREE DIMENSIONAL STRUCTURE OF PLASMEPSIN II IN COMPLEX WITH HYDROXYETHYLAMINE-BASED INHIBITOR  |   HYDROLASE, MALARIA, DRUG DESIGN 
4cku:D   (PRO297) to   (LEU324)  THREE DIMENSIONAL STRUCTURE OF PLASMEPSIN II IN COMPLEX WITH HYDROXYETHYLAMINE-BASED INHIBITOR  |   HYDROLASE, MALARIA, DRUG DESIGN 
4cku:E   (PRO297) to   (LEU324)  THREE DIMENSIONAL STRUCTURE OF PLASMEPSIN II IN COMPLEX WITH HYDROXYETHYLAMINE-BASED INHIBITOR  |   HYDROLASE, MALARIA, DRUG DESIGN 
4cku:F   (PRO297) to   (LEU324)  THREE DIMENSIONAL STRUCTURE OF PLASMEPSIN II IN COMPLEX WITH HYDROXYETHYLAMINE-BASED INHIBITOR  |   HYDROLASE, MALARIA, DRUG DESIGN 
4ryc:A   (THR298) to   (LEU324)  RENIN IN COMPLEXED WITH 4-METHOXY-3-(3-METHOXYPROPOXY)-N-{[(3S,4S)-4- {[(4-METHYLPHENYL)SULFONYL]AMINO}PYRROLIDIN-3-YL]METHYL}-N-(PROPAN-2- YL)BENZAMIDE INHIBITOR  |   HYDROLASE, HYDROLASE-HYDROLASE INHIBITOR COMPLEX 
4ryc:B   (THR298) to   (LEU324)  RENIN IN COMPLEXED WITH 4-METHOXY-3-(3-METHOXYPROPOXY)-N-{[(3S,4S)-4- {[(4-METHYLPHENYL)SULFONYL]AMINO}PYRROLIDIN-3-YL]METHYL}-N-(PROPAN-2- YL)BENZAMIDE INHIBITOR  |   HYDROLASE, HYDROLASE-HYDROLASE INHIBITOR COMPLEX 
4cms:A   (LYS298) to   (LYS324)  X-RAY ANALYSES OF ASPARTIC PROTEINASES IV. STRUCTURE AND REFINEMENT AT 2.2 ANGSTROMS RESOLUTION OF BOVINE CHYMOSIN  |   HYDROLASE (ACID PROTEINASE) 
4ryg:A   (THR298) to   (LEU324)  RENIN IN COMPLEXED WITH N-({(3S,4S)-4-[(BENZYLSULFONYL) AMINO]PYRROLIDIN-3-YL}METHYL)-4-METHOXY-3-(3-METHOXYPROPOXY)-N- (PROPAN-2-YL)BENZAMIDE INHIBITOR  |   HYDROLASE, HYDROLASE-HYDROLASE INHIBITOR COMPLEX 
4ryg:B   (THR298) to   (LEU324)  RENIN IN COMPLEXED WITH N-({(3S,4S)-4-[(BENZYLSULFONYL) AMINO]PYRROLIDIN-3-YL}METHYL)-4-METHOXY-3-(3-METHOXYPROPOXY)-N- (PROPAN-2-YL)BENZAMIDE INHIBITOR  |   HYDROLASE, HYDROLASE-HYDROLASE INHIBITOR COMPLEX 
4s1g:A   (THR378) to   (LEU404)  REIN IN COMPLEX WITH (S)-1-(3-FLUORO-5-(((S)-1-PHENYLETHYL)CARBAMOYL) BENZYL)-4-ISOPROPYL-4-METHYL-6-OXOTETRAHYDROPYRIMIDIN-2(1H)-IMINIUM  |   ASPARTIC PROTEASE, BLOOD PREASURE, ANGIOTENSINOGEN, HYDROLASE- HYDROLASE INHIBITOR COMPLEX 
4s1g:B   (THR378) to   (LEU404)  REIN IN COMPLEX WITH (S)-1-(3-FLUORO-5-(((S)-1-PHENYLETHYL)CARBAMOYL) BENZYL)-4-ISOPROPYL-4-METHYL-6-OXOTETRAHYDROPYRIMIDIN-2(1H)-IMINIUM  |   ASPARTIC PROTEASE, BLOOD PREASURE, ANGIOTENSINOGEN, HYDROLASE- HYDROLASE INHIBITOR COMPLEX 
3o9l:B   (THR312) to   (LEU338)  DESIGN AND OPTIMISATION OF NEW PIPERIDINES AS RENIN INHIBITORS  |   HYDROLASE, PROTEASE, GLYCOSILATION, BLOOD, HYDROLASE-HYDROLASE INHIBITOR COMPLEX 
3o9l:D   (THR312) to   (LEU338)  DESIGN AND OPTIMISATION OF NEW PIPERIDINES AS RENIN INHIBITORS  |   HYDROLASE, PROTEASE, GLYCOSILATION, BLOOD, HYDROLASE-HYDROLASE INHIBITOR COMPLEX 
3oad:B   (THR312) to   (LEU338)  DESIGN AND OPTIMIZATION OF NEW PIPERIDINES AS RENIN INHIBITORS  |   PROTEASE, BLOOD, HYDROLASE 
3oad:D   (THR312) to   (LEU338)  DESIGN AND OPTIMIZATION OF NEW PIPERIDINES AS RENIN INHIBITORS  |   PROTEASE, BLOOD, HYDROLASE 
3oag:B   (THR312) to   (LEU338)  DESIGN AND OPTIMIZATION OF NEW PIPERIDINES AS RENIN INHIBITORS  |   HYDROLASE, PROTEASE, GLYCOSILATION, BLOOD, HYDROLASE - HYDROLASE INHIBITOR COMPLEX 
3oag:D   (THR312) to   (LEU338)  DESIGN AND OPTIMIZATION OF NEW PIPERIDINES AS RENIN INHIBITORS  |   HYDROLASE, PROTEASE, GLYCOSILATION, BLOOD, HYDROLASE - HYDROLASE INHIBITOR COMPLEX 
3d91:A   (THR312) to   (LEU338)  HUMAN RENIN IN COMPLEX WITH REMIKIREN  |   RENIN, REMIKIREN, ALTERNATIVE SPLICING, ASPARTYL PROTEASE, CLEAVAGE ON PAIR OF BASIC RESIDUES, DISEASE MUTATION, GLYCOPROTEIN, HYDROLASE, MEMBRANE, POLYMORPHISM, PROTEASE, SECRETED, ZYMOGEN 
3d91:B   (THR312) to   (LEU338)  HUMAN RENIN IN COMPLEX WITH REMIKIREN  |   RENIN, REMIKIREN, ALTERNATIVE SPLICING, ASPARTYL PROTEASE, CLEAVAGE ON PAIR OF BASIC RESIDUES, DISEASE MUTATION, GLYCOPROTEIN, HYDROLASE, MEMBRANE, POLYMORPHISM, PROTEASE, SECRETED, ZYMOGEN 
4trz:C   (GLY391) to   (VAL417)  STRUCTURE OF BACE1 COMPLEX WITH 2-THIOPHENYL HEA-TYPE INHIBITOR  |   HYDRASE PROTEINASE CONVERTING, DESIGNED INHIBITOR, HYDRASE-INHIBITOR COMPLEX, HYDROLASE-HYDROLASE INHIBITOR COMPLEX 
3oot:A   (THR298) to   (LEU324)  CRYSTAL STRUCTURE ANALYSIS OF RENIN-INDOLE-PIPERAZIN INHIBITOR COMPLEXES  |   RENIN HUMAN, ASPARTYL PROTEASE, RENIN INHIBITION, HYPERTENSION, HYDROLASE 
3oot:B   (THR298) to   (LEU324)  CRYSTAL STRUCTURE ANALYSIS OF RENIN-INDOLE-PIPERAZIN INHIBITOR COMPLEXES  |   RENIN HUMAN, ASPARTYL PROTEASE, RENIN INHIBITION, HYPERTENSION, HYDROLASE 
4d8c:B   (GLY319) to   (VAL345)  CRYSTAL STRUCTURE OF HUMAN BETA SECRETASE IN COMPLEX WITH NVP-BXD552, DERIVED FROM A CO-CRYSTALLIZATION EXPERIMENT  |   BETA-SECRETASE, MEMAPSIN2, BACE1, ASPARTIC PROTEINASE, ALZHEIMER'S DISEASE, ENZYME INHIBITOR COMPLEX, STRUCTURE-BASED DRUG DESIGN, HYDROLASE, HYDROLASE-HYDROLASE INHIBITOR COMPLEX 
3oqf:A   (THR298) to   (LEU324)  CRYSTAL STRUCTURE ANALYSIS OF RENIN-INDOLE-PIPERAZINE INHIBITOR COMPLEXES  |   RENIN HUMAN, ASPARTYL PROTEASE, RENIN INHIBITION, HYPERTENSION, HYDROLASE 
3oqf:B   (THR298) to   (LEU324)  CRYSTAL STRUCTURE ANALYSIS OF RENIN-INDOLE-PIPERAZINE INHIBITOR COMPLEXES  |   RENIN HUMAN, ASPARTYL PROTEASE, RENIN INHIBITION, HYPERTENSION, HYDROLASE 
3oqk:A   (THR298) to   (LEU324)  CRYSTAL STRUCTURE ANALYSIS OF RENIN-INDOLE-PIPERAZIN INHIBITOR COMPLEXES  |   RENIN HUMAN, ASPARTYL PROTEASE, RENIN INHIBITION, HYPERTENSION, HYDROLASE 
3oqk:B   (THR298) to   (LEU324)  CRYSTAL STRUCTURE ANALYSIS OF RENIN-INDOLE-PIPERAZIN INHIBITOR COMPLEXES  |   RENIN HUMAN, ASPARTYL PROTEASE, RENIN INHIBITION, HYPERTENSION, HYDROLASE 
3dv1:C   (GLY330) to   (VAL356)  CRYSTAL STRUCTURE OF HUMAN BETA-SECRETASE IN COMPLEX WITH NVP-ARV999  |   BETA-SECRETASE, BACE1, MEMAPSIN2, ASPARTIC PROTEASE, ENZYME INHIBITOR COMPLEX, ALZHEIMER'S DISEASE, ALTERNATIVE SPLICING, ASPARTYL PROTEASE, GLYCOPROTEIN, HYDROLASE, MEMBRANE, TRANSMEMBRANE, ZYMOGEN 
5hct:A   (ILE302) to   (SER329)  ENDOTHIAPEPSIN IN COMPLEX WITH BIACYLHYDRAZONE  |   HYDROLASE, INHIBITION 
3own:A   (THR309) to   (LEU335)  POTENT MACROCYCLIC RENIN INHIBITORS  |   RENIN, PROTEASE, ASPARTYL PROTEASE, HYDROLASE, HYDROLASE-HYDROLASE INHIBITOR COMPLEX 
3own:B   (THR309) to   (LEU335)  POTENT MACROCYCLIC RENIN INHIBITORS  |   RENIN, PROTEASE, ASPARTYL PROTEASE, HYDROLASE, HYDROLASE-HYDROLASE INHIBITOR COMPLEX 
4dh6:A   (GLY330) to   (VAL356)  STRUCTURE OF BACE-1 (BETA-SECRETASE) IN COMPLEX WITH (2R)-N-((2S,3R)- 1-(BENZO[D][1,3]DIOXOL-5-YL)-3-HYDROXY-4-((S)-6'-NEOPENTYL-3',4'- DIHYDROSPIRO[CYCLOBUTANE-1,2'-PYRANO[2,3-B]PYRIDINE]-4'-YLAMINO) BUTAN-2-YL)-2-METHOXYPROPANAMIDE  |   BACE-1, BETA-SECRETASE, ASPARTYL PROTEASE, HYDROLASE-HYDROLASE INHIBITOR COMPLEX 
4djy:B   (GLY391) to   (VAL417)  STRUCTURE OF BACE BOUND TO (R)-5-CYCLOPROPYL-2-IMINO-3-METHYL-5-(3-(5- (PROP-1-YN-1-YL)PYRIDIN-3-YL)PHENYL)IMIDAZOLIDIN-4-ONE  |   BACE1, ALZHEIMERS, HYDROLASE-HYDROLASE INHIBITOR COMPLEX 
3pb5:A   (ILE302) to   (SER329)  ENDOTHIAPEPSIN IN COMPLEX WITH A FRAGMENT  |   HYDROLASE-HYDROLASE INHIBITOR COMPLEX 
3pbd:A   (ILE302) to   (SER329)  ENDOTHIAPEPSIN IN COMPLEX WITH A FRAGMENT  |   HYDROLASE-HYDROLASE INHIBITOR COMPLEX 
3pbz:A   (ILE302) to   (SER329)  ENDOTHIAPEPSIN IN COMPLEX WITH A FRAGMENT  |   HYDROLASE-HYDROLASE INHIBITOR COMPLEX 
3pcw:A   (ILE302) to   (SER329)  ENDOTHIAPEPSIN IN COMPLEX WITH A FRAGMENT  |   HYDROLASE-HYDROLASE INHIBITOR COMPLEX 
3pcz:A   (ILE302) to   (SER329)  ENDOTHIAPEPSIN IN COMPLEX WITH BENZAMIDINE  |   HYDROLASE 
3pep:A   (GLU297) to   (PRO324)  REVISED 2.3 ANGSTROMS STRUCTURE OF PORCINE PEPSIN. EVIDENCE FOR A FLEXIBLE SUBDOMAIN  |   HYDROLASE (ACID PROTEINASE) 
4dus:A   (THR331) to   (VAL356)  STRUCTURE OF BACE-1 (BETA-SECRETASE) IN COMPLEX WITH N-((2S,3R)-1-(4- FLUOROPHENYL)-3-HYDROXY-4-((6'-NEOPENTYL-3',4'- DIHYDROSPIRO[CYCLOBUTANE-1,2'-PYRANO[2,3-B]PYRIDIN]-4'-YL)AMINO) BUTAN-2-YL)ACETAMIDE  |   HYDROLASE, ASPARTYL PROTEASE, APP, HYDROLASE-HYDROLASE INHIBITOR COMPLEX 
3pgi:A   (ILE302) to   (SER329)  ENDOTHIAPEPSIN IN COMPLEX WITH A FRAGMENT  |   HYDROLASE-HYDROLASE INHIBITOR COMPLEX 
3pi0:A   (ILE302) to   (SER329)  ENDOTHIAPEPSIN IN COMPLEX WITH A FRAGMENT  |   HYDROLASE-HYDROLASE INHIBITOR COMPLEX 
5i3v:A   (GLY330) to   (VAL356)  CRYSTAL STRUCTURE OF BACE1 IN COMPLEX WITH AMINOQUINOLINE COMPOUND 1  |   ASPARTIC PROTEASE, AMYLOID PRECURSOR PROTEIN, ALZHEIMER'S DISEASE, HYDROLASE-HYDROLASE INHIBITOR COMPLEX 
5i3w:A   (GLY330) to   (VAL356)  CRYSTAL STRUCTURE OF BACE1 IN COMPLEX WITH 2-AMINOOXAZOLINE-3- AZAXANTHENE INHIBITOR 2  |   ASPARTIC PROTEASE, AMYLOID PRECURSOR PROTEIN, ALZHEIMER'S DISEASE, HYDROLASE-HYDROLASE INHIBITOR COMPLEX 
3pld:A   (ILE302) to   (SER329)  ENDOTHIAPEPSIN IN COMPLEX WITH A FRAGMENT  |   HYDROLASE-HYDROLASE INHIBITOR COMPLEX 
3pm4:A   (ILE302) to   (SER329)  ENDOTHIAPEPSIN IN COMPLEX WITH A FRAGMENT  |   HYDROLASE-HYDROLASE INHIBITOR COMPLEX 
3pmu:A   (ILE302) to   (SER329)  ENDOTHIAPEPSIN IN COMPLEX WITH A FRAGMENT  |   HYDROLASE-HYDROLASE INHIBITOR COMPLEX 
5i70:B   (ASN297) to   (VAL324)  CRYSTAL STRUCTURE OF PLASMEPSIN IV  |   PLASMEPSIN, ASPARTIC PROTEASE, MALARIA, CATHEPSIN D LIKE, HYDROLASE- HYDROLASE INHIBITOR COMPLEX 
5i70:A   (ASN297) to   (VAL324)  CRYSTAL STRUCTURE OF PLASMEPSIN IV  |   PLASMEPSIN, ASPARTIC PROTEASE, MALARIA, CATHEPSIN D LIKE, HYDROLASE- HYDROLASE INHIBITOR COMPLEX 
3prs:A   (ILE302) to   (SER329)  ENDOTHIAPEPSIN IN COMPLEX WITH RITONAVIR  |   HYDROLASE-HYDROLASE INHIBITOR COMPLEX 
3psg:A   (GLU297) to   (PRO324)  THE HIGH RESOLUTION CRYSTAL STRUCTURE OF PORCINE PEPSINOGEN  |   HYDROLASE(ACID PROTEINASE ZYMOGEN) 
3psy:A   (ILE302) to   (SER329)  ENDOTHIAPEPSIN IN COMPLEX WITH AN INHIBITOR BASED ON THE GEWALD REACTION  |   HYDROLASE, HYDROLASE-HYDROLASE INHIBITOR COMPLEX 
3pww:A   (ILE302) to   (SER329)  ENDOTHIAPEPSIN IN COMPLEX WITH SAQUINAVIR  |   HYDROLASE-HYDROLASE INHIBITOR COMPLEX 
3q3t:A   (THR298) to   (LEU324)  ALKYL AMINE RENIN INHIBITORS: FILLING S1 FROM S3  |   ASPARTATE PROTEASE, HYPERTENSION, RENIN INHIBITORS, GLYCOPROTEIN, ZYMOGEN, HYDROLASE-HYDROLASE INHIBITOR COMPLEX 
3q3t:B   (THR298) to   (LEU324)  ALKYL AMINE RENIN INHIBITORS: FILLING S1 FROM S3  |   ASPARTATE PROTEASE, HYPERTENSION, RENIN INHIBITORS, GLYCOPROTEIN, ZYMOGEN, HYDROLASE-HYDROLASE INHIBITOR COMPLEX 
3q4b:A   (THR298) to   (LEU324)  CLINICALLY USEFUL ALKYL AMINE RENIN INHIBITORS  |   ASPARTATE PROTEASE, HYPERTENSION, RENIN EXPRESSION, RENIN INHIBITOR, ASPARTYL PROTEASE, CLEAVAGE ON PAIR OF BASIC RESIDUES, GLYCOPROTEIN, MEMBRANE, PROTEASE, SECRETED, HYDROLASE-HYDROLASE INHIBITOR COMPLEX 
3q4b:B   (THR298) to   (LEU324)  CLINICALLY USEFUL ALKYL AMINE RENIN INHIBITORS  |   ASPARTATE PROTEASE, HYPERTENSION, RENIN EXPRESSION, RENIN INHIBITOR, ASPARTYL PROTEASE, CLEAVAGE ON PAIR OF BASIC RESIDUES, GLYCOPROTEIN, MEMBRANE, PROTEASE, SECRETED, HYDROLASE-HYDROLASE INHIBITOR COMPLEX 
3q5h:A   (THR298) to   (LEU324)  CLINICALLY USEFUL ALKYL AMINE RENIN INHIBITORS  |   ASPARTATE PROTEASE, HYPERTENSION, RENIN EXPRESSION, RENIN INHIBITOR, ASPARTYL PROTEASE, CLEAVAGE ON PAIR OF BASIC RESIDUES, DISEASE MUTATION, GLYCOPROTEIN, MEMBRANE, PROTEASE, SECRETED, HYDROLASE- HYDROLASE INHIBITOR COMPLEX 
3q5h:B   (THR298) to   (LEU324)  CLINICALLY USEFUL ALKYL AMINE RENIN INHIBITORS  |   ASPARTATE PROTEASE, HYPERTENSION, RENIN EXPRESSION, RENIN INHIBITOR, ASPARTYL PROTEASE, CLEAVAGE ON PAIR OF BASIC RESIDUES, DISEASE MUTATION, GLYCOPROTEIN, MEMBRANE, PROTEASE, SECRETED, HYDROLASE- HYDROLASE INHIBITOR COMPLEX 
4er4:E   (ILE299) to   (SER325)  HIGH-RESOLUTION X-RAY ANALYSES OF RENIN INHIBITOR-ASPARTIC PROTEINASE COMPLEXES  |   HYDROLASE, ACID PROTEINASE, HYDROLASE-HYDROLASE INHIBITOR COMPLEX 
3q6y:A   (ILE302) to   (SER329)  ENDOTHIAPEPSIN IN COMPLEX WITH A PYRROLIDINE BASED INHIBITOR  |   HYDROLASE-HYDROLASE INHIBITOR COMPLEX 
4exh:B    (TYR90) to   (GLY116)  THE CRYSTAL STRUCTURE OF XMRV PROTEASE COMPLEXED WITH ACETYL-PEPSTATIN  |   BETA SHEET, DIMER, PROTEASE, ACETYL-PEPSTAIN, VIRUS, HYDROLASE-HYDROL INHIBITOR COMPLEX, HYDROLASE-HYDROLASE INHIBITOR COMPLEX 
4fco:A   (GLY378) to   (VAL404)  CRYSTAL STRUCTURE OF BACE1 WITH ITS INHIBITOR  |   HYDROLASE, HYDROLASE-HYDROLASE INHIBITOR COMPLEX 
3qrv:A   (ASN297) to   (LEU324)  CRYSTAL STRUCTURE OF PLASMEPSIN I (PMI) FROM PLASMODIUM FALCIPARUM  |   ASPARTIC PROTEASE, MALARIA, HYDROLASE 
3qrv:B   (ASN297) to   (LEU324)  CRYSTAL STRUCTURE OF PLASMEPSIN I (PMI) FROM PLASMODIUM FALCIPARUM  |   ASPARTIC PROTEASE, MALARIA, HYDROLASE 
3qs1:A   (ASN297) to   (LEU324)  CRYSTAL STRUCTURE OF KNI-10006 COMPLEX OF PLASMEPSIN I (PMI) FROM PLASMODIUM FALCIPARUM  |   ASPARTIC PROTEASE, MALARIA, KNI, HYDROLASE-HYDROLASE INHIBITOR COMPLEX 
3qs1:B   (ASN297) to   (LEU324)  CRYSTAL STRUCTURE OF KNI-10006 COMPLEX OF PLASMEPSIN I (PMI) FROM PLASMODIUM FALCIPARUM  |   ASPARTIC PROTEASE, MALARIA, KNI, HYDROLASE-HYDROLASE INHIBITOR COMPLEX 
3qs1:C   (ASN297) to   (LEU324)  CRYSTAL STRUCTURE OF KNI-10006 COMPLEX OF PLASMEPSIN I (PMI) FROM PLASMODIUM FALCIPARUM  |   ASPARTIC PROTEASE, MALARIA, KNI, HYDROLASE-HYDROLASE INHIBITOR COMPLEX 
3qs1:D   (ASN297) to   (LEU324)  CRYSTAL STRUCTURE OF KNI-10006 COMPLEX OF PLASMEPSIN I (PMI) FROM PLASMODIUM FALCIPARUM  |   ASPARTIC PROTEASE, MALARIA, KNI, HYDROLASE-HYDROLASE INHIBITOR COMPLEX 
3qvc:A   (ASN297) to   (LEU324)  CRYSTAL STRUCTURE OF HISTO-ASPARTIC PROTEASE (HAP) ZYMOGEN FROM PLASMODIUM FALCIPARUM  |   HISTO-ASPARTIC PROTEASE, HAP, PLASMEPSIN, ASPARTIC PROTEASE, MALARIA, ZYMOGEN, HYDROLASE 
3qvi:A   (ASN297) to   (LEU324)  CRYSTAL STRUCTURE OF KNI-10395 BOUND HISTO-ASPARTIC PROTEASE (HAP) FROM PLASMODIUM FALCIPARUM  |   HISTO-ASPARTIC PROTEASE, HAP, PLASMEPSIN, ASPARTIC PROTEASE, MALARIA, KNI, KNI-10395, HYDROLASE-HYDROLASE INHIBITOR COMPLEX 
3qvi:B   (ASN297) to   (LEU324)  CRYSTAL STRUCTURE OF KNI-10395 BOUND HISTO-ASPARTIC PROTEASE (HAP) FROM PLASMODIUM FALCIPARUM  |   HISTO-ASPARTIC PROTEASE, HAP, PLASMEPSIN, ASPARTIC PROTEASE, MALARIA, KNI, KNI-10395, HYDROLASE-HYDROLASE INHIBITOR COMPLEX 
3qvi:C   (ASN297) to   (LEU324)  CRYSTAL STRUCTURE OF KNI-10395 BOUND HISTO-ASPARTIC PROTEASE (HAP) FROM PLASMODIUM FALCIPARUM  |   HISTO-ASPARTIC PROTEASE, HAP, PLASMEPSIN, ASPARTIC PROTEASE, MALARIA, KNI, KNI-10395, HYDROLASE-HYDROLASE INHIBITOR COMPLEX 
3qvi:D   (ASN297) to   (LEU324)  CRYSTAL STRUCTURE OF KNI-10395 BOUND HISTO-ASPARTIC PROTEASE (HAP) FROM PLASMODIUM FALCIPARUM  |   HISTO-ASPARTIC PROTEASE, HAP, PLASMEPSIN, ASPARTIC PROTEASE, MALARIA, KNI, KNI-10395, HYDROLASE-HYDROLASE INHIBITOR COMPLEX 
4fgx:A   (GLY378) to   (VAL404)  CRYSTAL STRUCTURE OF BACE1 WITH NOVEL INHIBITOR  |   HYDROLASE, HYDROLASE-HYDROLASE INHIBITOR COMPLEX 
4gid:B   (GLY378) to   (VAL404)  STRUCTURE OF BETA-SECRETASE COMPLEXED WITH INHIBITOR  |   ASPARTIC PROTEASE, BETA SECRETASE, APP, BACE, A-BETA, PROTEASE, MEMAPSIN, ALZHEIMER, DRUG DESIGN, HYDROLASE-HYDROLASE INHIBITOR COMPLEX 
4gj5:A   (THR298) to   (LEU324)  CRYSTAL STRUCTURE OF RENIN IN COMPLEX WITH NVP-AMQ838 (COMPOUND 5)  |   RENIN INHIBITOR, PHARMACOPHORE SEARCH, TRANS-3,4-DISUBSTITUTED PYRROLIDINE, HYDROLASE-HYDROLASE INHIBITOR COMPLEX 
4gj5:B   (THR298) to   (LEU324)  CRYSTAL STRUCTURE OF RENIN IN COMPLEX WITH NVP-AMQ838 (COMPOUND 5)  |   RENIN INHIBITOR, PHARMACOPHORE SEARCH, TRANS-3,4-DISUBSTITUTED PYRROLIDINE, HYDROLASE-HYDROLASE INHIBITOR COMPLEX 
4gj7:A   (THR298) to   (LEU324)  CRYSTAL STRUCTURE OF RENIN IN COMPLEX WITH NVP-BCA079 (COMPOUND 12A)  |   RENIN INHIBITOR, PHARMACOPHORE SEARCH, TRANS-3,4-DISUBSTITUTED PYRROLIDINE, HYDROLASE-HYDROLASE INHIBITOR COMPLEX 
4gj7:B   (THR298) to   (LEU324)  CRYSTAL STRUCTURE OF RENIN IN COMPLEX WITH NVP-BCA079 (COMPOUND 12A)  |   RENIN INHIBITOR, PHARMACOPHORE SEARCH, TRANS-3,4-DISUBSTITUTED PYRROLIDINE, HYDROLASE-HYDROLASE INHIBITOR COMPLEX 
4gj8:A   (THR298) to   (LEU324)  CRYSTAL STRUCTURE OF RENIN IN COMPLEX WITH PKF909-724 (COMPOUND 3)  |   RENIN INHIBITOR, FRAGMENT BASED SCREENING, 3,5-DISUBSTITUTED PIPERIDINES, HYDROLASE-HYDROLASE INHIBITOR COMPLEX 
4gj8:B   (THR298) to   (LEU324)  CRYSTAL STRUCTURE OF RENIN IN COMPLEX WITH PKF909-724 (COMPOUND 3)  |   RENIN INHIBITOR, FRAGMENT BASED SCREENING, 3,5-DISUBSTITUTED PIPERIDINES, HYDROLASE-HYDROLASE INHIBITOR COMPLEX 
4gj9:A   (THR298) to   (LEU324)  CRYSTAL STRUCTURE OF RENIN IN COMPLEX WITH GP055321 (COMPOUND 4)  |   RENIN INHIBITOR, FRAGMENT BASED SCREENING, 3,5-DISUBSTITUTED PIPERIDINES, HYDROLASE-HYDROLASE INHIBITOR COMPLEX 
4gj9:B   (THR298) to   (LEU324)  CRYSTAL STRUCTURE OF RENIN IN COMPLEX WITH GP055321 (COMPOUND 4)  |   RENIN INHIBITOR, FRAGMENT BASED SCREENING, 3,5-DISUBSTITUTED PIPERIDINES, HYDROLASE-HYDROLASE INHIBITOR COMPLEX 
4gja:A   (THR298) to   (LEU324)  CRYSTAL STRUCTURE OF RENIN IN COMPLEX WITH NVP-AYL747 (COMPOUND 5)  |   RENIN INHIBITOR, FRAGMENT BASED SCREENING, 3,5-DISUBSTITUTED PIPERIDINES, HYDROLASE-HYDROLASE INHIBITOR COMPLEX 
4gja:B   (THR298) to   (LEU324)  CRYSTAL STRUCTURE OF RENIN IN COMPLEX WITH NVP-AYL747 (COMPOUND 5)  |   RENIN INHIBITOR, FRAGMENT BASED SCREENING, 3,5-DISUBSTITUTED PIPERIDINES, HYDROLASE-HYDROLASE INHIBITOR COMPLEX 
4gjb:A   (THR298) to   (LEU324)  CRYSTAL STRUCTURE OF RENIN IN COMPLEX WITH NVP-BBV031 (COMPOUND 6)  |   RENIN INHIBITOR, FRAGMENT BASED SCREENING, 3,5-DISUBSTITUTED PIPERIDINES, HYDROLASE-HYDROLASE INHIBITOR COMPLEX 
4gjb:B   (THR298) to   (LEU324)  CRYSTAL STRUCTURE OF RENIN IN COMPLEX WITH NVP-BBV031 (COMPOUND 6)  |   RENIN INHIBITOR, FRAGMENT BASED SCREENING, 3,5-DISUBSTITUTED PIPERIDINES, HYDROLASE-HYDROLASE INHIBITOR COMPLEX 
4gjc:A   (THR298) to   (LEU324)  CRYSTAL STRUCTURE OF RENIN IN COMPLEX WITH NVP-BCH965 (COMPOUND 9)  |   RENIN INHIBITOR, FRAGMENT BASED SCREENING, 3,5-DISUBSTITUTED PIPERIDINES, HYDROLASE-HYDROLASE INHIBITOR COMPLEX 
4gjc:B   (THR298) to   (LEU324)  CRYSTAL STRUCTURE OF RENIN IN COMPLEX WITH NVP-BCH965 (COMPOUND 9)  |   RENIN INHIBITOR, FRAGMENT BASED SCREENING, 3,5-DISUBSTITUTED PIPERIDINES, HYDROLASE-HYDROLASE INHIBITOR COMPLEX 
4gjd:A   (THR298) to   (LEU324)  CRYSTAL STRUCTURE OF RENIN IN COMPLEX WITH NVP-BGQ311 (COMPOUND 12)  |   RENIN INHIBITOR, FRAGMENT BASED SCREENING, 3,5-DISUBSTITUTED PIPERIDINES, HYDROLASE-HYDROLASE INHIBITOR COMPLEX 
4gjd:B   (THR298) to   (LEU324)  CRYSTAL STRUCTURE OF RENIN IN COMPLEX WITH NVP-BGQ311 (COMPOUND 12)  |   RENIN INHIBITOR, FRAGMENT BASED SCREENING, 3,5-DISUBSTITUTED PIPERIDINES, HYDROLASE-HYDROLASE INHIBITOR COMPLEX 
5koq:A   (THR312) to   (LEU338)  DISCOVERY OF TAK-272: A NOVEL, POTENT AND ORALLY ACTIVE RENIN IN- HIBITOR  |   PROTEIN-INHIBITOR COMPLEX, HYDROLASE-HYDROLASE INHIBITOR COMPLEX 
5koq:B   (THR312) to   (LEU338)  DISCOVERY OF TAK-272: A NOVEL, POTENT AND ORALLY ACTIVE RENIN IN- HIBITOR  |   PROTEIN-INHIBITOR COMPLEX, HYDROLASE-HYDROLASE INHIBITOR COMPLEX 
5kos:A   (THR312) to   (LEU338)  DISCOVERY OF TAK-272: A NOVEL, POTENT AND ORALLY ACTIVE RENIN IN- HIBITOR  |   PROTEIN-INHIBITOR COMPLEX, HYDROLASE-HYDROLASE INHIBITOR COMPLEX 
5kos:B   (THR312) to   (LEU338)  DISCOVERY OF TAK-272: A NOVEL, POTENT AND ORALLY ACTIVE RENIN IN- HIBITOR  |   PROTEIN-INHIBITOR COMPLEX, HYDROLASE-HYDROLASE INHIBITOR COMPLEX 
5oyq:A   (ILE302) to   (SER329)  AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 1  |   FRAGMENT SCREENING, METHOD DEVELOPMENT, ASPARTIC PROTEASE, HYDROLASE 
5oyr:A   (ILE302) to   (SER329)  AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 2  |   FRAGMENT SCREENING, METHOD DEVELOPMENT, ASPARTIC PROTEASE, HYDROLASE 
5oys:A   (ILE302) to   (SER329)  AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 3  |   FRAGMENT SCREENING, METHOD DEVELOPMENT, ASPARTIC PROTEASE, HYDROLASE 
5oyt:A   (ILE302) to   (SER329)  AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 4  |   FRAGMENT SCREENING, METHOD DEVELOPMENT, ASPARTIC PROTEASE, HYDROLASE 
5oyu:A   (ILE302) to   (SER329)  AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 5  |   FRAGMENT SCREENING, METHOD DEVELOPMENT, ASPARTIC PROTEASE, HYDROLASE 
5oyv:A   (ILE302) to   (SER329)  AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 6  |   FRAGMENT SCREENING, METHOD DEVELOPMENT, ASPARTIC PROTEASE, HYDROLASE 
5oyw:A   (ILE302) to   (SER329)  AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 7  |   FRAGMENT SCREENING, METHOD DEVELOPMENT, ASPARTIC PROTEASE, HYDROLASE 
5oyx:A   (ILE302) to   (SER329)  AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 8  |   FRAGMENT SCREENING, METHOD DEVELOPMENT, ASPARTIC PROTEASE, HYDROLASE 
5oyy:A   (ILE302) to   (SER329)  AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 9  |   FRAGMENT SCREENING, METHOD DEVELOPMENT, ASPARTIC PROTEASE, HYDROLASE 
5oyz:A   (ILE302) to   (SER329)  AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 10  |   FRAGMENT SCREENING, METHOD DEVELOPMENT, ASPARTIC PROTEASE, HYDROLASE 
5oz0:A   (ILE302) to   (SER329)  AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 11  |   FRAGMENT SCREENING, METHOD DEVELOPMENT, ASPARTIC PROTEASE, HYDROLASE 
5oz1:A   (ILE302) to   (SER329)  AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 12  |   FRAGMENT SCREENING, METHOD DEVELOPMENT, ASPARTIC PROTEASE, HYDROLASE 
5oz2:A   (ILE302) to   (SER329)  AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 13  |   FRAGMENT SCREENING, METHOD DEVELOPMENT, ASPARTIC PROTEASE, HYDROLASE 
5oz3:A   (ILE302) to   (SER329)  AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 14  |   FRAGMENT SCREENING, METHOD DEVELOPMENT, ASPARTIC PROTEASE, HYDROLASE 
5oz5:A   (ILE302) to   (SER329)  AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 16  |   FRAGMENT SCREENING, METHOD DEVELOPMENT, ASPARTIC PROTEASE, HYDROLASE 
5oz6:A   (ILE302) to   (SER329)  AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 17  |   FRAGMENT SCREENING, METHOD DEVELOPMENT, ASPARTIC PROTEASE, HYDROLASE 
5oz7:A   (ILE302) to   (SER329)  AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 18  |   FRAGMENT SCREENING, METHOD DEVELOPMENT, ASPARTIC PROTEASE, HYDROLASE 
5oz8:A   (ILE302) to   (SER329)  AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 19  |   FRAGMENT SCREENING, METHOD DEVELOPMENT, ASPARTIC PROTEASE, HYDROLASE 
5oz9:A   (ILE302) to   (SER329)  AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 20  |   FRAGMENT SCREENING, METHOD DEVELOPMENT, ASPARTIC PROTEASE, HYDROLASE 
5oza:A   (ILE302) to   (SER329)  AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 21  |   FRAGMENT SCREENING, METHOD DEVELOPMENT, ASPARTIC PROTEASE, HYDROLASE 
5ozb:A   (ILE302) to   (SER329)  AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 22  |   FRAGMENT SCREENING, METHOD DEVELOPMENT, ASPARTIC PROTEASE, HYDROLASE 
5ozc:A   (ILE302) to   (SER329)  AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 23  |   FRAGMENT SCREENING, METHOD DEVELOPMENT, ASPARTIC PROTEASE, HYDROLASE 
5ozd:A   (ILE302) to   (SER329)  AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 24  |   FRAGMENT SCREENING, METHOD DEVELOPMENT, ASPARTIC PROTEASE, HYDROLASE 
5oze:A   (ILE302) to   (SER329)  AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 25  |   FRAGMENT SCREENING, METHOD DEVELOPMENT, ASPARTIC PROTEASE, HYDROLASE 
5ozf:A   (ILE302) to   (SER329)  AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 26  |   FRAGMENT SCREENING, METHOD DEVELOPMENT, ASPARTIC PROTEASE, HYDROLASE 
5ozg:A   (ILE302) to   (SER329)  AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 27  |   FRAGMENT SCREENING, METHOD DEVELOPMENT, ASPARTIC PROTEASE, HYDROLASE 
5ozh:A   (ILE302) to   (SER329)  AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 28  |   FRAGMENT SCREENING, METHOD DEVELOPMENT, ASPARTIC PROTEASE, HYDROLASE 
5ozi:A   (ILE302) to   (SER329)  AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 29  |   FRAGMENT SCREENING, METHOD DEVELOPMENT, ASPARTIC PROTEASE, HYDROLASE 
5ozk:A   (ILE302) to   (SER329)  AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 31  |   FRAGMENT SCREENING, METHOD DEVELOPMENT, ASPARTIC PROTEASE, HYDROLASE 
5ozl:A   (ILE302) to   (SER329)  AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 32  |   FRAGMENT SCREENING, METHOD DEVELOPMENT, ASPARTIC PROTEASE, HYDROLASE 
5ozm:A   (ILE302) to   (SER329)  AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 33  |   FRAGMENT SCREENING, METHOD DEVELOPMENT, ASPARTIC PROTEASE, HYDROLASE 
5ozn:A   (ILE302) to   (SER329)  AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 34  |   FRAGMENT SCREENING, METHOD DEVELOPMENT, ASPARTIC PROTEASE, HYDROLASE 
5ozo:A   (ILE302) to   (SER329)  AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 35  |   FRAGMENT SCREENING, METHOD DEVELOPMENT, ASPARTIC PROTEASE, HYDROLASE 
5ozp:A   (ILE302) to   (SER329)  AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 36  |   FRAGMENT SCREENING, METHOD DEVELOPMENT, ASPARTIC PROTEASE, HYDROLASE 
5ozq:A   (ILE302) to   (SER329)  AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 37  |   FRAGMENT SCREENING, METHOD DEVELOPMENT, ASPARTIC PROTEASE, HYDROLASE 
5ozr:A   (ILE302) to   (SER329)  AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 38  |   FRAGMENT SCREENING, METHOD DEVELOPMENT, ASPARTIC PROTEASE, HYDROLASE 
5ozs:A   (ILE302) to   (SER329)  AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 39  |   FRAGMENT SCREENING, METHOD DEVELOPMENT, ASPARTIC PROTEASE, HYDROLASE 
5ozt:A   (ILE302) to   (SER329)  AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 40  |   FRAGMENT SCREENING, METHOD DEVELOPMENT, ASPARTIC PROTEASE, HYDROLASE 
5ozu:A   (ILE302) to   (SER329)  AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 41  |   FRAGMENT SCREENING, METHOD DEVELOPMENT, ASPARTIC PROTEASE, HYDROLASE 
5ozv:A   (ILE302) to   (SER329)  AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 42  |   FRAGMENT SCREENING, METHOD DEVELOPMENT, ASPARTIC PROTEASE, HYDROLASE 
5ozw:A   (ILE302) to   (SER329)  AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 43  |   FRAGMENT SCREENING, METHOD DEVELOPMENT, ASPARTIC PROTEASE, HYDROLASE 
5ozx:A   (ILE302) to   (SER329)  AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 44  |   FRAGMENT SCREENING, METHOD DEVELOPMENT, ASPARTIC PROTEASE, HYDROLASE 
5ozy:A   (ILE302) to   (SER329)  AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 45  |   FRAGMENT SCREENING, METHOD DEVELOPMENT, ASPARTIC PROTEASE, HYDROLASE 
5ozz:A   (ILE302) to   (SER329)  AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 46  |   FRAGMENT SCREENING, METHOD DEVELOPMENT, ASPARTIC PROTEASE, HYDROLASE 
5p00:A   (ILE302) to   (SER329)  AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 47  |   FRAGMENT SCREENING, METHOD DEVELOPMENT, ASPARTIC PROTEASE, HYDROLASE 
5p02:A   (ILE302) to   (SER329)  AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 49  |   FRAGMENT SCREENING, METHOD DEVELOPMENT, ASPARTIC PROTEASE, HYDROLASE 
5p03:A   (ILE302) to   (SER329)  AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 50  |   FRAGMENT SCREENING, METHOD DEVELOPMENT, ASPARTIC PROTEASE, HYDROLASE 
5p04:A   (ILE302) to   (SER329)  AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 51  |   FRAGMENT SCREENING, METHOD DEVELOPMENT, ASPARTIC PROTEASE, HYDROLASE 
5p06:A   (ILE302) to   (SER329)  AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 53  |   FRAGMENT SCREENING, METHOD DEVELOPMENT, ASPARTIC PROTEASE, HYDROLASE 
5p07:A   (ILE302) to   (SER329)  AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 54  |   FRAGMENT SCREENING, METHOD DEVELOPMENT, ASPARTIC PROTEASE, HYDROLASE 
5p08:A   (ILE302) to   (SER329)  AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 55  |   FRAGMENT SCREENING, METHOD DEVELOPMENT, ASPARTIC PROTEASE, HYDROLASE 
5p09:A   (ILE302) to   (SER329)  AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 56  |   FRAGMENT SCREENING, METHOD DEVELOPMENT, ASPARTIC PROTEASE, HYDROLASE 
5p0b:A   (ILE302) to   (SER329)  AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 58  |   FRAGMENT SCREENING, METHOD DEVELOPMENT, ASPARTIC PROTEASE, HYDROLASE 
5p0d:A   (ILE302) to   (SER329)  AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 60  |   FRAGMENT SCREENING, METHOD DEVELOPMENT, ASPARTIC PROTEASE, HYDROLASE 
5p0f:A   (ILE302) to   (SER329)  AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 62  |   FRAGMENT SCREENING, METHOD DEVELOPMENT, ASPARTIC PROTEASE, HYDROLASE 
5p0g:A   (ILE302) to   (SER329)  AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 63  |   FRAGMENT SCREENING, METHOD DEVELOPMENT, ASPARTIC PROTEASE, HYDROLASE 
5p0h:A   (ILE302) to   (SER329)  AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 64  |   FRAGMENT SCREENING, METHOD DEVELOPMENT, ASPARTIC PROTEASE, HYDROLASE 
5p0i:A   (ILE302) to   (SER329)  AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 65  |   FRAGMENT SCREENING, METHOD DEVELOPMENT, ASPARTIC PROTEASE, HYDROLASE 
5p0j:A   (ILE302) to   (SER329)  AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 66  |   FRAGMENT SCREENING, METHOD DEVELOPMENT, ASPARTIC PROTEASE, HYDROLASE 
5p0k:A   (ILE302) to   (SER329)  AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 67  |   FRAGMENT SCREENING, METHOD DEVELOPMENT, ASPARTIC PROTEASE, HYDROLASE 
5p0l:A   (ILE302) to   (SER329)  AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 68  |   FRAGMENT SCREENING, METHOD DEVELOPMENT, ASPARTIC PROTEASE, HYDROLASE 
5p0m:A   (ILE302) to   (SER329)  AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 69  |   FRAGMENT SCREENING, METHOD DEVELOPMENT, ASPARTIC PROTEASE, HYDROLASE 
5p0n:A   (ILE302) to   (SER329)  AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 70  |   FRAGMENT SCREENING, METHOD DEVELOPMENT, ASPARTIC PROTEASE, HYDROLASE 
5p0o:A   (ILE302) to   (SER329)  AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 71  |   FRAGMENT SCREENING, METHOD DEVELOPMENT, ASPARTIC PROTEASE, HYDROLASE 
5p0p:A   (ILE302) to   (SER329)  AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 72  |   FRAGMENT SCREENING, METHOD DEVELOPMENT, ASPARTIC PROTEASE, HYDROLASE 
5p0q:A   (ILE302) to   (SER329)  AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 73  |   FRAGMENT SCREENING, METHOD DEVELOPMENT, ASPARTIC PROTEASE, HYDROLASE 
5p0r:A   (ILE302) to   (SER329)  AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 74  |   FRAGMENT SCREENING, METHOD DEVELOPMENT, ASPARTIC PROTEASE, HYDROLASE 
5p0s:A   (ILE302) to   (SER329)  AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 75  |   FRAGMENT SCREENING, METHOD DEVELOPMENT, ASPARTIC PROTEASE, HYDROLASE 
5p0t:A   (ILE302) to   (SER329)  AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 76  |   FRAGMENT SCREENING, METHOD DEVELOPMENT, ASPARTIC PROTEASE, HYDROLASE 
5p0u:A   (ILE302) to   (SER329)  AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 77  |   FRAGMENT SCREENING, METHOD DEVELOPMENT, ASPARTIC PROTEASE, HYDROLASE 
5p0v:A   (ILE302) to   (SER329)  AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 78  |   FRAGMENT SCREENING, METHOD DEVELOPMENT, ASPARTIC PROTEASE, HYDROLASE 
5p0x:A   (ILE302) to   (SER329)  AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 80  |   FRAGMENT SCREENING, METHOD DEVELOPMENT, ASPARTIC PROTEASE, HYDROLASE 
5p0y:A   (ILE302) to   (SER329)  AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 81  |   FRAGMENT SCREENING, METHOD DEVELOPMENT, ASPARTIC PROTEASE, HYDROLASE 
5p0z:A   (ILE302) to   (SER329)  AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 82  |   FRAGMENT SCREENING, METHOD DEVELOPMENT, ASPARTIC PROTEASE, HYDROLASE 
5p10:A   (ILE302) to   (SER329)  AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 83  |   FRAGMENT SCREENING, METHOD DEVELOPMENT, ASPARTIC PROTEASE, HYDROLASE 
5p11:A   (ILE302) to   (SER329)  AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 84  |   FRAGMENT SCREENING, METHOD DEVELOPMENT, ASPARTIC PROTEASE, HYDROLASE 
5p12:A   (ILE302) to   (SER329)  AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 85  |   FRAGMENT SCREENING, METHOD DEVELOPMENT, ASPARTIC PROTEASE, HYDROLASE 
5p14:A   (ILE302) to   (SER329)  AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 87  |   FRAGMENT SCREENING, METHOD DEVELOPMENT, ASPARTIC PROTEASE, HYDROLASE 
5p15:A   (ILE302) to   (SER329)  AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 88  |   FRAGMENT SCREENING, METHOD DEVELOPMENT, ASPARTIC PROTEASE, HYDROLASE 
5p16:A   (ILE302) to   (SER329)  AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 89  |   FRAGMENT SCREENING, METHOD DEVELOPMENT, ASPARTIC PROTEASE, HYDROLASE 
5p17:A   (ILE302) to   (SER329)  AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 90  |   FRAGMENT SCREENING, METHOD DEVELOPMENT, ASPARTIC PROTEASE, HYDROLASE 
5p18:A   (ILE302) to   (SER329)  AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 91  |   FRAGMENT SCREENING, METHOD DEVELOPMENT, ASPARTIC PROTEASE, HYDROLASE 
5p19:A   (ILE302) to   (SER329)  AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 92  |   FRAGMENT SCREENING, METHOD DEVELOPMENT, ASPARTIC PROTEASE, HYDROLASE 
5p1a:A   (ILE302) to   (SER329)  AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 93  |   FRAGMENT SCREENING, METHOD DEVELOPMENT, ASPARTIC PROTEASE, HYDROLASE 
5p1b:A   (ILE302) to   (SER329)  AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 94  |   FRAGMENT SCREENING, METHOD DEVELOPMENT, ASPARTIC PROTEASE, HYDROLASE 
5p1d:A   (ILE302) to   (SER329)  AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 96  |   FRAGMENT SCREENING, METHOD DEVELOPMENT, ASPARTIC PROTEASE, HYDROLASE 
5p1e:A   (ILE302) to   (SER329)  AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 97  |   FRAGMENT SCREENING, METHOD DEVELOPMENT, ASPARTIC PROTEASE, HYDROLASE 
5p1f:A   (ILE302) to   (SER329)  AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 98  |   FRAGMENT SCREENING, METHOD DEVELOPMENT, ASPARTIC PROTEASE, HYDROLASE 
5p1g:A   (ILE302) to   (SER329)  AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 99  |   FRAGMENT SCREENING, METHOD DEVELOPMENT, ASPARTIC PROTEASE, HYDROLASE 
5p1i:A   (ILE302) to   (SER329)  AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 101  |   FRAGMENT SCREENING, METHOD DEVELOPMENT, ASPARTIC PROTEASE, HYDROLASE 
5p1j:A   (ILE302) to   (SER329)  AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 102  |   FRAGMENT SCREENING, METHOD DEVELOPMENT, ASPARTIC PROTEASE, HYDROLASE 
5p1k:A   (ILE302) to   (SER329)  AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 103  |   FRAGMENT SCREENING, METHOD DEVELOPMENT, ASPARTIC PROTEASE, HYDROLASE 
5p1l:A   (ILE302) to   (SER329)  AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 104  |   FRAGMENT SCREENING, METHOD DEVELOPMENT, ASPARTIC PROTEASE, HYDROLASE 
5p1m:A   (ILE302) to   (SER329)  AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 105  |   FRAGMENT SCREENING, METHOD DEVELOPMENT, ASPARTIC PROTEASE, HYDROLASE 
5p1p:A   (ILE302) to   (SER329)  AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 108  |   FRAGMENT SCREENING, METHOD DEVELOPMENT, ASPARTIC PROTEASE, HYDROLASE 
5p1r:A   (ILE302) to   (SER329)  AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 110  |   FRAGMENT SCREENING, METHOD DEVELOPMENT, ASPARTIC PROTEASE, HYDROLASE 
5p1s:A   (ILE302) to   (SER329)  AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 111  |   FRAGMENT SCREENING, METHOD DEVELOPMENT, ASPARTIC PROTEASE, HYDROLASE 
5p1u:A   (ILE302) to   (SER329)  AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 113  |   FRAGMENT SCREENING, METHOD DEVELOPMENT, ASPARTIC PROTEASE, HYDROLASE 
5p1w:A   (ILE302) to   (SER329)  AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 115  |   FRAGMENT SCREENING, METHOD DEVELOPMENT, ASPARTIC PROTEASE, HYDROLASE 
5p1x:A   (ILE302) to   (SER329)  AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 116  |   FRAGMENT SCREENING, METHOD DEVELOPMENT, ASPARTIC PROTEASE, HYDROLASE 
5p1y:A   (ILE302) to   (SER329)  AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 117  |   FRAGMENT SCREENING, METHOD DEVELOPMENT, ASPARTIC PROTEASE, HYDROLASE 
5p1z:A   (ILE302) to   (SER329)  AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 118  |   FRAGMENT SCREENING, METHOD DEVELOPMENT, ASPARTIC PROTEASE, HYDROLASE 
5p20:A   (ILE302) to   (SER329)  AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 119  |   FRAGMENT SCREENING, METHOD DEVELOPMENT, ASPARTIC PROTEASE, HYDROLASE 
5p22:A   (ILE302) to   (SER329)  AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 120  |   FRAGMENT SCREENING, METHOD DEVELOPMENT, ASPARTIC PROTEASE, HYDROLASE 
5p23:A   (ILE302) to   (SER329)  AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 121  |   FRAGMENT SCREENING, METHOD DEVELOPMENT, ASPARTIC PROTEASE, HYDROLASE 
5p24:A   (ILE302) to   (SER329)  AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 122  |   FRAGMENT SCREENING, METHOD DEVELOPMENT, ASPARTIC PROTEASE, HYDROLASE 
5p25:A   (ILE302) to   (SER329)  AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 123  |   FRAGMENT SCREENING, METHOD DEVELOPMENT, ASPARTIC PROTEASE, HYDROLASE 
5p26:A   (ILE302) to   (SER329)  AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 124  |   FRAGMENT SCREENING, METHOD DEVELOPMENT, ASPARTIC PROTEASE, HYDROLASE 
5p27:A   (ILE302) to   (SER329)  AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 125  |   FRAGMENT SCREENING, METHOD DEVELOPMENT, ASPARTIC PROTEASE, HYDROLASE 
5p28:A   (ILE302) to   (SER329)  AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 126  |   FRAGMENT SCREENING, METHOD DEVELOPMENT, ASPARTIC PROTEASE, HYDROLASE 
5p29:A   (ILE302) to   (SER329)  AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 127  |   FRAGMENT SCREENING, METHOD DEVELOPMENT, ASPARTIC PROTEASE, HYDROLASE 
5p2b:A   (ILE302) to   (SER329)  AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 129  |   FRAGMENT SCREENING, METHOD DEVELOPMENT, ASPARTIC PROTEASE, HYDROLASE 
5p2d:A   (ILE302) to   (SER329)  AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 131  |   FRAGMENT SCREENING, METHOD DEVELOPMENT, ASPARTIC PROTEASE, HYDROLASE 
5p2f:A   (ILE302) to   (SER329)  AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 133  |   FRAGMENT SCREENING, METHOD DEVELOPMENT, ASPARTIC PROTEASE, HYDROLASE 
5p2g:A   (ILE302) to   (SER329)  AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 134  |   FRAGMENT SCREENING, METHOD DEVELOPMENT, ASPARTIC PROTEASE, HYDROLASE 
5p2h:A   (ILE302) to   (SER329)  AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 135  |   FRAGMENT SCREENING, METHOD DEVELOPMENT, ASPARTIC PROTEASE, HYDROLASE 
5p2k:A   (ILE302) to   (SER329)  AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 138  |   FRAGMENT SCREENING, METHOD DEVELOPMENT, ASPARTIC PROTEASE, HYDROLASE 
5p2l:A   (ILE302) to   (SER329)  AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 139  |   FRAGMENT SCREENING, METHOD DEVELOPMENT, ASPARTIC PROTEASE, HYDROLASE 
5p2m:A   (ILE302) to   (SER329)  AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 140  |   FRAGMENT SCREENING, METHOD DEVELOPMENT, ASPARTIC PROTEASE, HYDROLASE 
5p2n:A   (ILE302) to   (SER329)  AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 141  |   FRAGMENT SCREENING, METHOD DEVELOPMENT, ASPARTIC PROTEASE, HYDROLASE 
5p2o:A   (ILE302) to   (SER329)  AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 142  |   FRAGMENT SCREENING, METHOD DEVELOPMENT, ASPARTIC PROTEASE, HYDROLASE 
5p2q:A   (ILE302) to   (SER329)  AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 143  |   FRAGMENT SCREENING, METHOD DEVELOPMENT, ASPARTIC PROTEASE, HYDROLASE 
5p2r:A   (ILE302) to   (SER329)  AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 144  |   FRAGMENT SCREENING, METHOD DEVELOPMENT, ASPARTIC PROTEASE, HYDROLASE 
5p2t:A   (ILE302) to   (SER329)  AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 146  |   FRAGMENT SCREENING, METHOD DEVELOPMENT, ASPARTIC PROTEASE, HYDROLASE 
5p2u:A   (ILE302) to   (SER329)  AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 147  |   FRAGMENT SCREENING, METHOD DEVELOPMENT, ASPARTIC PROTEASE, HYDROLASE 
5p2v:A   (ILE302) to   (SER329)  AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 148  |   FRAGMENT SCREENING, METHOD DEVELOPMENT, ASPARTIC PROTEASE, HYDROLASE 
5p2w:A   (ILE302) to   (SER329)  AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 149  |   FRAGMENT SCREENING, METHOD DEVELOPMENT, ASPARTIC PROTEASE, HYDROLASE 
5p2x:A   (ILE302) to   (SER329)  AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 150  |   FRAGMENT SCREENING, METHOD DEVELOPMENT, ASPARTIC PROTEASE, HYDROLASE 
5p2z:A   (ILE302) to   (SER329)  AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 152  |   FRAGMENT SCREENING, METHOD DEVELOPMENT, ASPARTIC PROTEASE, HYDROLASE 
5p30:A   (ILE302) to   (SER329)  AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 153  |   FRAGMENT SCREENING, METHOD DEVELOPMENT, ASPARTIC PROTEASE, HYDROLASE 
5p31:A   (ILE302) to   (SER329)  AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 154  |   FRAGMENT SCREENING, METHOD DEVELOPMENT, ASPARTIC PROTEASE, HYDROLASE 
5p32:A   (ILE302) to   (SER329)  AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 155  |   FRAGMENT SCREENING, METHOD DEVELOPMENT, ASPARTIC PROTEASE, HYDROLASE 
5p33:A   (ILE302) to   (SER329)  AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 156  |   FRAGMENT SCREENING, METHOD DEVELOPMENT, ASPARTIC PROTEASE, HYDROLASE 
5p34:A   (ILE302) to   (SER329)  AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 157  |   FRAGMENT SCREENING, METHOD DEVELOPMENT, ASPARTIC PROTEASE, HYDROLASE 
5p35:A   (ILE302) to   (SER329)  AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 158  |   FRAGMENT SCREENING, METHOD DEVELOPMENT, ASPARTIC PROTEASE, HYDROLASE 
5p36:A   (ILE302) to   (SER329)  AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 159  |   FRAGMENT SCREENING, METHOD DEVELOPMENT, ASPARTIC PROTEASE, HYDROLASE 
5p37:A   (ILE302) to   (SER329)  AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 160  |   FRAGMENT SCREENING, METHOD DEVELOPMENT, ASPARTIC PROTEASE, HYDROLASE 
5p38:A   (ILE302) to   (SER329)  AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 161  |   FRAGMENT SCREENING, METHOD DEVELOPMENT, ASPARTIC PROTEASE, HYDROLASE 
5p3b:A   (ILE302) to   (SER329)  AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 164  |   FRAGMENT SCREENING, METHOD DEVELOPMENT, ASPARTIC PROTEASE, HYDROLASE 
5p3c:A   (ILE302) to   (SER329)  AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 165  |   FRAGMENT SCREENING, METHOD DEVELOPMENT, ASPARTIC PROTEASE, HYDROLASE 
5p3d:A   (ILE302) to   (SER329)  AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 166  |   FRAGMENT SCREENING, METHOD DEVELOPMENT, ASPARTIC PROTEASE, HYDROLASE 
5p3e:A   (ILE302) to   (SER329)  AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 167  |   FRAGMENT SCREENING, METHOD DEVELOPMENT, ASPARTIC PROTEASE, HYDROLASE 
5p3g:A   (ILE302) to   (SER329)  AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 169  |   FRAGMENT SCREENING, METHOD DEVELOPMENT, ASPARTIC PROTEASE, HYDROLASE 
5p3i:A   (ILE302) to   (SER329)  AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 171  |   FRAGMENT SCREENING, METHOD DEVELOPMENT, ASPARTIC PROTEASE, HYDROLASE 
5p3j:A   (ILE302) to   (SER329)  AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 172  |   FRAGMENT SCREENING, METHOD DEVELOPMENT, ASPARTIC PROTEASE, HYDROLASE 
5p3l:A   (ILE302) to   (SER329)  AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 174  |   FRAGMENT SCREENING, METHOD DEVELOPMENT, ASPARTIC PROTEASE, HYDROLASE 
5p3m:A   (ILE302) to   (SER329)  AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 175  |   FRAGMENT SCREENING, METHOD DEVELOPMENT, ASPARTIC PROTEASE, HYDROLASE 
5p3n:A   (ILE302) to   (SER329)  AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 176  |   FRAGMENT SCREENING, METHOD DEVELOPMENT, ASPARTIC PROTEASE, HYDROLASE 
5p3o:A   (ILE302) to   (SER329)  AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 177  |   FRAGMENT SCREENING, METHOD DEVELOPMENT, ASPARTIC PROTEASE, HYDROLASE 
5p3q:A   (ILE302) to   (SER329)  AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 179  |   FRAGMENT SCREENING, METHOD DEVELOPMENT, ASPARTIC PROTEASE, HYDROLASE 
5p3r:A   (ILE302) to   (SER329)  AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 180  |   FRAGMENT SCREENING, METHOD DEVELOPMENT, ASPARTIC PROTEASE, HYDROLASE 
5p3s:A   (ILE302) to   (SER329)  AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 181  |   FRAGMENT SCREENING, METHOD DEVELOPMENT, ASPARTIC PROTEASE, HYDROLASE 
5p3t:A   (ILE302) to   (SER329)  AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 182  |   FRAGMENT SCREENING, METHOD DEVELOPMENT, ASPARTIC PROTEASE, HYDROLASE 
5p3u:A   (ILE302) to   (SER329)  AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 183  |   FRAGMENT SCREENING, METHOD DEVELOPMENT, ASPARTIC PROTEASE, HYDROLASE 
5p3v:A   (ILE302) to   (SER329)  AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 184  |   FRAGMENT SCREENING, METHOD DEVELOPMENT, ASPARTIC PROTEASE, HYDROLASE 
5p3w:A   (ILE302) to   (SER329)  AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 185  |   FRAGMENT SCREENING, METHOD DEVELOPMENT, ASPARTIC PROTEASE, HYDROLASE 
5p3x:A   (ILE302) to   (SER329)  AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 186  |   FRAGMENT SCREENING, METHOD DEVELOPMENT, ASPARTIC PROTEASE, HYDROLASE 
5p3y:A   (ILE302) to   (SER329)  AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 187  |   FRAGMENT SCREENING, METHOD DEVELOPMENT, ASPARTIC PROTEASE, HYDROLASE 
5p3z:A   (ILE302) to   (SER329)  AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 188  |   FRAGMENT SCREENING, METHOD DEVELOPMENT, ASPARTIC PROTEASE, HYDROLASE 
5p40:A   (ILE302) to   (SER329)  AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 189  |   FRAGMENT SCREENING, METHOD DEVELOPMENT, ASPARTIC PROTEASE, HYDROLASE 
5p41:A   (ILE302) to   (SER329)  AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 190  |   FRAGMENT SCREENING, METHOD DEVELOPMENT, ASPARTIC PROTEASE, HYDROLASE 
5p42:A   (ILE302) to   (SER329)  AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 191  |   FRAGMENT SCREENING, METHOD DEVELOPMENT, ASPARTIC PROTEASE, HYDROLASE 
5p43:A   (ILE302) to   (SER329)  AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 192  |   FRAGMENT SCREENING, METHOD DEVELOPMENT, ASPARTIC PROTEASE, HYDROLASE 
5p44:A   (ILE302) to   (SER329)  AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 193  |   FRAGMENT SCREENING, METHOD DEVELOPMENT, ASPARTIC PROTEASE, HYDROLASE 
5p45:A   (ILE302) to   (SER329)  AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 194  |   FRAGMENT SCREENING, METHOD DEVELOPMENT, ASPARTIC PROTEASE, HYDROLASE 
5p46:A   (ILE302) to   (SER329)  AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 195  |   FRAGMENT SCREENING, METHOD DEVELOPMENT, ASPARTIC PROTEASE, HYDROLASE 
5p47:A   (ILE302) to   (SER329)  AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 196  |   FRAGMENT SCREENING, METHOD DEVELOPMENT, ASPARTIC PROTEASE, HYDROLASE 
5p48:A   (ILE302) to   (SER329)  AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 197  |   FRAGMENT SCREENING, METHOD DEVELOPMENT, ASPARTIC PROTEASE, HYDROLASE 
5p49:A   (ILE302) to   (SER329)  AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 198  |   FRAGMENT SCREENING, METHOD DEVELOPMENT, ASPARTIC PROTEASE, HYDROLASE 
5p4a:A   (ILE302) to   (SER329)  AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 199  |   FRAGMENT SCREENING, METHOD DEVELOPMENT, ASPARTIC PROTEASE, HYDROLASE 
5p4b:A   (ILE302) to   (SER329)  AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 200  |   FRAGMENT SCREENING, METHOD DEVELOPMENT, ASPARTIC PROTEASE, HYDROLASE 
5p4c:A   (ILE302) to   (SER329)  AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 201  |   FRAGMENT SCREENING, METHOD DEVELOPMENT, ASPARTIC PROTEASE, HYDROLASE 
5p4d:A   (ILE302) to   (SER329)  AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 202  |   FRAGMENT SCREENING, METHOD DEVELOPMENT, ASPARTIC PROTEASE, HYDROLASE 
5p4e:A   (ILE302) to   (SER329)  AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 203  |   FRAGMENT SCREENING, METHOD DEVELOPMENT, ASPARTIC PROTEASE, HYDROLASE 
5p4f:A   (ILE302) to   (SER329)  AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 204  |   FRAGMENT SCREENING, METHOD DEVELOPMENT, ASPARTIC PROTEASE, HYDROLASE 
5p4g:A   (ILE302) to   (SER329)  AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 205  |   FRAGMENT SCREENING, METHOD DEVELOPMENT, ASPARTIC PROTEASE, HYDROLASE 
5p4h:A   (ILE302) to   (SER329)  AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 206  |   FRAGMENT SCREENING, METHOD DEVELOPMENT, ASPARTIC PROTEASE, HYDROLASE 
5p4i:A   (ILE302) to   (SER329)  AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 207  |   FRAGMENT SCREENING, METHOD DEVELOPMENT, ASPARTIC PROTEASE, HYDROLASE 
5p4j:A   (ILE302) to   (SER329)  AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 208  |   FRAGMENT SCREENING, METHOD DEVELOPMENT, ASPARTIC PROTEASE, HYDROLASE 
5p4k:A   (ILE302) to   (SER329)  AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 209  |   FRAGMENT SCREENING, METHOD DEVELOPMENT, ASPARTIC PROTEASE, HYDROLASE 
5p4l:A   (ILE302) to   (SER329)  AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 210  |   FRAGMENT SCREENING, METHOD DEVELOPMENT, ASPARTIC PROTEASE, HYDROLASE 
5p4m:A   (ILE302) to   (SER329)  AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 211  |   FRAGMENT SCREENING, METHOD DEVELOPMENT, ASPARTIC PROTEASE, HYDROLASE 
5p4o:A   (ILE302) to   (SER329)  AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 213  |   FRAGMENT SCREENING, METHOD DEVELOPMENT, ASPARTIC PROTEASE, HYDROLASE 
5p4p:A   (ILE302) to   (SER329)  AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 214  |   FRAGMENT SCREENING, METHOD DEVELOPMENT, ASPARTIC PROTEASE, HYDROLASE 
5p4q:A   (ILE302) to   (SER329)  AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 215  |   FRAGMENT SCREENING, METHOD DEVELOPMENT, ASPARTIC PROTEASE, HYDROLASE 
5p4r:A   (ILE302) to   (SER329)  AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 216  |   FRAGMENT SCREENING, METHOD DEVELOPMENT, ASPARTIC PROTEASE, HYDROLASE 
5p4s:A   (ILE302) to   (SER329)  AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 217  |   FRAGMENT SCREENING, METHOD DEVELOPMENT, ASPARTIC PROTEASE, HYDROLASE 
5p4t:A   (ILE302) to   (SER329)  AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 218  |   FRAGMENT SCREENING, METHOD DEVELOPMENT, ASPARTIC PROTEASE, HYDROLASE 
5p4v:A   (ILE302) to   (SER329)  AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 220  |   FRAGMENT SCREENING, METHOD DEVELOPMENT, ASPARTIC PROTEASE, HYDROLASE 
5p4w:A   (ILE302) to   (SER329)  AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 221  |   FRAGMENT SCREENING, METHOD DEVELOPMENT, ASPARTIC PROTEASE, HYDROLASE 
5p4y:A   (ILE302) to   (SER329)  AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 223  |   FRAGMENT SCREENING, METHOD DEVELOPMENT, ASPARTIC PROTEASE, HYDROLASE 
5p4z:A   (ILE302) to   (SER329)  AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 224  |   FRAGMENT SCREENING, METHOD DEVELOPMENT, ASPARTIC PROTEASE, HYDROLASE 
5p53:A   (ILE302) to   (SER329)  AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 228  |   FRAGMENT SCREENING, METHOD DEVELOPMENT, ASPARTIC PROTEASE, HYDROLASE 
5p54:A   (ILE302) to   (SER329)  AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 229  |   FRAGMENT SCREENING, METHOD DEVELOPMENT, ASPARTIC PROTEASE, HYDROLASE 
5p55:A   (ILE302) to   (SER329)  AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 230  |   FRAGMENT SCREENING, METHOD DEVELOPMENT, ASPARTIC PROTEASE, HYDROLASE 
5p56:A   (ILE302) to   (SER329)  AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 231  |   FRAGMENT SCREENING, METHOD DEVELOPMENT, ASPARTIC PROTEASE, HYDROLASE 
5p58:A   (ILE302) to   (SER329)  AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 233  |   FRAGMENT SCREENING, METHOD DEVELOPMENT, ASPARTIC PROTEASE, HYDROLASE 
5p59:A   (ILE302) to   (SER329)  AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 234  |   FRAGMENT SCREENING, METHOD DEVELOPMENT, ASPARTIC PROTEASE, HYDROLASE 
5p5a:A   (ILE302) to   (SER329)  AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 235  |   FRAGMENT SCREENING, METHOD DEVELOPMENT, ASPARTIC PROTEASE, HYDROLASE 
5p5c:A   (ILE302) to   (SER329)  AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 237  |   FRAGMENT SCREENING, METHOD DEVELOPMENT, ASPARTIC PROTEASE, HYDROLASE 
5p5d:A   (ILE302) to   (SER329)  AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 238  |   FRAGMENT SCREENING, METHOD DEVELOPMENT, ASPARTIC PROTEASE, HYDROLASE 
5p5e:A   (ILE302) to   (SER329)  AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 239  |   FRAGMENT SCREENING, METHOD DEVELOPMENT, ASPARTIC PROTEASE, HYDROLASE 
5p5f:A   (ILE302) to   (SER329)  AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 240  |   FRAGMENT SCREENING, METHOD DEVELOPMENT, ASPARTIC PROTEASE, HYDROLASE 
5p5g:A   (ILE302) to   (SER329)  AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 241  |   FRAGMENT SCREENING, METHOD DEVELOPMENT, ASPARTIC PROTEASE, HYDROLASE 
5p5h:A   (ILE302) to   (SER329)  AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 242  |   FRAGMENT SCREENING, METHOD DEVELOPMENT, ASPARTIC PROTEASE, HYDROLASE 
5p5i:A   (ILE302) to   (SER329)  AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 243  |   FRAGMENT SCREENING, METHOD DEVELOPMENT, ASPARTIC PROTEASE, HYDROLASE 
5p5j:A   (ILE302) to   (SER329)  AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 244  |   FRAGMENT SCREENING, METHOD DEVELOPMENT, ASPARTIC PROTEASE, HYDROLASE 
5p5k:A   (ILE302) to   (SER329)  AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 245  |   FRAGMENT SCREENING, METHOD DEVELOPMENT, ASPARTIC PROTEASE, HYDROLASE 
5p5l:A   (ILE302) to   (SER329)  AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 246  |   FRAGMENT SCREENING, METHOD DEVELOPMENT, ASPARTIC PROTEASE, HYDROLASE 
5p5m:A   (ILE302) to   (SER329)  AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 247  |   FRAGMENT SCREENING, METHOD DEVELOPMENT, ASPARTIC PROTEASE, HYDROLASE 
5p5n:A   (ILE302) to   (SER329)  AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 248  |   FRAGMENT SCREENING, METHOD DEVELOPMENT, ASPARTIC PROTEASE, HYDROLASE 
5p5o:A   (ILE302) to   (SER329)  AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 249  |   FRAGMENT SCREENING, METHOD DEVELOPMENT, ASPARTIC PROTEASE, HYDROLASE 
5p5q:A   (ILE302) to   (SER329)  AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 251  |   FRAGMENT SCREENING, METHOD DEVELOPMENT, ASPARTIC PROTEASE, HYDROLASE 
5p5r:A   (ILE302) to   (SER329)  AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 252  |   FRAGMENT SCREENING, METHOD DEVELOPMENT, ASPARTIC PROTEASE, HYDROLASE 
5p5s:A   (ILE302) to   (SER329)  AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 253  |   FRAGMENT SCREENING, METHOD DEVELOPMENT, ASPARTIC PROTEASE, HYDROLASE 
5p5t:A   (ILE302) to   (SER329)  AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 254  |   FRAGMENT SCREENING, METHOD DEVELOPMENT, ASPARTIC PROTEASE, HYDROLASE 
5p5u:A   (ILE302) to   (SER329)  AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 255  |   FRAGMENT SCREENING, METHOD DEVELOPMENT, ASPARTIC PROTEASE, HYDROLASE 
5p5v:A   (ILE302) to   (SER329)  AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 256  |   FRAGMENT SCREENING, METHOD DEVELOPMENT, ASPARTIC PROTEASE, HYDROLASE 
5p5w:A   (ILE302) to   (SER329)  AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 257  |   FRAGMENT SCREENING, METHOD DEVELOPMENT, ASPARTIC PROTEASE, HYDROLASE 
5p5x:A   (ILE302) to   (SER329)  AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 258  |   FRAGMENT SCREENING, METHOD DEVELOPMENT, ASPARTIC PROTEASE, HYDROLASE 
5p5y:A   (ILE302) to   (SER329)  AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 259  |   FRAGMENT SCREENING, METHOD DEVELOPMENT, ASPARTIC PROTEASE, HYDROLASE 
5p5z:A   (ILE302) to   (SER329)  AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 260  |   FRAGMENT SCREENING, METHOD DEVELOPMENT, ASPARTIC PROTEASE, HYDROLASE 
5p61:A   (ILE302) to   (SER329)  AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 262  |   FRAGMENT SCREENING, METHOD DEVELOPMENT, ASPARTIC PROTEASE, HYDROLASE 
5p62:A   (ILE302) to   (SER329)  AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 263  |   FRAGMENT SCREENING, METHOD DEVELOPMENT, ASPARTIC PROTEASE, HYDROLASE 
5p63:A   (ILE302) to   (SER329)  AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 264  |   FRAGMENT SCREENING, METHOD DEVELOPMENT, ASPARTIC PROTEASE, HYDROLASE 
5p64:A   (ILE302) to   (SER329)  AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 265  |   FRAGMENT SCREENING, METHOD DEVELOPMENT, ASPARTIC PROTEASE, HYDROLASE 
5p65:A   (ILE302) to   (SER329)  AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 266  |   FRAGMENT SCREENING, METHOD DEVELOPMENT, ASPARTIC PROTEASE, HYDROLASE 
5p66:A   (ILE302) to   (SER329)  AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 267  |   FRAGMENT SCREENING, METHOD DEVELOPMENT, ASPARTIC PROTEASE, HYDROLASE 
5p68:A   (ILE302) to   (SER329)  AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 269  |   FRAGMENT SCREENING, METHOD DEVELOPMENT, ASPARTIC PROTEASE, HYDROLASE 
5p6a:A   (ILE302) to   (SER329)  AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 271  |   FRAGMENT SCREENING, METHOD DEVELOPMENT, ASPARTIC PROTEASE, HYDROLASE 
5p6c:A   (ILE302) to   (SER329)  AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 273  |   FRAGMENT SCREENING, METHOD DEVELOPMENT, ASPARTIC PROTEASE, HYDROLASE 
5p6d:A   (ILE302) to   (SER329)  AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 274  |   FRAGMENT SCREENING, METHOD DEVELOPMENT, ASPARTIC PROTEASE, HYDROLASE 
5p6e:A   (ILE302) to   (SER329)  AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 275  |   FRAGMENT SCREENING, METHOD DEVELOPMENT, ASPARTIC PROTEASE, HYDROLASE 
5p6g:A   (ILE302) to   (SER329)  AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 277  |   FRAGMENT SCREENING, METHOD DEVELOPMENT, ASPARTIC PROTEASE, HYDROLASE 
5p6h:A   (ILE302) to   (SER329)  AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 278  |   FRAGMENT SCREENING, METHOD DEVELOPMENT, ASPARTIC PROTEASE, HYDROLASE 
5p6i:A   (ILE302) to   (SER329)  AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 279  |   FRAGMENT SCREENING, METHOD DEVELOPMENT, ASPARTIC PROTEASE, HYDROLASE 
5p6j:A   (ILE302) to   (SER329)  AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 280  |   FRAGMENT SCREENING, METHOD DEVELOPMENT, ASPARTIC PROTEASE, HYDROLASE 
5p6k:A   (ILE302) to   (SER329)  AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 281  |   FRAGMENT SCREENING, METHOD DEVELOPMENT, ASPARTIC PROTEASE, HYDROLASE 
5p6l:A   (ILE302) to   (SER329)  AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 282  |   FRAGMENT SCREENING, METHOD DEVELOPMENT, ASPARTIC PROTEASE, HYDROLASE 
5p6m:A   (ILE302) to   (SER329)  AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 283  |   FRAGMENT SCREENING, METHOD DEVELOPMENT, ASPARTIC PROTEASE, HYDROLASE 
5p6n:A   (ILE302) to   (SER329)  AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 284  |   FRAGMENT SCREENING, METHOD DEVELOPMENT, ASPARTIC PROTEASE, HYDROLASE 
5p6o:A   (ILE302) to   (SER329)  AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 285  |   FRAGMENT SCREENING, METHOD DEVELOPMENT, ASPARTIC PROTEASE, HYDROLASE 
5p6p:A   (ILE302) to   (SER329)  AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 286  |   FRAGMENT SCREENING, METHOD DEVELOPMENT, ASPARTIC PROTEASE, HYDROLASE 
5p6q:A   (ILE302) to   (SER329)  AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 287  |   FRAGMENT SCREENING, METHOD DEVELOPMENT, ASPARTIC PROTEASE, HYDROLASE 
5p6r:A   (ILE302) to   (SER329)  AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 288  |   FRAGMENT SCREENING, METHOD DEVELOPMENT, ASPARTIC PROTEASE, HYDROLASE 
5p6s:A   (ILE302) to   (SER329)  AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 289  |   FRAGMENT SCREENING, METHOD DEVELOPMENT, ASPARTIC PROTEASE, HYDROLASE 
5p6t:A   (ILE302) to   (SER329)  AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 290  |   FRAGMENT SCREENING, METHOD DEVELOPMENT, ASPARTIC PROTEASE, HYDROLASE 
5p6u:A   (ILE302) to   (SER329)  AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 291  |   FRAGMENT SCREENING, METHOD DEVELOPMENT, ASPARTIC PROTEASE, HYDROLASE 
5p6v:A   (ILE302) to   (SER329)  AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 292  |   FRAGMENT SCREENING, METHOD DEVELOPMENT, ASPARTIC PROTEASE, HYDROLASE 
5p6w:A   (ILE302) to   (SER329)  AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 293  |   FRAGMENT SCREENING, METHOD DEVELOPMENT, ASPARTIC PROTEASE, HYDROLASE 
5p6x:A   (ILE302) to   (SER329)  AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 294  |   FRAGMENT SCREENING, METHOD DEVELOPMENT, ASPARTIC PROTEASE, HYDROLASE 
5p6y:A   (ILE302) to   (SER329)  AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 295  |   FRAGMENT SCREENING, METHOD DEVELOPMENT, ASPARTIC PROTEASE, HYDROLASE 
5p6z:A   (ILE302) to   (SER329)  AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 296  |   FRAGMENT SCREENING, METHOD DEVELOPMENT, ASPARTIC PROTEASE, HYDROLASE 
5p70:A   (ILE302) to   (SER329)  AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 297  |   FRAGMENT SCREENING, METHOD DEVELOPMENT, ASPARTIC PROTEASE, HYDROLASE 
5p71:A   (ILE302) to   (SER329)  AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 298  |   FRAGMENT SCREENING, METHOD DEVELOPMENT, ASPARTIC PROTEASE, HYDROLASE 
5p72:A   (ILE302) to   (SER329)  AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 299  |   FRAGMENT SCREENING, METHOD DEVELOPMENT, ASPARTIC PROTEASE, HYDROLASE 
5p75:A   (ILE302) to   (SER329)  AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 302  |   FRAGMENT SCREENING, METHOD DEVELOPMENT, ASPARTIC PROTEASE, HYDROLASE 
5p76:A   (ILE302) to   (SER329)  AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 303  |   FRAGMENT SCREENING, METHOD DEVELOPMENT, ASPARTIC PROTEASE, HYDROLASE 
5p77:A   (ILE302) to   (SER329)  AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 304  |   FRAGMENT SCREENING, METHOD DEVELOPMENT, ASPARTIC PROTEASE, HYDROLASE 
5p78:A   (ILE302) to   (SER329)  AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 305  |   FRAGMENT SCREENING, METHOD DEVELOPMENT, ASPARTIC PROTEASE, HYDROLASE 
5p7a:A   (ILE302) to   (SER329)  AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 307  |   FRAGMENT SCREENING, METHOD DEVELOPMENT, ASPARTIC PROTEASE, HYDROLASE 
5p7b:A   (ILE302) to   (SER329)  AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 308  |   FRAGMENT SCREENING, METHOD DEVELOPMENT, ASPARTIC PROTEASE, HYDROLASE 
5p7c:A   (ILE302) to   (SER329)  AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 309  |   FRAGMENT SCREENING, METHOD DEVELOPMENT, ASPARTIC PROTEASE, HYDROLASE 
5p7d:A   (ILE302) to   (SER329)  AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 310  |   FRAGMENT SCREENING, METHOD DEVELOPMENT, ASPARTIC PROTEASE, HYDROLASE 
5p7e:A   (ILE302) to   (SER329)  AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 311  |   FRAGMENT SCREENING, METHOD DEVELOPMENT, ASPARTIC PROTEASE, HYDROLASE 
5p7i:A   (ILE302) to   (SER329)  AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 315  |   FRAGMENT SCREENING, METHOD DEVELOPMENT, ASPARTIC PROTEASE, HYDROLASE 
5p7j:A   (ILE302) to   (SER329)  AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 316  |   FRAGMENT SCREENING, METHOD DEVELOPMENT, ASPARTIC PROTEASE, HYDROLASE 
5p7m:A   (ILE302) to   (SER329)  AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 319  |   FRAGMENT SCREENING, METHOD DEVELOPMENT, ASPARTIC PROTEASE, HYDROLASE 
5p7n:A   (ILE302) to   (SER329)  AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 320  |   FRAGMENT SCREENING, METHOD DEVELOPMENT, ASPARTIC PROTEASE, HYDROLASE 
5p7o:A   (ILE302) to   (SER329)  AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 321  |   FRAGMENT SCREENING, METHOD DEVELOPMENT, ASPARTIC PROTEASE, HYDROLASE 
5p7p:A   (ILE302) to   (SER329)  AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 322  |   FRAGMENT SCREENING, METHOD DEVELOPMENT, ASPARTIC PROTEASE, HYDROLASE 
5p7q:A   (ILE302) to   (SER329)  AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 323  |   FRAGMENT SCREENING, METHOD DEVELOPMENT, ASPARTIC PROTEASE, HYDROLASE 
5p7r:A   (ILE302) to   (SER329)  AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 324  |   FRAGMENT SCREENING, METHOD DEVELOPMENT, ASPARTIC PROTEASE, HYDROLASE 
5p7t:A   (ILE302) to   (SER329)  AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 326  |   FRAGMENT SCREENING, METHOD DEVELOPMENT, ASPARTIC PROTEASE, HYDROLASE 
5p7u:A   (ILE302) to   (SER329)  AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 327  |   FRAGMENT SCREENING, METHOD DEVELOPMENT, ASPARTIC PROTEASE, HYDROLASE 
5p7v:A   (ILE302) to   (SER329)  AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 328  |   FRAGMENT SCREENING, METHOD DEVELOPMENT, ASPARTIC PROTEASE, HYDROLASE 
5p7w:A   (ILE302) to   (SER329)  AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 329  |   FRAGMENT SCREENING, METHOD DEVELOPMENT, ASPARTIC PROTEASE, HYDROLASE 
5p7x:A   (ILE302) to   (SER329)  AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 330  |   FRAGMENT SCREENING, METHOD DEVELOPMENT, ASPARTIC PROTEASE, HYDROLASE 
5p7y:A   (ILE302) to   (SER329)  AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 331  |   FRAGMENT SCREENING, METHOD DEVELOPMENT, ASPARTIC PROTEASE, HYDROLASE 
5p7z:A   (ILE302) to   (SER329)  AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 332  |   FRAGMENT SCREENING, METHOD DEVELOPMENT, ASPARTIC PROTEASE, HYDROLASE 
5p80:A   (ILE302) to   (SER329)  AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 333  |   FRAGMENT SCREENING, METHOD DEVELOPMENT, ASPARTIC PROTEASE, HYDROLASE 
5p81:A   (ILE302) to   (SER329)  AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 334  |   FRAGMENT SCREENING, METHOD DEVELOPMENT, ASPARTIC PROTEASE, HYDROLASE 
5p82:A   (ILE302) to   (SER329)  AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 335  |   FRAGMENT SCREENING, METHOD DEVELOPMENT, ASPARTIC PROTEASE, HYDROLASE 
5p83:A   (ILE302) to   (SER329)  AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 336  |   FRAGMENT SCREENING, METHOD DEVELOPMENT, ASPARTIC PROTEASE, HYDROLASE 
5p84:A   (ILE302) to   (SER329)  AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 337  |   FRAGMENT SCREENING, METHOD DEVELOPMENT, ASPARTIC PROTEASE, HYDROLASE 
5p85:A   (ILE302) to   (SER329)  AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 338  |   FRAGMENT SCREENING, METHOD DEVELOPMENT, ASPARTIC PROTEASE, HYDROLASE 
5p86:A   (ILE302) to   (SER329)  AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 339  |   FRAGMENT SCREENING, METHOD DEVELOPMENT, ASPARTIC PROTEASE, HYDROLASE 
5p87:A   (ILE302) to   (SER329)  AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 340  |   FRAGMENT SCREENING, METHOD DEVELOPMENT, ASPARTIC PROTEASE, HYDROLASE 
5p88:A   (ILE302) to   (SER329)  AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 341  |   FRAGMENT SCREENING, METHOD DEVELOPMENT, ASPARTIC PROTEASE, HYDROLASE 
5p89:A   (ILE302) to   (SER329)  AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 342  |   FRAGMENT SCREENING, METHOD DEVELOPMENT, ASPARTIC PROTEASE, HYDROLASE 
5p8a:A   (ILE302) to   (SER329)  AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 343  |   FRAGMENT SCREENING, METHOD DEVELOPMENT, ASPARTIC PROTEASE, HYDROLASE 
5p8b:A   (ILE302) to   (SER329)  AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 344  |   FRAGMENT SCREENING, METHOD DEVELOPMENT, ASPARTIC PROTEASE, HYDROLASE 
5p8c:A   (ILE302) to   (SER329)  AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 345  |   FRAGMENT SCREENING, METHOD DEVELOPMENT, ASPARTIC PROTEASE, HYDROLASE 
5p8d:A   (ILE302) to   (SER329)  AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 346  |   FRAGMENT SCREENING, METHOD DEVELOPMENT, ASPARTIC PROTEASE, HYDROLASE 
5p8e:A   (ILE302) to   (SER329)  AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 347  |   FRAGMENT SCREENING, METHOD DEVELOPMENT, ASPARTIC PROTEASE, HYDROLASE 
5p8f:A   (ILE302) to   (SER329)  AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 348  |   FRAGMENT SCREENING, METHOD DEVELOPMENT, ASPARTIC PROTEASE, HYDROLASE 
5p8h:A   (ILE302) to   (SER329)  AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 350  |   FRAGMENT SCREENING, METHOD DEVELOPMENT, ASPARTIC PROTEASE, HYDROLASE 
5p8j:A   (ILE302) to   (SER329)  AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 352  |   FRAGMENT SCREENING, METHOD DEVELOPMENT, ASPARTIC PROTEASE, HYDROLASE 
5p8k:A   (ILE302) to   (SER329)  AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 353  |   FRAGMENT SCREENING, METHOD DEVELOPMENT, ASPARTIC PROTEASE, HYDROLASE 
5p8l:A   (ILE302) to   (SER329)  AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 354  |   FRAGMENT SCREENING, METHOD DEVELOPMENT, ASPARTIC PROTEASE, HYDROLASE 
5p8m:A   (ILE302) to   (SER329)  AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 355  |   FRAGMENT SCREENING, METHOD DEVELOPMENT, ASPARTIC PROTEASE, HYDROLASE 
5p8n:A   (ILE302) to   (SER329)  AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 356  |   FRAGMENT SCREENING, METHOD DEVELOPMENT, ASPARTIC PROTEASE, HYDROLASE 
5p8o:A   (ILE302) to   (SER329)  AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 357  |   FRAGMENT SCREENING, METHOD DEVELOPMENT, ASPARTIC PROTEASE, HYDROLASE 
5p8p:A   (ILE302) to   (SER329)  AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 358  |   FRAGMENT SCREENING, METHOD DEVELOPMENT, ASPARTIC PROTEASE, HYDROLASE 
5p8r:A   (ILE302) to   (SER329)  AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 360  |   FRAGMENT SCREENING, METHOD DEVELOPMENT, ASPARTIC PROTEASE, HYDROLASE 
5p8s:A   (ILE302) to   (SER329)  AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 361  |   FRAGMENT SCREENING, METHOD DEVELOPMENT, ASPARTIC PROTEASE, HYDROLASE 
5p8t:A   (ILE302) to   (SER329)  AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 362  |   FRAGMENT SCREENING, METHOD DEVELOPMENT, ASPARTIC PROTEASE, HYDROLASE 
5p8u:A   (ILE302) to   (SER329)  AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 363  |   FRAGMENT SCREENING, METHOD DEVELOPMENT, ASPARTIC PROTEASE, HYDROLASE 
5p8v:A   (ILE302) to   (SER329)  AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 364  |   FRAGMENT SCREENING, METHOD DEVELOPMENT, ASPARTIC PROTEASE, HYDROLASE 
5pep:A   (GLU298) to   (PRO325)  X-RAY ANALYSES OF ASPARTIC PROTEASES. II. THREE-DIMENSIONAL STRUCTURE OF THE HEXAGONAL CRYSTAL FORM OF PORCINE PEPSIN AT 2.3 ANGSTROMS RESOLUTION  |   HYDROLASE(ACID PROTEINASE) 
5sxn:A   (THR312) to   (LEU338)  STRUCTURE-BASED DESIGN OF A NEW SERIES OF N-PIPERIDIN-3-YLPYRIMIDINE- 5-CARBOXAMIDES AS RENIN INHIBITORS  |   PROTEIN-LIGAND COMPLEX, HYDROLASE-HYDROLASE INHIBITOR COMPLEX 
5sxn:B   (THR312) to   (LEU338)  STRUCTURE-BASED DESIGN OF A NEW SERIES OF N-PIPERIDIN-3-YLPYRIMIDINE- 5-CARBOXAMIDES AS RENIN INHIBITORS  |   PROTEIN-LIGAND COMPLEX, HYDROLASE-HYDROLASE INHIBITOR COMPLEX 
5sy3:A   (THR312) to   (LEU338)  STRUCTURE-BASED DESIGN OF A NEW SERIES OF N-PIPERIDIN-3-YLPYRIMIDINE- 5-CARBOXAMIDES AS RENIN INHIBITORS  |   PROTEIN-LIGAND COMPLEX, HYDROLASE-HYDROLASE INHIBITOR COMPLEX 
5sy3:B   (THR312) to   (LEU338)  STRUCTURE-BASED DESIGN OF A NEW SERIES OF N-PIPERIDIN-3-YLPYRIMIDINE- 5-CARBOXAMIDES AS RENIN INHIBITORS  |   PROTEIN-LIGAND COMPLEX, HYDROLASE-HYDROLASE INHIBITOR COMPLEX 
5sz9:A   (THR312) to   (LEU338)  STRUCTURE-BASED DESIGN OF A NEW SERIES OF N-PIPERIDIN-3-YLPYRIMIDINE- 5-CARBOXAMIDES AS RENIN INHIBITORS  |   PROTEIN-LIGAND COMPLEX, HYDROLASE-HYDROLASE INHIBITOR COMPLEX 
5sz9:B   (THR312) to   (LEU338)  STRUCTURE-BASED DESIGN OF A NEW SERIES OF N-PIPERIDIN-3-YLPYRIMIDINE- 5-CARBOXAMIDES AS RENIN INHIBITORS  |   PROTEIN-LIGAND COMPLEX, HYDROLASE-HYDROLASE INHIBITOR COMPLEX 
5t4s:A   (THR312) to   (LEU338)  NOVEL APPROACH OF FRAGMENT-BASED LEAD DISCOVERY APPLIED TO RENIN INHIBITORS  |   PROTEIN-LIGAND COMPLEX, HYDROLASE-HYDROLASE INHIBITOR COMPLEX 
5t4s:B   (THR312) to   (LEU338)  NOVEL APPROACH OF FRAGMENT-BASED LEAD DISCOVERY APPLIED TO RENIN INHIBITORS  |   PROTEIN-LIGAND COMPLEX, HYDROLASE-HYDROLASE INHIBITOR COMPLEX 
6apr:E   (GLY295) to   (PRO322)  STRUCTURES OF COMPLEXES OF RHIZOPUSPEPSIN WITH PEPSTATIN AND OTHER STATINE-CONTAINING INHIBITORS  |   ACID PROTEINASE, HYDROLASE-HYDROLASE INHIBITOR COMPLEX 
3rsx:A   (GLY330) to   (VAL356)  STRUCTURE OF BACE-1 (BETA-SECRETASE) IN COMPLEX WITH 6-(THIOPHEN-3- YL)QUINOLIN-2-AMINE  |   ASPARTIC PROTEASE, ASPARTYL PROTEASE, HYDROLASE-HYDROLASE INHIBITOR COMPLEX 
1apt:E   (PHE295) to   (PRO321)  CRYSTALLOGRAPHIC ANALYSIS OF A PEPSTATIN ANALOGUE BINDING TO THE ASPARTYL PROTEINASE PENICILLOPEPSIN AT 1.8 ANGSTROMS RESOLUTION  |   ACID PROTEINASE, HYDROLASE-HYDROLASE INHIBITOR COMPLEX 
1apu:E   (PHE295) to   (PRO321)  CRYSTALLOGRAPHIC ANALYSIS OF A PEPSTATIN ANALOGUE BINDING TO THE ASPARTYL PROTEINASE PENICILLOPEPSIN AT 1.8 ANGSTROMS RESOLUTION  |   ACID PROTEINASE, HYDROLASE-HYDROLASE INHIBITOR COMPLEX 
1apv:E   (PHE295) to   (PRO321)  CRYSTALLOGRAPHIC ANALYSIS OF TRANSITION STATE MIMICS BOUND TO PENICILLOPEPSIN: DIFLUOROSTATINE-AND DIFLUOROSTATONE-CONTAINING PEPTIDES  |   ACID PROTEINASE, HYDROLASE-HYDROLASE INHIBITOR COMPLEX 
1avf:A   (PRO300) to   (THR327)  ACTIVATION INTERMEDIATE 2 OF HUMAN GASTRICSIN FROM HUMAN STOMACH  |   ASPARTYL PROTEASE, GASTRICSIN, ASPARTIC PROTEINASE, INTERMEDIATE, ACTIVATION, ACID 
1avf:J   (PRO300) to   (THR327)  ACTIVATION INTERMEDIATE 2 OF HUMAN GASTRICSIN FROM HUMAN STOMACH  |   ASPARTYL PROTEASE, GASTRICSIN, ASPARTIC PROTEINASE, INTERMEDIATE, ACTIVATION, ACID 
2p8h:A   (GLY330) to   (VAL356)  CRYSTAL STRUCTURE OF HUMAN BETA SECRETASE COMPLEXED WITH INHIBITOR  |   ASPARTYL PROTEASE, BACE, HYDROLASE 
2psg:A   (GLU297) to   (PRO324)  REFINED STRUCTURE OF PORCINE PEPSINOGEN AT 1.8 ANGSTROMS RESOLUTION  |   HYDROLASE(ACID PROTEINASE ZYMOGEN) 
3sm1:B    (TYR90) to   (GLY116)  THE CRYSTAL STRUCTURE OF XMRV PROTEASE COMPLEXED WITH PEPSTATIN A  |   BETA SHEET, DIMER, PROTEASE, PEPSTAIN A, VIRUS, HYDROLASE-HYDROLASE INHIBITOR COMPLEX 
3g70:A   (THR312) to   (LEU338)  DESIGN AND PREPARATION OF POTENT, NON-PEPTIDIC, BIOAVAILABLE RENIN INHIBITORS  |   HUMAN RENIN, ASPARTYL PROTEASE, CLEAVAGE ON PAIR OF BASIC RESIDUES, DISEASE MUTATION, GLYCOPROTEIN, HYDROLASE, MEMBRANE, PROTEASE, SECRETED, ZYMOGEN 
3g70:B   (THR312) to   (LEU338)  DESIGN AND PREPARATION OF POTENT, NON-PEPTIDIC, BIOAVAILABLE RENIN INHIBITORS  |   HUMAN RENIN, ASPARTYL PROTEASE, CLEAVAGE ON PAIR OF BASIC RESIDUES, DISEASE MUTATION, GLYCOPROTEIN, HYDROLASE, MEMBRANE, PROTEASE, SECRETED, ZYMOGEN 
3t6i:A   (ILE302) to   (SER329)  ENDOTHIAPEPSIN IN COMPLEX WITH AN AZEPIN DERIVATIVE  |   HYDROLASE-HYDROLASE INHIBITOR COMPLEX 
4y39:A   (ILE302) to   (SER329)  ENDOTHIAPEPSIN IN COMPLEX WITH FRAGMENT 75  |   FRAGMENT SCREENING, HYDROLASE, INHIBITION 
4y3f:A   (ILE302) to   (SER329)  ENDOTHIAPEPSIN IN COMPLEX WITH FRAGMENT 78  |   FRAGMENT SCREENING, ASPARTIC PROTEASE, INHIBITION, HYDROLASE 
4y3z:A   (ILE302) to   (SER329)  ENDOTHIAPEPSIN IN COMPLEX WITH FRAGMENT 41  |   FRAGMENT SCREENING, HYDROLASE, INHIBITION 
4y41:A   (ILE302) to   (SER329)  ENDOTHIAPEPSIN IN COMPLEX WITH FRAGMENT 112  |   FRAGMENT SCREENING, ASPARTIC PROTEASE, INHIBITION, HYDROLASE 
4y4g:A   (ILE302) to   (SER329)  ENDOTHIAPEPSIN IN COMPLEX WITH FRAGMENT B53  |   FRAGMENT SCREENING, ASPARTIC PROTEASE INHIBITION, HYDROLASE 
4y4u:A   (ILE302) to   (SER329)  ENDOTHIAPEPSIN IN COMPLEX WITH FRAGMENT 14  |   FRAGMENT SCREENING, ASPARTIC PROTEASE, INHIBITION, HYDROLASE 
4y4x:A   (ILE302) to   (SER329)  ENDOTHIAPEPSIN IN COMPLEX WITH FRAGMENT 51  |   FRAGMENT SCREENING, HYDROLASE, INHIBITION 
4y50:A   (ILE302) to   (SER329)  ENDOTHIAPEPSIN IN COMPLEX WITH FRAGMENT 81  |   FRAGMENT SCREENING, HYDROLASE, INHIBITION 
1e81:E   (ILE299) to   (SER325)  ENDOTHIAPEPSIN COMPLEX WITH RENIN INHIBITOR MERCK-KGAA-EMD61395  |   ACID PROTEINASE, HYDROLASE-HYDROLASE INHIBITOR COMPLEX 
4ycy:A   (ILE302) to   (SER329)  ENDOTHIAPEPSIN IN COMPLEX WITH FRAGMENT 218  |   FRAGMENT SCREENING, HYDROLASE, INHIBITION 
4yd4:A   (ILE302) to   (SER329)  ENDOTHIAPEPSIN IN COMPLEX WITH FRAGMENT 227  |   FRAGMENT SCREENING, HYDROLASE, INHIBITION 
4yd7:A   (ILE302) to   (SER329)  ENDOTHIAPEPSIN IN COMPLEX WITH FRAGMENT 255  |   FRAGMENT SCREENING, HYDROLASE, INHIBITION 
1epr:E   (ILE299) to   (SER325)  ENDOTHIA ASPARTIC PROTEINASE (ENDOTHIAPEPSIN) COMPLEXED WITH PD-135, 040  |   HYDROLASE-HYDROLASE INHIBITOR COMPLEX, ACID PROTEINASE 
2v0z:C   (THR298) to   (LEU324)  CRYSTAL STRUCTURE OF RENIN WITH INHIBITOR 10 (ALISKIREN)  |   GLYCOPROTEIN, INHIBITOR-COMPLEX, ASPARTYL PROTEASE, ZYMOGEN, PROTEASE, HYDROLASE, POLYMORPHISM, ALTERNATIVE SPLICING, HYDROLASE(ACID PROTEINASE), CLEAVAGE ON PAIR OF BASIC RESIDUES 
2v0z:O   (THR298) to   (LEU324)  CRYSTAL STRUCTURE OF RENIN WITH INHIBITOR 10 (ALISKIREN)  |   GLYCOPROTEIN, INHIBITOR-COMPLEX, ASPARTYL PROTEASE, ZYMOGEN, PROTEASE, HYDROLASE, POLYMORPHISM, ALTERNATIVE SPLICING, HYDROLASE(ACID PROTEINASE), CLEAVAGE ON PAIR OF BASIC RESIDUES 
1flh:A   (GLU297) to   (PRO324)  CRYSTAL STRUCTURE OF HUMAN UROPEPSIN AT 2.45 A RESOLUTION  |   ACID PROTEINASE, HYDROLASE 
3ufl:A   (GLY330) to   (VAL356)  DISCOVERY OF PYRROLIDINE-BASED B-SECRETASE INHIBITORS: LEAD ADVANCEMENT THROUGH CONFORMATIONAL DESIGN FOR MAINTENANCE OF LIGAND BINDING EFFICIENCY  |   ASPARTYL PROTEASE, HYDROLASE-HYDROLASE INHIBITOR COMPLEX 
4z22:A   (PRO297) to   (LEU324)  STRUCTURE OF PLASMEPSIN II FROM PLASMODIUM FALCIPARUM COMPLEXED WITH INHIBITOR DR718A  |   PLASMEPSIN II, MALARIA, INHIBITOR, HYDROLASE 
4z22:B   (PRO297) to   (LEU324)  STRUCTURE OF PLASMEPSIN II FROM PLASMODIUM FALCIPARUM COMPLEXED WITH INHIBITOR DR718A  |   PLASMEPSIN II, MALARIA, INHIBITOR, HYDROLASE 
3uqw:A   (GLY330) to   (VAL356)  CRYSTAL STRUCTURE OF BACE1 WITH ITS INHIBITOR  |   HYDROLASE, BETA-SECRETASE, BACE1, MEMAPSIN 2, HYDROLASE-HYDROLASE INHIBITOR COMPLEX 
2vkm:B   (GLY330) to   (VAL356)  CRYSTAL STRUCTURE OF GRL-8234 BOUND TO BACE (BETA-SECRETASE)  |   ALTERNATIVE SPLICING, ASPARTYL PROTEASE, ASPARTIC PROTEASE, GLYCOPROTEIN, TRANSMEMBRANE, BETA SECRETASE, APP, BACE, A-BETA, X- RAY, ZYMOGEN, MEMBRANE, PROTEASE, MEMAPSIN, HYDROLASE, ALZHEIMER, DRUG DESIGN 
4ze6:A   (ILE302) to   (SER329)  ENDOTHIAPEPSIN IN COMPLEX WITH FRAGMENT B39  |   FRAGMENT SCREENING, ASPARTIC PROTEASE INHIBITION, HYDROLASE 
2g1r:A   (THR307) to   (LEU333)  KETOPIPERAZINE-BASED RENIN INHIBITORS: OPTIMIZATION OF THE C RING  |   PROTEIN-LIGAND COMPLEXES, HYDROLASE 
2g1r:B   (THR307) to   (LEU333)  KETOPIPERAZINE-BASED RENIN INHIBITORS: OPTIMIZATION OF THE C RING  |   PROTEIN-LIGAND COMPLEXES, HYDROLASE 
3vcm:A   (THR298) to   (LEU324)  CRYSTAL STRUCTURE OF HUMAN PRORENIN  |   ASPARTIC PROTEASES, PRORENIN RECEPTOR, HYDROLASE 
3vcm:B   (THR298) to   (LEU324)  CRYSTAL STRUCTURE OF HUMAN PRORENIN  |   ASPARTIC PROTEASES, PRORENIN RECEPTOR, HYDROLASE 
2wec:A   (PHE295) to   (PRO321)  ACID PROTEINASE (PENICILLOPEPSIN) (E.C.3.4.23.20) COMPLEX WITH PHOSPHONATE INHIBITOR: METHYL(2S)-[1-(((N-(1- NAPHTHALENEACETYL))-L-VALYL)AMINOMETHYL)HYDROXY PHOSPHINYLOXY]-3-PHENYLPROPANOATE, SODIUM SALT  |   PENICILLOPEPSIN, PHOSPHONATE INHIBITOR, HYDROLASE 
2wed:A   (PHE295) to   (PRO321)  ACID PROTEINASE (PENICILLOPEPSIN) (E.C.3.4.23.20) COMPLEX WITH PHOSPHONATE MACROCYCLIC INHIBITOR:METHYL[CYCLO-7[(2R)- ((N-VALYL)AMINO)-2-(HYDROXYL-(1S)-1-METHYOXYCARBONYL-2- PHENYLETHOXY)PHOSPHINYLOXY-ETHYL]-1-NAPHTHALENEACETAMIDE], SODIUM SALT  |   PENICILLOPEPSIN, MACROCYCLIC INHIBITOR, HYDROLASE 
3vye:A   (THR312) to   (LEU338)  HUMAN RENIN IN COMPLEX WITH INHIBITOR 7  |   ASPARTYL PROTEASE, RAS, HYDROLASE-HYDROLASE INHIBITOR COMPLEX 
3vye:B   (THR312) to   (LEU338)  HUMAN RENIN IN COMPLEX WITH INHIBITOR 7  |   ASPARTYL PROTEASE, RAS, HYDROLASE-HYDROLASE INHIBITOR COMPLEX 
2i1a:A   (ASP286) to   (ILE310)  A RETROVIRAL PROTEASE-LIKE DOMAIN IN THE EUKARYOTIC PROTEIN DDI1  |   ACID PROTEASE FOLD, DIMER, RETROVIRAL PROTEASE DOMAIN, PROTEIN TURNOVER 
2i1a:B   (ASP286) to   (ILE310)  A RETROVIRAL PROTEASE-LIKE DOMAIN IN THE EUKARYOTIC PROTEIN DDI1  |   ACID PROTEASE FOLD, DIMER, RETROVIRAL PROTEASE DOMAIN, PROTEIN TURNOVER 
2i1a:C   (ASP286) to   (ALA311)  A RETROVIRAL PROTEASE-LIKE DOMAIN IN THE EUKARYOTIC PROTEIN DDI1  |   ACID PROTEASE FOLD, DIMER, RETROVIRAL PROTEASE DOMAIN, PROTEIN TURNOVER 
2i1a:D   (ASP286) to   (ALA311)  A RETROVIRAL PROTEASE-LIKE DOMAIN IN THE EUKARYOTIC PROTEIN DDI1  |   ACID PROTEASE FOLD, DIMER, RETROVIRAL PROTEASE DOMAIN, PROTEIN TURNOVER 
1uh9:A   (PHE296) to   (PRO322)  CRYSTAL STRUCTURE OF RHIZOPUSPEPSIN AT PH 7.0  |   PEPSIN, ASPARTIC PROTEINASE, HYDROLASE 
1izd:A   (PHE295) to   (ALA321)  CRYSTAL STRUCTURE OF ASPERGILLUS ORYZAE ASPARTIC PROTEINASE  |   SUGAR BINDING, ACID PROTEASE, HYDROLASE 
3zov:A   (GLY391) to   (VAL417)  CRYSTAL STRUCTURE OF BACE-1 IN COMPLEX WITH CHEMICAL LIGAND  |   HYDROLASE 
4obz:B   (PRO317) to   (GLU344)  STRUCTURE OF CATHEPSIN D WITH INHIBITOR 2-(3,4-DIMETHOXYPHENYL)-N-[N- (4-METHYLBENZYL)CARBAMIMIDOYL]ACETAMIDE  |   LYSOSOMAL ASPARTIC PROTEASE, HYDROLASE-HYDROLASE INHIBITOR COMPLEX 
4obz:D   (PRO317) to   (GLU344)  STRUCTURE OF CATHEPSIN D WITH INHIBITOR 2-(3,4-DIMETHOXYPHENYL)-N-[N- (4-METHYLBENZYL)CARBAMIMIDOYL]ACETAMIDE  |   LYSOSOMAL ASPARTIC PROTEASE, HYDROLASE-HYDROLASE INHIBITOR COMPLEX 
4oc6:B   (PRO317) to   (GLU344)  STRUCTURE OF CATHEPSIN D WITH INHIBITOR 2-BROMO-N-[(2S,3S)-4-{[2-(2,4- DICHLOROPHENYL)ETHYL][3-(1,3-DIOXO-1,3-DIHYDRO-2H-ISOINDOL-2-YL) PROPANOYL]AMINO}-3-HYDROXY-1-(3-PHENOXYPHENYL)BUTAN-2-YL]-4,5- DIMETHOXYBENZAMIDE  |   LYSOSOMAL ASPARTIC PROTEASE, HYDROLASE-HYDROLASE INHIBITOR COMPLEX 
1lee:A   (PRO297) to   (LEU324)  CRYSTAL STRUCTURE OF PLASMEPSIN FROM P. FALCIPARUM IN COMPLEX WITH INHIBITOR RS367  |   PLASMEPSIN, ASPARTIC PROTEASE, PLASMODIUM FALCIPARUM, HYDROLASE 
3k1w:A   (THR312) to   (LEU338)  NEW CLASSES OF POTENT AND BIOAVAILABLE HUMAN RENIN INHIBITORS  |   RENIN, PROTEASE, ALTERNATIVE SPLICING, ASPARTYL PROTEASE, CLEAVAGE ON PAIR OF BASIC RESIDUES, DISEASE MUTATION, DISULFIDE BOND, GLYCOPROTEIN, HYDROLASE, MEMBRANE, POLYMORPHISM, SECRETED, ZYMOGEN 
3k1w:B   (THR312) to   (LEU338)  NEW CLASSES OF POTENT AND BIOAVAILABLE HUMAN RENIN INHIBITORS  |   RENIN, PROTEASE, ALTERNATIVE SPLICING, ASPARTYL PROTEASE, CLEAVAGE ON PAIR OF BASIC RESIDUES, DISEASE MUTATION, DISULFIDE BOND, GLYCOPROTEIN, HYDROLASE, MEMBRANE, POLYMORPHISM, SECRETED, ZYMOGEN 
4aa8:A   (LYS295) to   (LYS321)  BOVINE CHYMOSIN AT 1.8A RESOLUTION  |   HYDROLASE, ASPARTIC PEPTIDASE, RENNET 
4amt:A   (THR355) to   (LEU381)  CRYSTAL STRUCTURE AT 2.6A OF HUMAN PRORENIN  |   HYDROLASE, HORMONE, 
5dq2:A   (ILE302) to   (SER329)  ENDOTHIAPEPSIN IN COMPLEX WITH FRAGMENT 48  |   FRAGMENT SCREENING, HYDROLASE, INHIBITION 
5dr3:A   (ILE302) to   (SER329)  ENDOTHIAPEPSIN IN COMPLEX WITH FRAGMENT 333  |   FRAGMENT SCREENING, HYDROLASE, INHIBITION 
5dr7:A   (ILE302) to   (SER329)  ENDOTHIAPEPSIN IN COMPLEX WITH FRAGMENT 311  |   FRAGMENT SCREENING, HYDROLASE, INHIBITION 
4apr:E   (GLY295) to   (PRO322)  STRUCTURES OF COMPLEXES OF RHIZOPUSPEPSIN WITH PEPSTATIN AND OTHER STATINE-CONTAINING INHIBITORS  |   ACID PROTEINASE, HYDROLASE-HYDROLASE INHIBITOR COMPLEX 
4q1n:A   (THR298) to   (LEU324)  STRUCTURE-BASED DESIGN OF 4-HYDROXY-3,5-SUBSTITUTED PIPERIDINES AS DIRECT RENIN INHIBITORS  |   ASPARTIC PROTEASE, ANGIOTENSIN, HYDROLASE-HYDROLASE INHIBITOR COMPLEX 
4q1n:B   (THR298) to   (LEU324)  STRUCTURE-BASED DESIGN OF 4-HYDROXY-3,5-SUBSTITUTED PIPERIDINES AS DIRECT RENIN INHIBITORS  |   ASPARTIC PROTEASE, ANGIOTENSIN, HYDROLASE-HYDROLASE INHIBITOR COMPLEX 
4auc:A   (LYS295) to   (LYS321)  BOVINE CHYMOSIN IN COMPLEX WITH PEPSTATIN A  |   HYDROLASE-HYDROLASE INHIBITOR COMPLEX, HYDROLASE, HYDROLASE INHIBITOR, PEPTIDASE, INHIBITION 
5er1:E   (ILE299) to   (SER325)  A RATIONAL APPROACH TO THE DESIGN OF ANTIHYPERTENSIVES. X-RAY STUDIES OF COMPLEXES BETWEEN ASPARTIC PROTEINASES AND AMINOALCOHOL RENIN INHIBITORS  |   ACID PROTEINASE, HYDROLASE-HYDROLASE INHIBITOR COMPLEX 
3ckp:A   (GLY330) to   (VAL356)  CRYSTAL STRUCTURE OF BACE-1 IN COMPLEX WITH INHIBITOR  |   BETA-SECRETASE, ASPARTYL PROTEASE, ALTERNATIVE SPLICING, GLYCOPROTEIN, HYDROLASE, MEMBRANE, TRANSMEMBRANE, ZYMOGEN 
3ckp:C   (GLY330) to   (VAL356)  CRYSTAL STRUCTURE OF BACE-1 IN COMPLEX WITH INHIBITOR  |   BETA-SECRETASE, ASPARTYL PROTEASE, ALTERNATIVE SPLICING, GLYCOPROTEIN, HYDROLASE, MEMBRANE, TRANSMEMBRANE, ZYMOGEN 
4rz1:A   (THR298) to   (LEU324)  RENIN IN COMPLEXED WITH (3S,4S)-4-({[4-METHOXY-3-(3-METHOXYPROPOXY) BENZOYL](PROPAN-2-YL)AMINO}METHYL)PYRROLIDIN-3-YL BENZYLCARBAMATE INHIBITOR  |   HYDROLASE, HYDROLASE-HYDROLASE INHIBITOR COMPLEX 
4rz1:B   (THR298) to   (LEU324)  RENIN IN COMPLEXED WITH (3S,4S)-4-({[4-METHOXY-3-(3-METHOXYPROPOXY) BENZOYL](PROPAN-2-YL)AMINO}METHYL)PYRROLIDIN-3-YL BENZYLCARBAMATE INHIBITOR  |   HYDROLASE, HYDROLASE-HYDROLASE INHIBITOR COMPLEX 
3dm6:C   (GLY330) to   (VAL356)  BETA-SECRETASE 1 COMPLEXED WITH STATINE-BASED INHIBITOR  |   BACE, BETA-SECRETASE, STATINE, INHIBITOR, ALTERNATIVE SPLICING, ASPARTYL PROTEASE, GLYCOPROTEIN, HYDROLASE, MEMBRANE, PROTEASE, TRANSMEMBRANE, ZYMOGEN 
4d83:B   (GLY319) to   (VAL345)  CRYSTAL STRUCTURE OF HUMAN BETA SECRETASE IN COMPLEX WITH NVP-BUR436, DERIVED FROM A CO-CRYSTALLIZATION EXPERIMENT  |   BETA-SECRETASE, MEMAPSIN2, BACE1, ASPARTIC PROTEINASE, ALZHEIMER'S DISEASE, ENZYME INHIBITOR COMPLEX, STRUCTURE-BASED DRUG DESIGN, HYDROLASE-HYDROLASE INHIBITOR COMPLEX 
3pll:A   (ILE302) to   (SER329)  ENDOTHIAPEPSIN IN COMPLEX WITH A FRAGMENT  |   HYDROLASE-HYDROLASE INHIBITOR COMPLEX 
5ie1:A   (GLY330) to   (VAL356)  CRYSTAL STRUCTURE OF BACE1 IN COMPLEX WITH 3-(2-AMINO-6-(O-TOLYL) QUINOLIN-3-YL)-N-(3,3-DIMETHYLBUTYL)PROPANAMIDE  |   ASPARTIC PROTEASE, ALZHEIMER'S DISEASE, APP, AMYLOID PRECURSOR PROTEIN, HYDROLASE 
5jod:A   (ASN297) to   (VAL324)  STRUCTURE OF PROPLASMEPSIN IV FROM PLASMODIUM FALCIPARUM  |   MALARIA, HYDROLASE 
5jod:B   (ASN297) to   (VAL324)  STRUCTURE OF PROPLASMEPSIN IV FROM PLASMODIUM FALCIPARUM  |   MALARIA, HYDROLASE 
4gj6:A   (THR298) to   (LEU324)  CRYSTAL STRUCTURE OF RENIN IN COMPLEX WITH NVP-AYZ832 (COMPOUND 6A)  |   RENIN INHIBITOR, PHARMACOPHORE SEARCH, TRANS-3,4-DISUBSTITUTED PYRROLIDINE, HYDROLASE-HYDROLASE INHIBITOR COMPLEX 
4gj6:B   (THR298) to   (LEU324)  CRYSTAL STRUCTURE OF RENIN IN COMPLEX WITH NVP-AYZ832 (COMPOUND 6A)  |   RENIN INHIBITOR, PHARMACOPHORE SEARCH, TRANS-3,4-DISUBSTITUTED PYRROLIDINE, HYDROLASE-HYDROLASE INHIBITOR COMPLEX 
5oz4:A   (ILE302) to   (SER329)  AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 15  |   FRAGMENT SCREENING, METHOD DEVELOPMENT, ASPARTIC PROTEASE, HYDROLASE 
5ozj:A   (ILE302) to   (SER329)  AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 30  |   FRAGMENT SCREENING, METHOD DEVELOPMENT, ASPARTIC PROTEASE, HYDROLASE 
5p01:A   (ILE302) to   (SER329)  AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 48  |   FRAGMENT SCREENING, METHOD DEVELOPMENT, ASPARTIC PROTEASE, HYDROLASE 
5p05:A   (ILE302) to   (SER329)  AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 52  |   FRAGMENT SCREENING, METHOD DEVELOPMENT, ASPARTIC PROTEASE, HYDROLASE 
5p0a:A   (ILE302) to   (SER329)  AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 57  |   FRAGMENT SCREENING, METHOD DEVELOPMENT, ASPARTIC PROTEASE, HYDROLASE 
5p0w:A   (ILE302) to   (SER329)  AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 79  |   FRAGMENT SCREENING, METHOD DEVELOPMENT, ASPARTIC PROTEASE, HYDROLASE 
5p13:A   (ILE302) to   (SER329)  AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 86  |   FRAGMENT SCREENING, METHOD DEVELOPMENT, ASPARTIC PROTEASE, HYDROLASE 
5p1c:A   (ILE302) to   (SER329)  AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 95  |   FRAGMENT SCREENING, METHOD DEVELOPMENT, ASPARTIC PROTEASE, HYDROLASE 
5p1h:A   (ILE302) to   (SER329)  AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 100  |   FRAGMENT SCREENING, METHOD DEVELOPMENT, ASPARTIC PROTEASE, HYDROLASE 
5p1n:A   (ILE302) to   (SER329)  AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 106  |   FRAGMENT SCREENING, METHOD DEVELOPMENT, ASPARTIC PROTEASE, HYDROLASE 
5p1o:A   (ILE302) to   (SER329)  AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 107  |   FRAGMENT SCREENING, METHOD DEVELOPMENT, ASPARTIC PROTEASE, HYDROLASE 
5p1q:A   (ILE302) to   (SER329)  AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 109  |   FRAGMENT SCREENING, METHOD DEVELOPMENT, ASPARTIC PROTEASE, HYDROLASE 
5p1t:A   (ILE302) to   (SER329)  AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 112  |   FRAGMENT SCREENING, METHOD DEVELOPMENT, ASPARTIC PROTEASE, HYDROLASE 
5p1v:A   (ILE302) to   (SER329)  AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 114  |   FRAGMENT SCREENING, METHOD DEVELOPMENT, ASPARTIC PROTEASE, HYDROLASE 
5p2a:A   (ILE302) to   (SER329)  AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 128  |   FRAGMENT SCREENING, METHOD DEVELOPMENT, ASPARTIC PROTEASE, HYDROLASE 
5p2c:A   (ILE302) to   (SER329)  AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 130  |   FRAGMENT SCREENING, METHOD DEVELOPMENT, ASPARTIC PROTEASE, HYDROLASE 
5p2e:A   (ILE302) to   (SER329)  AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 132  |   FRAGMENT SCREENING, METHOD DEVELOPMENT, ASPARTIC PROTEASE, HYDROLASE 
5p2i:A   (ILE302) to   (SER329)  AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 136  |   FRAGMENT SCREENING, METHOD DEVELOPMENT, ASPARTIC PROTEASE, HYDROLASE 
5p2j:A   (ILE302) to   (SER329)  AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 137  |   FRAGMENT SCREENING, METHOD DEVELOPMENT, ASPARTIC PROTEASE, HYDROLASE 
5p2s:A   (ILE302) to   (SER329)  AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 145  |   FRAGMENT SCREENING, METHOD DEVELOPMENT, ASPARTIC PROTEASE, HYDROLASE 
5p2y:A   (ILE302) to   (SER329)  AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 151  |   FRAGMENT SCREENING, METHOD DEVELOPMENT, ASPARTIC PROTEASE, HYDROLASE 
5p39:A   (ILE302) to   (SER329)  AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 162  |   FRAGMENT SCREENING, METHOD DEVELOPMENT, ASPARTIC PROTEASE, HYDROLASE 
5p3a:A   (ILE302) to   (SER329)  AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 163  |   FRAGMENT SCREENING, METHOD DEVELOPMENT, ASPARTIC PROTEASE, HYDROLASE 
5p3f:A   (ILE302) to   (SER329)  AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 168  |   FRAGMENT SCREENING, METHOD DEVELOPMENT, ASPARTIC PROTEASE, HYDROLASE 
5p3h:A   (ILE302) to   (SER329)  AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 170  |   FRAGMENT SCREENING, METHOD DEVELOPMENT, ASPARTIC PROTEASE, HYDROLASE 
5p4n:A   (ILE302) to   (SER329)  AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 212  |   FRAGMENT SCREENING, METHOD DEVELOPMENT, ASPARTIC PROTEASE, HYDROLASE 
5p4u:A   (ILE302) to   (SER329)  AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 219  |   FRAGMENT SCREENING, METHOD DEVELOPMENT, ASPARTIC PROTEASE, HYDROLASE 
5p4x:A   (ILE302) to   (SER329)  AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 222  |   FRAGMENT SCREENING, METHOD DEVELOPMENT, ASPARTIC PROTEASE, HYDROLASE 
5p50:A   (ILE302) to   (SER329)  AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 225  |   FRAGMENT SCREENING, METHOD DEVELOPMENT, ASPARTIC PROTEASE, HYDROLASE 
5p51:A   (ILE302) to   (SER329)  AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 226  |   FRAGMENT SCREENING, METHOD DEVELOPMENT, ASPARTIC PROTEASE, HYDROLASE 
5p52:A   (ILE302) to   (SER329)  AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 227  |   FRAGMENT SCREENING, METHOD DEVELOPMENT, ASPARTIC PROTEASE, HYDROLASE 
5p57:A   (ILE302) to   (SER329)  AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 232  |   FRAGMENT SCREENING, METHOD DEVELOPMENT, ASPARTIC PROTEASE, HYDROLASE 
5p5b:A   (ILE302) to   (SER329)  AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 236  |   FRAGMENT SCREENING, METHOD DEVELOPMENT, ASPARTIC PROTEASE, HYDROLASE 
5p5p:A   (ILE302) to   (SER329)  AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 250  |   FRAGMENT SCREENING, METHOD DEVELOPMENT, ASPARTIC PROTEASE, HYDROLASE 
5p60:A   (ILE302) to   (SER329)  AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 261  |   FRAGMENT SCREENING, METHOD DEVELOPMENT, ASPARTIC PROTEASE, HYDROLASE 
5p67:A   (ILE302) to   (SER329)  AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 268  |   FRAGMENT SCREENING, METHOD DEVELOPMENT, ASPARTIC PROTEASE, HYDROLASE 
5p69:A   (ILE302) to   (SER329)  AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 270  |   FRAGMENT SCREENING, METHOD DEVELOPMENT, ASPARTIC PROTEASE, HYDROLASE 
5p6b:A   (ILE302) to   (SER329)  AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 272  |   FRAGMENT SCREENING, METHOD DEVELOPMENT, ASPARTIC PROTEASE, HYDROLASE 
5p6f:A   (ILE302) to   (SER329)  AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 276  |   FRAGMENT SCREENING, METHOD DEVELOPMENT, ASPARTIC PROTEASE, HYDROLASE 
5p73:A   (ILE302) to   (SER329)  AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 300  |   FRAGMENT SCREENING, METHOD DEVELOPMENT, ASPARTIC PROTEASE, HYDROLASE 
5p74:A   (ILE302) to   (SER329)  AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 301  |   FRAGMENT SCREENING, METHOD DEVELOPMENT, ASPARTIC PROTEASE, HYDROLASE 
5p79:A   (ILE302) to   (SER329)  AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 306  |   FRAGMENT SCREENING, METHOD DEVELOPMENT, ASPARTIC PROTEASE, HYDROLASE 
5p7f:A   (ILE302) to   (SER329)  AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 312  |   FRAGMENT SCREENING, METHOD DEVELOPMENT, ASPARTIC PROTEASE, HYDROLASE 
5p7g:A   (ILE302) to   (SER329)  AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 313  |   FRAGMENT SCREENING, METHOD DEVELOPMENT, ASPARTIC PROTEASE, HYDROLASE 
5p7h:A   (ILE302) to   (SER329)  AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 314  |   FRAGMENT SCREENING, METHOD DEVELOPMENT, ASPARTIC PROTEASE, HYDROLASE 
5p7k:A   (ILE302) to   (SER329)  AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 317  |   FRAGMENT SCREENING, METHOD DEVELOPMENT, ASPARTIC PROTEASE, HYDROLASE 
5p7l:A   (ILE302) to   (SER329)  AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 318  |   FRAGMENT SCREENING, METHOD DEVELOPMENT, ASPARTIC PROTEASE, HYDROLASE 
5p7s:A   (ILE302) to   (SER329)  AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 325  |   FRAGMENT SCREENING, METHOD DEVELOPMENT, ASPARTIC PROTEASE, HYDROLASE 
5p8g:A   (ILE302) to   (SER329)  AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 349  |   FRAGMENT SCREENING, METHOD DEVELOPMENT, ASPARTIC PROTEASE, HYDROLASE 
5p8i:A   (ILE302) to   (SER329)  AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 351  |   FRAGMENT SCREENING, METHOD DEVELOPMENT, ASPARTIC PROTEASE, HYDROLASE 
5p8q:A   (ILE302) to   (SER329)  AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 359  |   FRAGMENT SCREENING, METHOD DEVELOPMENT, ASPARTIC PROTEASE, HYDROLASE 
5sy2:A   (THR312) to   (LEU338)  STRUCTURE-BASED DESIGN OF A NEW SERIES OF N-PIPERIDIN-3-YLPYRIMIDINE- 5-CARBOXAMIDES AS RENIN INHIBITORS  |   PROTEIN-LIGAND COMPLEX, HYDROLASE-HYDROLASE INHIBITOR COMPLEX 
5sy2:B   (THR312) to   (LEU338)  STRUCTURE-BASED DESIGN OF A NEW SERIES OF N-PIPERIDIN-3-YLPYRIMIDINE- 5-CARBOXAMIDES AS RENIN INHIBITORS  |   PROTEIN-LIGAND COMPLEX, HYDROLASE-HYDROLASE INHIBITOR COMPLEX